Status: Approved , Date: 3 June 2016 1Janssen Research & Development*
Clinical Protocol
A Randomized, Double -blind, Multicenter, Active -controlled Study to Evaluate the 
Efficacy, Safety, and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral 
Antidepressant in Adult Subjects with Treatment- resistant Depression
Trial of R apid-a cting Intra nasal Esketamine for Treatment -resistant Major Depressive Disorder 
(TRANSFORM -2)
Protocol ESKETINTRD3002; Phase 3
AMENDMENT 2
JNJ-54135419 (esketamine)
*Janssen Research & Development is a global organization that operates through different legal entities in 
various countries. Therefore, the legal entity acting as the sponsor for Janssen Research & Development 
studies may vary, such as, but not limited to Janssen Biotech, Inc.; Janssen Products, LP; Janssen 
Biologics, BV; Janssen -Cilag International NV; Janssen, Inc; Janssen- Cilag International NV ; Janssen 
Sciences Ireland UC; or Janssen Research & Development, LLC. The term “sponsor” is used throughout 
the protocol to represent these various legal entities; the sponsor is identified on the Contact [CONTACT_23756] .
This compound is being investigated in Phase 3 clinical studie s.
This study  will be conducted under US Food & Drug Administration IND regulations (21 CFR 
Part 312).
EudraCT NUMBER: 2014 -004585 -22
Status: Approved
Date: 3 June 2016
Prepared by: [CONTACT_12945] & Development, LLC
EDMS number and version :EDMS- ERI-93094732, 3.0
GCP Compliance: This study will be conducted in compliance with Good Clinical Practice, and applicable regulatory 
requirements .
Confidentiality Statement
The information in this document contains trade secrets and commercial information that are privileged or confidential and may 
not be disclosed unless such disclosure is required by [CONTACT_784]. In any event, persons to whom the 
information is disclosed must be informed that the inform ation is privileged or confidential and may not be further disclosed by 
[CONTACT_476]. These restrictions on disclosure will apply equally to all future information supplied to you that is indicated as priv ileged or 
confidential.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3002 Amendment 2
Status: Approved , Date: [ADDRESS_508573] OF IN -TEXT T ABLES A ND FIGU RES ................................................................................................ 5
PROTOCOL A MENDMENTS ....................................................................................................................... 6
SYNOPSIS .................................................................................................................................................. 31
TIME AND EVENTS SCHE DULE (Screening/Prospective Observational Phase and Double -
blind Induction Phase) .............................................................................................................................. 43
TIME AND EVENTS SCHE DULE (F ollow -up Phase ).............................................................................. 50
ABBREVIA TIONS ...................................................................................................................................... 53
1. INTRODUCTION ................................................................................................................................ 55
1.1. Background .................................................................................................................................... 56
1.1.1. Summary  of Nonclinical Findings ............................................................................................... 56
1.1.2. Clinical Studies ........................................................................................................................... 59
[IP_ADDRESS]. Pharmacokinetics and Product Metabolism ............................................................................ 59
[IP_ADDRESS]. Pharmacodynamics and Efficacy ............................................................................................ 61
[IP_ADDRESS]. Safety and Tolerability ............................................................................................................. 62
1.1.3. Marketing Experience ................................................................................................................. 66
1.2. Active Comparators in Double -blind Induction Phase ................................................................... 66
1.2.1. Selective Serotonin Reuptake Inhibitors ..................................................................................... 67
[IP_ADDRESS]. Escitalopram ............................................................................................................................ 67
[IP_ADDRESS]. Sertraline ................................................................................................................................ .67
1.2.2. Serotonin and Norepi[INVESTIGATOR_154804] e Inhibitors ................................................................... 68
[IP_ADDRESS]. Duloxetine ................................................................................................................................ 68
[IP_ADDRESS]. Venlafaxine Extended -release ................................................................................................ .69
1.3. Overall Rationale for the Study ...................................................................................................... 70
2. OBJECTIVES A ND HYPOT HESIS ................................................................................................... 70
2.1. Objectives ...................................................................................................................................... 70
2.2. Hypothesis ..................................................................................................................................... 71
3. STUDY DESIGN A ND RA TIONA LE................................................................................................ .71
3.1. Overview of Study Design .............................................................................................................. 71
3.2. Study Design Rationale .................................................................................................................. 74
3.2.1. Study Population ......................................................................................................................... 74
3.2.2. Study Phases .............................................................................................................................. 75
3.2.3. Blinding and Randomization ....................................................................................................... 76
3.2.4. Treatment Groups and Dose Selection ...................................................................................... 77
3.2.5. Efficacy  Measures ...................................................................................................................... 78
3.2.6. Safety Evaluations ...................................................................................................................... 79
3.2.7. Medical Resource Utilization ...................................................................................................... 80
3.2.8. Other Assessments .................................................................................................................... 81
3.2.9. Pharmacokinetic Assessments ................................................................................................... 81
3.2.10. Biom arker, Pharmacogenomic (DNA), and Expression (RNA) Evaluations .............................. 81
4. STUDY POPUL ATION...................................................................................................................... 82
4.1. Inclusion Criteria ............................................................................................................................ 82
4.2. Exclusion Criteria ........................................................................................................................... 85
4.3. Prohibitions and Restrictions ......................................................................................................... 90
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3002 Amendment 2
Status: Approved , Date: 3 June 2016 35. TREA TMENT A LLOCA TION AND BLINDING ................................................................................. 91
6. DOSA GE A ND A DMINISTR ATION.................................................................................................. 92
6.1. Screening/Prospective Observational Phase ................................................................................ 92
6.2. Double -Blind Induction Phase ........................................................................................................ 93
6.2.1. Guidance on Blood Pres sure Monitoring on Intranasal Treatment Session Day s..................... 95
6.3. Follow -up Phase ............................................................................................................................ 96
7. TREA TMENT COMPLIA NCE ............................................................................................................ 96
8. PRESTUDY A ND CONCOMI TANT THERA PY................................................................................ 96
9. STUDY EVA LUATIONS .................................................................................................................... 98
9.1. Study Procedures ........................................................................................................................... 98
9.1.1. Overview ..................................................................................................................................... 98
9.1.2. Screening/Prospective Observational Phase ............................................................................. 99
9.1.3. Double -Blind Induction Phase .................................................................................................. 101
9.1.4. Follow -up Phase ....................................................................................................................... 102
9.2. Efficacy ......................................................................................................................................... 103
9.2.1. Evaluations ............................................................................................................................... 103
[IP_ADDRESS]. Primary Efficacy  Evaluation ................................................................................................... 103
[IP_ADDRESS]. Key Secondary Efficacy  Evaluation (Clinician -completed) .................................................... 103
[IP_ADDRESS]. Key Secondary Efficacy  Evaluation (Patient -reported Outcome) .......................................... 103
[IP_ADDRESS].1. SDS .................................................................................................................................... 103
[IP_ADDRESS].2. PHQ -9................................................................................................................................ 104
[IP_ADDRESS]. Other Secondary Efficacy  Evaluations (Clinician- completed) ............................................... 104
[IP_ADDRESS].1. CGI-S................................................................................................................................ .104
[IP_ADDRESS]. Other Secondary Efficacy  Evaluations (Patien t-reported Outcomes) ................................... 104
[IP_ADDRESS].1. GAD-7 ................................................................................................................................ 104
[IP_ADDRESS].2. EQ-5D-5L........................................................................................................................... 104
9.2.2. Endpoints .................................................................................................................................. 105
[IP_ADDRESS]. Primary Endpoint ................................................................................................................... 105
[IP_ADDRESS]. Secondary Endpoints ............................................................................................................ 105
9.3. Pharmacokinetics ......................................................................................................................... 106
9.3.1. Evaluations ............................................................................................................................... 106
9.3.2. Analytical Procedures ............................................................................................................... 106
9.3.3. Pharmacokinetic Parameters ................................................................................................... 106
9.4. Pharmacokinetic/Pharmacodynamic Evaluations ........................................................................ 106
9.5. Biom arker, Pharmacogenomic (DNA), and Expression (RNA) Evaluations ................................ [ADDRESS_508574] COMPLETION/W ITHDRA WAL..................................................................................... [ADDRESS_508575] Information ...................................................................................................................... 119
11.2. Sample Size Determination ......................................................................................................... 119
11.3. Efficacy  Analyses ......................................................................................................................... 120
11.4. Pharmacokinetic Analy ses........................................................................................................... 121
11.5. Pharmacokinetic/Pharmacodynamic Analyses ............................................................................ 121
11.6. Biom arker and Pharmacogenomic Analyses ............................................................................... 121
11.7. Medical Resource Utilization Analyses ........................................................................................ 121
11.8. Safety Analyses ........................................................................................................................... 122
11.9. Independent Data Monitoring Committee .................................................................................... 123
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3002 Amendment 2
Status: Approved , Date: [ADDRESS_508576] Qu ality.......................................................................... 129
14. STUDY DRUG INFORM ATION....................................................................................................... 130
14.1. Physical Description of Study Drug(s) ......................................................................................... [ADDRESS_508577] (IEC/IRB) ................................ .136
16.2.3. Informed Consent ..................................................................................................................... 137
16.2.4. Privacy of Personal Data .......................................................................................................... 138
16.2.5. Long- Term Retention of Samples for Additional Future Research .......................................... 138
16.2.6. Countr y Selecti on..................................................................................................................... 139
17. ADM INISTRA TIVE REQUI REM ENTS ............................................................................................ 139
17.1. Protocol Amendments .................................................................................................................. 139
17.2. Regulatory Documentation .......................................................................................................... 139
17.2.1. Regulatory Approval/Notification .............................................................................................. [ADDRESS_508578] Identification, Enrollment, and Screening Logs .............................................................. 140
17.4. Source Documentation ................................................................................................................. 140
17.5. Case Report Form Completion .................................................................................................... 141
17.6. Data Quality Assurance/Quality Control ...................................................................................... [ADDRESS_508579] Retention ......................................................................................................................... 142
17.8. Monitoring .................................................................................................................................... 143
17.9. Study Com pletion/Termination ..................................................................................................... 143
17.9.1. Study Com pletion ..................................................................................................................... 143
17.9.2. Study Termination ..................................................................................................................... 143
17.10. On-site Audits ............................................................................................................................... 144
17.11. Use of Information and Publication .............................................................................................. 144
REFERENCES .......................................................................................................................................... 146
INVESTIGA TOR A GREEME NT............................................................................................................... 158
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3002 Amendment 2
Status: Approved , Date: [ADDRESS_508580] OF A TTACHMENTS
Attachment 1: Prohibited Concomitant Medications with Intranasal Study Medication 
(Esketamine or Placebo) .......................................................................................... 151
Attachment 2: [LOCATION_001] Heart Association Classification of Cardiac Disease ............................... 154
Attachment 3: Oral Antidepressant Titration Schedule for Double -Blind Induction Phase .............. 155
Attachment 4: Anticipated Events .................................................................................................... [ADDRESS_508581] OF IN -TEXT TA BLES A ND FIGU RES
TABLES
Table 1: Adverse Reactions Listed as Very Common, Common, or Frequent Occurrences in 
the Product Information of Anesthetic Ketamine and Esketamine ........................................... 63
Table 2: Intranasal Treatment Administration during t he Double -blind Induction Phase ....................... 93
Table 3: Volume of Blood to Be Collected From Each Subject .............................................................. 99
FIGURES
Figure 1: Study Design for ESKETINTRD3002 ...................................................................................... 74
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3002 Amendment 2
Status: Approved , Date: [ADDRESS_508582] recent amendment.
Amendment 2 (03June 2016 )
This amendment is considered to be substantial based on the criteria set forth in Article 10(a) of Directive 
2001/20/EC of the European Parliament and the Council of the European Union . 
The overall reason for the amendment: Based on feedback received from Investigators involved in the study, the 
subject entry criteria are being revised to i mprove recruitment.
Applicable Section(s) Description of Change(s)
Rationale: To im prove recruitment, the antidepressant treatment requirements at study entry (ie, time of signing the 
ICF) in inclusion criterion no. 3.1were changed. In addition, the definition of nonresponse at the end of the 
screening/prospective observational phase was revised.
4.1. Inclusion Criteria Inclusion criterion no. 3 .1was revised as follows (bold text added):
At the start of the screening/prospective observational phase, subject must have had non-
response (≤25% improvement) to ≥ 12but ≤5 (if current epi[INVESTIGATOR_154806] > [ADDRESS_508583] 2 years) oral antidepressant treatments in the current epi[INVESTIGATOR_154807], assessed using the MGH- ATRQ and confirmed by [CONTACT_154899] (eg,
medical/pharmacy/prescription records )or a l etter from a treating physician ,etc.). In 
addition, the sSubject must be istaking one of the a different oral antidepressant 
treatment (s) with nonresponse that is documented (on the MGH -ATRQ) for at least the 
previous 2 weeks (ie, this oral antidepressant treatment must have been taken for at least 
6 weeks at or above the minimal therapeutic dose with a lack of clinically meaningful 
improvement) at the start of the screening/prospective observational phase.
-For specific tricyclic antidepressants which are ongoing and being taken at a 
dose below  the MGH -ATRQ minimum therapeutic dose, a blood level that is 
within t he therapeutic (antidepressant) range, is acceptable to establish the 
adequacy of the antidepressant treatment.
-Subjects must have been beadherent to the continued oral antidepressant 
treatment medication(s) (w ithout adjustment in dosage) through the 
screening/prospective observational phase, as documented on the PAQ. Missing 
≥4 days of antidepressant medication in the prior 2 -week period w ill be 
considered as inadequate adherence.
-Subjects who are non -responders to their current oral antidepressant 
medica tion(s) from the screening/prospective observational phase (as assessed by 
[CONTACT_6222], remote raters) may be eligible for randomization if all other entry 
criteria are met. Non-response at the end of the screening/prospective 
observational phase is define d as ≤25% im provement in the MADRS total 
score from  Week 1 to Week 4 and a MADRS total score of ≥28 on Week 2 
and Week 4.   
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3002 Amendment 2
Status: Approved , Date: 3 June 2016 7Applicable Section(s) Description of Change(s)
Synopsis, Overview of 
Study Design; 
Synopsis, Study 
Population; Synopsis, 
Dosage and 
Administration; 3.1. 
Overvie w of Study 
Design; 3.2.1. Study 
Population; 6.1. 
Screening/Prospective 
Observational Phase ; 
9.1.2. 
Screening/Prospective 
Observational PhaseText regarding antidepressant treatment during the screening/prosp ective observational 
phase was revised as follows (bold text added):
“…the subject must have had documented non -response to at least 1 antidepressant 
treatm ent (based on MGH -ATRQ criteria) in the current epi[INVESTIGATOR_17108], and 
the subject is betaking one of the a different oral antidepressant treatment (s)with 
nonresponse ( ≤25% improvement) that will be documented (on the MGH ATRQ) for at 
least the previous 2 weeks (ie, this oral antidepressant treatment must have been taken
for at least 6 w eeks at or above the minimum therapeutic dose with a lack of clinically 
meaningful improvement ). This antidepressant treatment, as well as any other ongoing 
medications being taken for depression (including adjunctive/augmentation therapi[INVESTIGATOR_014]), 
will continue unchanged, at the same dosage, from the start of Week 1 through the end of 
Week 4 of the screening/prospective observational phase. Dose adjustment is permitted 
per clinical judgment, but the oral antidepressant treatment is to remain at or above 
the minimum therapeut ic dose (per the MGH -ATRQ) through the end of Week 4. ”
Synopsis, Study 
Population; 3.2.1. 
Study Population; 
9.1.2. 
Screening/Prospective 
Observational PhaseCriteria for the minimum number of oral antidepressant treatments in the current epi[INVESTIGATOR_403362] -response at the start of the screening/prospective observational 
phase was revised from ≥2 to ≥1.
Synopsis, Overview of 
Study Design; 
Synopsis, Study 
Population; 3.1. 
Overvie w of Study 
Design; 3.2.1. Study 
Population; 6.1. 
Screening/Prospect ive 
Observational Phase ; 
9.1.2. 
Screening/Prospective 
Observational PhaseCriteria for non -response at the end of the screening/prospective observational phase was 
revised as follows (bold text added):
Non-response at the end of the screening/prospective observational phase is defined as 
≤25% improvement in the MADRS total score for 2 consecutive visits from  Week 1 to 
Week 4 and a MADRS total score of ≥ [ADDRESS_508584] 
selection criteria for the screening/ prospective observational phase.
16.1. Study -specific 
Design ConsiderationsText w as revised as follo ws (bold text added):
For eligibility, subjects must have had non -response to at least [ADDRESS_508585] and be currently taking non-responders to their current an
antidepressant treatment with non -response being observed with at the start of the 
screening/prospective observational phase that will be continued as prospective 
treatment in the screening/prospective observational phase. Only subjects w ith non -
response to their current antidepressant treatment after [ADDRESS_508586] ively observed 
treatment (for a total duration of antidepressant treatment of at least 106weeks by [CONTACT_154900]/prospective observational phase), will be eligible to proceed to the 
double- blind induction phase, when reall subject swillreceive a new  oral antidepressant in 
addition to intranasal esketamine or placebo.
Rationale: The list of key secondary objectives, evaluations, and endpoints has been reordered to correspond to the 
revised order of the planned analysis.
Synopsis, Objectives 
and Hypothesis; 2.1. 
ObjectivesKey secondary objectives reorder ed to show  “Depressive symptoms (subject -reported)” as 
the third key secondary objective .
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3002 Amendment 2
Status: Approved , Date: 3 June 2016 8Applicable Section(s) Description of Change(s)
Synopsis, Efficacy 
Evaluations/EndpointsUnder the “Key Secondary Evaluations and Endpoints” heading, text describing the onset 
of clinical response was moved to the first key secondary evaluation, text describing the 
SDS was moved to second, and text describing PHQ -[ADDRESS_508587]. Numbering 
described in the text was revised accordingly.
Synopsis, Statistical 
Methods; 9. 2.2.2. 
Secondary Endpoints; 
11.3. Efficacy 
AnalysesText revised to indicate that analysis of key secondary efficacy endpoints will be analyzed 
in the following order: first, onset of clinical response results; second, SDS results, and 
third, PHQ- [ADDRESS_508588] 
changes in the order of analysis and adjustments to the testing procedure.
[IP_ADDRESS]. Key 
Secondary Efficacy 
Evaluation (Patient -
reported Outcome)Order of key secondary patient -reported outcome efficacy evaluations was revised to 
show description of SDS before that of PHQ-9.
Rationale: Due to current recruitment dynamics, a sample size r eestimation is not recommended as it would be 
based almost entirely on a US population.
Synopsis, Statistical 
Methods; 3.1. 
Overvie w of Study 
Design; 5. Treatment 
Allocation and 
Blinding ;11. 
Statistical Methods;
11.2. Sample Size 
Determination; 11.9. 
Independent Data 
Monitoring Committee Text regarding interim analysis for sample size re- estimation has been deleted.
Sections following Section [ADDRESS_508589] been renumbered.
Rationale: Analysis of onset of clinical response revised to indicate that subjects are allowed one excursion.
Synopsis, Efficacy 
Evaluations/Endpoints; 
Synopsis, Statistical 
Methods; 3.2.5. 
Efficacy Measures; 
[IP_ADDRESS]. Key 
Secondary Efficacy 
Evaluation (Clinician -
completed); [IP_ADDRESS]. 
Secondary E ndpoints; 
11.3. Efficacy 
AnalysesThe description of the onset of clinical response was revised as follows (bold text added):
Clinical response is defined as ≥50% improvement in MADRS total score by [CONTACT_2006] 2 (ie, 
the day after taking the first dose of double -blind intranasal medication) that continues 
through the end of the double -blind phase with one excursion allowed .
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3002 Amendment 2
Status: Approved , Date: 3 June 2016 9Applicable Section(s) Description of Change(s)
Ration ale: Inclusion criterion no. 11 .1was revised to specify the same requirements for contraception for female 
partners of male subjects as specified for female subjects.
4.1. Inclusion Criteria The text of inclusion criterion no. 11 .1has been changed as follow s (bold text added):
During the study (ie, from Day 1 of the double -blind induction phase, prior to 
randomization) and for a minimum of 1 spermatogenesis cycle (defined as approximately 
90 days) after receiving the last dose of intranasal study medication, in addition to the u ser 
independent highly effective method of contraception, a man who is sexually active with 
a wom an of childbearing potential
-must be practicing a highly effective method of contraception with his 
female partner from  those listed above (see examples of hig hly effective 
methods of contraception provided for fem ale subjects). who is sexually 
active with a w oman of childbearing potential must agree to use a double -barrier 
method of contraception (eg, diaphragm or cervical/vault caps plus condom with 
spermicida l foam/gel/film/cream/suppository) .
-who is sexually active with a woman who is pregnant must use a condom if his 
partner is pregnant .
-must agree not to donate sperm.
Alternatively female partners of childbearing potential may be practicing a highly 
effecti ve method of birth control, eg, established use of oral, injected, or implanted 
horm onal methods of contraception; placement of an intrauterine device (IUD) or 
intrauterine system (IUS); or male partner sterilization. Note: If the childbearing potential 
changes after start of the study, a female partner of a male study subject, must begin a 
highly effective method of birth control, as described above.
Rationale: Exclusion criterion no. [ADDRESS_508590] degree atrioventricular (AV) 
block as the analyses of PR intervals from subjects in Phase [ADDRESS_508591] of 
esketamine on PR interval.
4.2. Exclusion Criteria Exclusion criterion no. 11 .1revised as follows (bold text added):
Subject has cli nically significant ECG abnormalities at the start of the 
screening/prospective observational phase or on Day 1 of the double -blind induction 
phase prior to randomization, defined as:
-During screening, a QT interval corrected according to Fridericia’s formula 
(QTcF): ≥450 msec; if the QTcF is prolonged on the initial ECG, the average 
QTcF of three ECG ’s, recorded [ADDRESS_508592] not be ≥450 msec.
-On Day 1 (predose), a QT interval corrected according to Fridericia’s formula 
(QTcF): ≥450 msec based on t he site -evaluated ECG; if the QTcF is prolonged 
on the initial ECG, the average QTcF of three ECG ’s, recorded [ADDRESS_508593] not be ≥[ADDRESS_508594] degree AV block w ith PR 
interval >200 msec (may  repeat ECG once, and use average of both readings, if 
the initial PR interval is <240 msec), com plete left bundle branch block (LBBB), 
or complete right bundle branch block (RBBB). 
-Features of new ischemia.
-Arrhythmia (except premature atrial contrac tions [PACs] and premature 
ventricular contractions [PVCs]).
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3002 Amendment 2
Status: Approved , Date: 3 June 2016 10Applicable Section(s) Description of Change(s)
Rationale: Exclusion criterion no. 14 .1was rev ised to allow prescription use of psychostimulants with dosing 
restrictions on intranasal treatment session days,to allow  subjects to safely use at other permitted times during study 
participation.
4.2. Exclusion Criteria Text in exclusion criterion no. 14 .1revised as follows (bold text added):
Subject has positive test result(s) for drugs of abuse (including barbiturates, methadone, 
opi[INVESTIGATOR_858], cocaine, phencyclid ine, and amphetamine/methamphetamine) at the start of the 
screening/prospective observational phase or Day [ADDRESS_508595] result at screening due to prescribed 
psychostimulants (eg, am phetam ine, methylphenidate, etc.) taken for an 
indication other than MDD are perm itted to continue to take this medication 
durin g the study in accordance with Attachm ent 1.
-Otherwise, Subjects subjects who have a positive test result at screening due to 
prescribed/over -the-counter opi[INVESTIGATOR_858] ,or barbiturates , or amphetamines may be 
permitted to continue in the screening/prospective observational phase if the 
medication is discontinued at least 1 w eek or 5 half -lives, whichever is longer, 
before Day 1 of the double -blind induction phase (prior to randomization) in 
accordance w ith Attachment 1 restrictions. The result of the Day 1 (prior to 
randomization) test for drugs of abuse must be negative for th e subject to be 
randomized.
o Retesting is not permitted for positive test result(s), except for reasons 
stated above.
Rationale: Clarifications made regarding the usage of antidepressant treatments for indications other than 
depression during the screeni ng/prospective observational phase, and the use of corticosteroids, psychostimulants, 
and ADHD medications.
8. Prestudy and 
Concomitant TherapyThe follow ing text was added:
Any medication that is listed on the MGH -ATRQ and is being taken at the start of the 
screening/prospective observational phase for a n indication other than depression (eg, 
insomnia) should be continued during the screening/prospective observational phase but 
must be discontinued before the start of the double -blind induction phase.
Attachment 1 For antidepressants, changed 3rdbullet to read “Even if used for other indications (eg, 
trazodone primarily for sleep ), trazodone the use of any medication listed on the ATRQ
is not permitted during the treatment phase” 
For corticosteroids, changed “oral” to “systemic”; allowed epi[INVESTIGATOR_81532] (previously 
prohibited); added that intermittent IM/IV corticosteroids are permitted (chronic use 
prohibited). 
For pseudoephedrine, clarified that is an orally administered agent (no t intranasal).
For psychostimulants, allowed continuous use (previously prohibited); added that 
prescribed psychostimulants taken for indications other than MDD can be continued but 
must not be taken within 12 hours prior to the intranasal treatment sessi on or for 2 hours 
after the intranasal treatment session. 
For ADHD medications, allowed continuous use (previously prohibited); added that these 
medications can be continued but must not be taken within 12 hours prior to the intranasal 
treatment session or for 2 hours after the intranasal treatment session.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3002 Amendment 2
Status: Approved , Date: 3 June 2016 11Applicable Section(s) Description of Change(s)
Rationale: In Amendment 1, inclusion of subjects who have thyroid -stimulating hormone (TSH) outside the normal 
ranges was permitted; however, the text indicating that a subject must have a normal TSH at screening was not 
removed from Amendment 1. This has been corrected in Amendment 2.
4.1 Inclusion Criteria The bullets in inclusion criterion no. 7 .1revised as follows:
-Subjects with a pre- existing history of thyroid disease/disorder w ho are treated 
with thyroid hormones must be on a stable dosage for 3 months prior to the start 
of the screening/prospective observational phase and must have thyroid -
stimulating hormone (TS H) within normal range in the screening/prospective 
observational phase.
-For any subject (regardless of thyroid history), if the thyroid -stimulating 
horm one ( TSH )value is out of range, a free thyroxine (FT4) w ill be conducted. 
If the FT4 is normal, the su bject can be enrolled. If the FT4 value is abnormal 
and considered to be clinically significant (after discussion with the m edical 
monitor) out of range , the subject is not eligible.
Rationale: Add MADRS assessment at Visit 3.2 during the follow -up phase and provide clarification in the 
footnotes regarding antidepressant treatment in the screening/prospective observational phase and guidance on 
repetition of the MADRS assessment.
Time and Events 
Schedule, Screening 
and Induction PhaseFootnote “a” revised to state (bold text added): Subjects who do not require a taper and 
are thus eligible to immediately proceed to the double- blind induction phase canwillhave 
Visit 1.3 and Visit 2.1 occur ringon the same day or within 1 week of each ot her (if not 
occurring the sam e day, the antidepressant treatment regim en should be continued 
and discontinued prior to Visit 2.1) .
Deleted “only” from footnote “d”.
Footnote “p” revised to state (bold text added): The MADRS should be administered no 
more than [ADDRESS_508596]’s scheduled targeted (not actual) clinic visit date 
(except Visit 2.10, which is within 1 day prior) . If performed on the day of the 
scheduled clinic visit for an intranasal treatment session, the MADRS must be performed 
prior to the intranasal treatment session.
Time and Events 
Schedule, Follow -up
PhaseA MADRS assessment was added to Visit 3.2.
Rationale: Revise the visit window  for Day 28 of the double -blind induction phase to allow more flexibility for 
conducting the visit.
Time and Events 
Schedule, Screening 
and Induction PhaseFor Visit 2.10 during the induction phase, the visit window  was revised to ±1 day (rather 
than -1 day). 
Rationale: To obtain AE and concomitant therapy data in between clinic visits.
Time and Events 
Schedule, Follow -up 
PhaseThe follow ing statement was added as footnote “f” to each remote assessment during the 
follow -up phase:
At each “Remote Assessment ” visit, site staff will contact [CONTACT_403377][INVESTIGATOR_014]
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3002 Amendment 2
Status: Approved , Date: 3 June 2016 12Applicable Section(s) Description of Change(s)
Rationale: To add information about 54135419TRD3008, an open -label safety extension study, which may be 
available for eligible subjects participating in ESKETINTRD3001.
Synopsis, Overview of 
Study Design; 3.1. 
Overvie w of Study 
Design; 9.1.4. Follow -
up PhaseThe follow ing text was added:
An open -label safety extension study, 54135419TRD3008, may be available (pending 
country and site approval) for eligible subjects participating in the ESKETINTRD3002 
study. Please refer to the 54135419TRD3008 protocol for full details when available.
Rationale: Removal of requirement to report arterial oxygen saturation < 93% and any treatment -emergent change 
in the nasal examination as adverse events because adverse event reporting in these instances should be at the 
discretion of the PI.
9.7. Safety Evaluations Any arterial oxygen saturation (SpO 2) <93% should be and lasting for more than 
2minutes, and confirmed by [CONTACT_170463] , will 
be reported as an adverse event .
The follow ing statement was deleted from the description of nasal examinations: Any 
treatment -emergent change or worsening from the baseline examination will be recorded 
as an adverse event.
Rationale: The maximum sertraline dose w as changed from 150 mg/day to 200 mg/day as the maximum dose 
allow ed by  [CONTACT_154903] 200 mg/day.    
[IP_ADDRESS]. Sertraline; 
Attachment 3 Maximum dose of sertraline changed from 150 mg/day to 200 mg/day. Titration schedule 
adjusted accordingly. 
Rationale: Revise text regarding uptitration of duloxetine dose, which referred to an incorrect phase of the study.
[IP_ADDRESS]. Duloxetine Text revised to state that certain subjects may be started on a 30 mg dose of duloxetine 
and up -titrated into the therapeutic range of 60 mg by [CONTACT_154904] 2 of the double-
blind induction phase (not the screening/prospective observational phase).
Rationale: Removal of LSD and MDMA from urine drug screen results that will lead to discontinuation as LSD is 
not measured in the current urine drug screen and prescribed psychostimulants are now  permitted.
4.3. Prohibitions and 
RestrictionsLysergic acid diethylamide (LSD) and MDMA w eredeleted from the list of drugs that 
will lead to discontinuation if detected in the urine drug screen during the study .
Rationale: Clarification of procedure to follow if subjects wish to withdraw from the st udy.
10.2 Withdraw al from 
the StudyUnder “Withdraw al of Consent”, the following text was revised to state (bold text added): 
Subjects who wish to withdraw from the study should be asked if they are agreeable to 
continue to an early withdrawal visit (if withdrawing from the double -blind 
induction phase) and the follow up phase, or to be contact[CONTACT_132610] -up 
information.
Rationale: Added definition of treatment -resistant depression (TRD) to the synops is.
Synopsis, Study 
PopulationDefinition of TRD from Section 3.2.1 also added to the synopsis under Study Population.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3002 Amendment 2
Status: Approved , Date: 3 June 2016 13Applicable Section(s) Description of Change(s)
Rationale: Clarification of adverse event reporting procedures in the instance of pregnancy. In addition, 
clarification that all SAEs must be reported using the SAE form.
12.3.1. All Adverse 
EventsText revised as follows (bold text added):
All adverse events and special reporting situations, whether serious or non -serious, will be 
reported from the time a signed and dated ICF is obtained until completion of the subject's 
last study -related procedure (which may include contact [CONTACT_20687] -up of safety), with the 
exception of pregnancy which will be reported up to [ADDRESS_508597] dose of 
study medication (fem ales) or [ADDRESS_508598] dose of study m edication 
(partners of m ale participants) .  Serious adverse events, including those spontaneously 
reported to the investigator, within [ADDRESS_508599] be 
reported using the Serious Adverse Event Form. The sponsor w ill evaluate any safety 
information that is spontaneously reported by [CONTACT_403378] e time frame 
specified in the protocol.
Rationale: Minor changes were made throughout the protocol for compliance with updated protocol template text, 
for clarification, and to correct errors.
Synopsis, Dosage and 
AdministrationFor consistency with the rest of the protocol, the following text was revised:
Study -site personnel will instruct subjects on how to administer, store, and take the oral 
antidepressant treatment supplied during this study for at -home use. On intranasal 
treatment sessions, it is recommended that oral antidepressant treatment be taken in the 
evening and at the same time of day throughout the study. A subject diary will be 
provided to capture oral antidepressant study medication use.
On intran asal dosing days, it is recommended that the oral antidepressant should not be 
taken until at least 3 hours after the intranasal treatment session.
Time and Events 
Schedule, Screening 
and Induction PhaseFootnote “p” was added to the MADRS assessment (7 -day recall) at Visit 1.2.
4.1. Inclusion Criteria The follow ing text was added to inclusion criterion no. 9.1:
Contraceptive use by [CONTACT_170465].
4.2. Exclusion Criteria Text in exclusion criterion no. 23 clarified as follows (bold text added):
Subject has a score of ≥[ADDRESS_508600] be ruled out (eg, apnea -hypopnea index [AHI] must be <30). A subject 
with obstructive sleep apnea can be included if he or she is using a positive airway 
pressure device or other treatment/therapy that is effectively treating (ie, AHI <30) his or 
her sleep apnea.
16.1. Study -specific 
Design ConsiderationsApproximate blood volume to be collected w as corrected to 116.0 mL ( instead of 
123.5 mL).
17.5 Case Report Form 
Com pletionDeleted text stating “All data relating to the study must be recorded in CRF.”
References Removed edition number and date from reference 42. 
Deleted references to Wiens BL (2003) as w ell as Wiens BL and Dmitrienko A (2005) as 
these are not referenced in the document due to text revisions.
Investigator 
Agreement PageRemoved the “LAST PAGE” designation.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3002 Amendment 2
Status: Approved , Date: 3 June 2016 14Amendment 1 (15January 2016)
This amendment is considered to be substantial based on the criteria set forth in Article 10(a) of Directive 
2001/20/EC of the European Parliament and the Council of the European Union 
The overall reason for the amendment: The overall reason for this amendment is to update and/or clarify protocol 
content based on ongoing feedback received during study initiation activities.
Applicable Section(s) Description of Change(s)
Rationale: Adding a clarification to the dosing instructions for esketamine in case of a missed dose during the 
Induction Phase.
Synopsis, Dosage and 
Administration; 
6.2.Double -blind
Induction PhaseThe follow ing text was added: If there is no intranasal treatment session on Day 15 
(eg, visit is missed), a dose reduction from 84 mg to 56 mg is permitted on Day 18 if 
required for t olerability; no dose increase is permitted.
Rationale: Correction of an error in one of the statistical parameters used in the sample size calculation for the 
study.
Synopsis, Sample Size 
Determination; 11.2. 
Sample Size 
DeterminationThe follow ing correction was made: The maximum sample size planned for this study 
was calculated assuming a treatment difference for the double -blind induction phase of 
6.5 points in MADRS total score betw een esketamine and the active comparator, a 
standar d deviation of 12, a 1 -sided significance level of 0.0125 0.025, and a drop -out 
rate of 25%.
Rationale: Clarify that “at least [ADDRESS_508601]” encompasses bilateral ECT treatments as well. 
Synopsis, Study 
Population;
4.2. Exclusion CriteriaExclusion criteria no.1 now  states “unilateral/bilateral” rather than only “unilateral.” 
Rationale: Indication that subjects who received vagal nerve stimulation in the current depressive epi[INVESTIGATOR_154810].
Synopsis, Study 
Population; 4.2. Exclusion 
CriteriaThe current exclusion criteria no. [ADDRESS_508602] who 
has received vagal nerve stimulation (VNS) in the current depressive epi[INVESTIGATOR_1865].
It previously stated subjects with vagal nerve stimulation (VNS) implant were 
excluded.
Rationale: Exclusion criteria expanded to include additional DSM -5 diagnostic codes (317, 318.0, 318.1, 318.2, 
315.8, and 319) for intellectual disability, and autism spectrum disorder.
Synopsis, Study 
Population;
4.2. Exclusion CriteriaExclusion criteria no. 3 expanded to include additional intellectual disability DSM -5 
diagnostic codes (317, 318.0, 318.1, 318.2, 315.8, and 319), and autism spectrum 
disorder.
Rational : Clarification of the description of MDD and obsessive compulsive dis order, under criteria for subject 
exclusion. 
Synopsis, Study 
Population;
4.2. Exclusion CriteriaThe text of the current exclusion criteria no.3. w as modified: 
-“MDD with psychosis” was revised to “MDD with psychotic features” 
-Only subjects w ith “current” obsessive compulsive disorder will be excluded.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3002 Amendment 2
Status: Approved , Date: 3 June 2016 15Applicable Section(s) Description of Change(s)
Rationale: Clarification of the conditions for exclusion of subjects w ith coronary artery disease.
4.2. Exclusion Criteria The text of exclusion criteria no.8. was modified such that the following
cardiovascular conditions will now  be excluded:
Coronary artery disease with myocardial infarction, unstable angina, “or” 
revascularization procedure (eg, coronary angioplasty or by[CONTACT_10956]) 
within 12 months before the start of the screening/pr ospective observational phase. 
Subjects who have had a revascularization performed > 12 months prior to 
screening and are clinically stable and symptom -free, “per investigator’s clinical 
judgment”, can be included.
Rationale: Clarification of the w ording used for describing a subject’s antihypertensive medication.
4.2. Exclusion Criteria The text of the current exclusion criteria no. 9. will now state:
antihypertensive “medication(s)” rather than “regimen”.
Rationale: Clarification of definition of clinically significant ECG abnormalities as defined by [CONTACT_154906]’s formula (QTcF).
4.2. Exclusion Criteria The text of the current exclusion criteria no.11 w as modified as follows:
The first subbullet, was separated into 2 separate bullets, and the following bold 
text was added:
-During screening, aQT interval corrected according to Fridericia’s formula 
(QTcF): ≥450 msec ; if the QTcF is prolonged on the initial ECG, the 
average QTcF of three ECG’s, recorded [ADDRESS_508603] not be
≥450 m sec.
-On Day 1 (predose) , a QT interval corrected according to Fridericia’s 
formula (QTcF): ≥450 m sec based on the site-evaluated ECG; if the QTcF is 
prolonged on the initial ECG, the average QTcF of three ECG’s, 
recorded [ADDRESS_508604] not be ≥450 msec .
In the second subbullet, the follow ing bold text w as added:
-Evidence of 2ndor 3rddegree AV block, or 1stdegree AV block with PR 
interval ˃200 msec “[may repeat the ECG once, and use average of both 
readings if the initial PR interval is <240 msec ]”
-“complete ” was added to LBBB and RBBB. 
Rationale: The use of concomitant medications that prolong the QT interval/corrected QT (QTc) are no longer 
excluded as there is no known increase in QTc signal associated with esketamine ,extensive ECG monitoring is in 
place and precautions in case of increase in QTc are added. .
4.2. Exclusion criteria The current exclusion criteria no 12 has been modified:
The follow ing text has been deleted, as:
The ‘use of concomitant medications that prolong the QT interval/corrected QT (QTc) 
interval’ no longer exclude a subject from study enrollment.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3002 Amendment 2
Status: Approved , Date: 3 June 2016 16Applicable Section(s) Description of Change(s)
Rationale: Inclusion of a repeat screening test for abnormal ALT and AST values during the screening/prospective 
observational phase.
4.2. Exclusion criteria The current exclusion criteria no. 13 has been modified:
Where the subject has a history of, or symptoms and signs suggestive for liver 
cirrhosis/alanine aminotransferase (ALT)/aspartate aminotransferase (AST) values ≥2x 
the upper limit (normal), the follow ing is applicable:
“Repeat of screening test for abnormal ALT and AST is permitted once  during the 
screening period provided per investigator discretion and provided that there is an 
alternative explanation for the out of range value.”
Rationale: Clarification that a positive test for cannabinoids on Day 1 is exclusionary, but not at screening. 
4.2. Exclusion Criteria The text of the current exclusion criteria no. 14 w as modified:
Clarification that whereas a positive test for cannabinoids at the start of the 
screening/prospective phase is not exclusionary, however a positive test for 
cannabinoids on Day 1 (predose) of the double -blind -treatment phase is exclusionary.
Rationale: The term “secondary diabetes” was removed from the exclusion criterion because, as stated in the 
criterion, any uncontrolled diabetes mellitus is exclusionary.
4.2. Exclusion Criteria The text of the current exclusion criteria no. 15 was modified to delet e the terms 
“secondary diabetes”.
Rationale: Provide clarification that investigator’s clinical judgment based on the assessment will be used to 
exclude subjects on the basis of any anatom ical or medical condition that may impede delivery or absorption of
intranasal study drug.
4.2. Exclusion Criteria The text of exclusion criteria no. 17 was modified to indicate that the ‘investigator’s 
clinical judgment based on the assessment’ will be used to determine eligibility.
Text that is redundant (ie, examples of structural or functional abnormalities) has been 
deleted.
Rationale: Exclusion criteria no. 18 is no longer required as it is covered as part of exclusion criteria no. 17.
4.2. Exclusion Criteria The text of exclusion criteria no. 18 has been deleted.
Rationale: Clarification that a subject is excluded if currently enrolled in an investigational study, which is 
interventional, and clarification that the limit for participation in 2 or more MDD or other psychiatric condition 
clinical interventional studies in the previous 1 year is based on studies with different investigational medications.
4.2. Exclusion Criteria The text of exclusion criteria no. 24 has been modified to include:
-Subject who has participated in 2 or more MDD or other psychiatric 
condition clinical interventional studies “(with different investigational 
medication)” in the previous [ADDRESS_508605] is currently enrolled in an investigational “interventional” study.
Rationale: Subjects w ith severe renal impairment (creatinine cleara nce < 30 ml/min) are being excluded (exclusion 
criterion no. 30), as a safety precaution, since the effect of impaired renal clearance on the PK of intranasal 
esketamine is not fully known and subjects may be more vulnerable to blood pressure increases.
4.2. Exclusion Criteria Added exclusion criteria no. 30 for all subjects: Severe renal impairment (creatinine 
clearance < 30 ml/min)
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3002 Amendment 2
Status: Approved , Date: 3 June 2016 17Applicable Section(s) Description of Change(s)
Rationale: Clarification to inclusion criterion regarding non -response to oral antidepressant treatments in current 
epi[INVESTIGATOR_28948] e of depression w as added. 
Synopsis, Study 
Population; 3.1. Overview  
of Study Design;
3.2.1. Study Population;
4.1. Inclusion Criteria ; 6.1 
Screening/Prospective 
Observational Phase;
9.1.2 Screening/ 
Prospective Observational 
PhaseThe text of the current inclusion criteria no. 3 w as modified :
Non-response ( ≤ 25% improvement) to ≥2 but ≤5 (if current epi[INVESTIGATOR_154806] >[ADDRESS_508606] 2 years) oral antidepressant 
treatments in current epi[INVESTIGATOR_17108].
Non-response is assessed using MADRS and confirmed by [CONTACT_403379] (eg, medical/pharmacy/prescription records or a letter from a treating 
physician). 
Subject must be  taking one of the oral antidepressant treatment(s) with non -
response that is documented on the MG H-ATRQ (ie, oral antidepressant 
treatment must be taken for at least 6 w eeks at the minimal therapeutic dose 
with a lack of clinically meaningful improvement) at the start of the 
screening/prospective observational phase.
- For specific tricyclic antidepress ants which are being taken at a dose 
below  the MGH -ATRQ minimum therapeutic dose, a blood level that is 
within the therapeutic (antidepressant) range, is acceptable to establish 
the adequacy of the antidepressant treatment.
Non-response at the end of the screening/prospective observational phase is 
defined as ≤ 25% improvement in the MADRS total score for 2 consecutive 
visits and a MADRS total score of ≥ 28 for 2 consecutive visits.
Rationale: Indicate that the severity of a subject’s depressive symptoms in their current major depressive epi[INVESTIGATOR_154813] a Site Independent Qualification Assessment. 
Synopsis, Study 
Population; 3.2.1. Study 
Population; 4.1. Inclusion 
Criteria ; 9.1.2. Screening/ 
Prospective Observational 
PeriodThe text of the current inclusion criteria no. 5 w as modified:
The subject’s current major depressive epi[INVESTIGATOR_1865], “depression symptom  severity (Week 
1MADRS total score ≥28 required )”, and antidepressant treatment response in the 
current depressive epi[INVESTIGATOR_1865], must be confirmed using a Site Independent Qualification 
Assessment . 
Rationale: Inclusion of an additional lab test which measures levels of free thyroxine (FT4), in the event that TSH 
values are out of range.
4.1. Inclusion Criteria The text of the inclusion criteria no. [ADDRESS_508607] 
for assessing levels of free thyroxine:
-For any subject (regardless of thyroid history), if the TSH value is out of range, a 
free thyroxine (FT4) will be conducted. If the FT4 is normal, the subject can be 
enrolled. If the FT4 value is out of range, the subject is not eligible.
Rationale: Clarification of the criteria for assessing pregnancy in women of childbearing potential.
4.1. Inclusion Criteria The text of the current inclusion criteria no.10 now  states that:
A wo man of childbearing potential must have a negative “highly sensitive” serum 
(β-human chorionic gonadotropin [β-hCG]) at the start of the 
screening/prospective observational phase.
A negative urine pregnancy test “must be obtained before the first dose of study 
drug” on Day 1 of the double- blind induction phase prior to randomization.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3002 Amendment 2
Status: Approved , Date: 3 June 2016 18Applicable Section(s) Description of Change(s)
Rationale: Inclusion criteria for methods of birth control were updated per new  Sponsor protected template 
requirements.
4.1. Inclusion Criteria The text of the current inclusion criteria no. 11 w as modified:
During the study (ie, from Day 1  o f the double- blind induction phase, prior to 
randomization) and for a minimum of 1 spermatogenesis cycle (defined as 
approximately 90 days) after receiving the last dose of intranasal study medication, in 
addition to the user independent highly effective method of contraception, a man
who is sexually active with a woman of childbearing potential must agree to use a 
double- barrier method of contracepti on (eg, diaphragm or cervical/vault caps plus 
condom with spermicidal foam/gel/film/cream/suppository).
who is sexually active with a woman who is pregnant must use a condom
must agree not to donate sperm
Rationale: Inclusion criteria for methods of birth control were updated per new Sponsor protected template 
requirements.
4.1. Inclusion Criteria The text of the current inclusion criteria no. 9 w as also modified:
Awoman must be either:
a. Not of childbearing potential defined as:
opostmenopausal
A postmenopausal state is defined as no menses for 12 months without an 
alternative medical cause. A high follicle stimulating hormone (FSH) level 
(˃40 IU/L or mIU/ml in the postmenopausal range) will be used to confirm a 
postmenopausal state in women not using horm onal contraception or 
horm onal replacement therapy, however in the absence of 12months of 
amenorrhea, a single FSH measurement is insufficient.
opermanently sterile
Perm anent sterilization methods include hysterectomy, bilateral 
salpi[INVESTIGATOR_1656], bilateral tubal occlusion/ligation procedures, and bilateral 
oophorectomy.
b. Of childbearing potential and
opracticing a highly effective method of contraception (failure rate of <1% 
per year when used consistently and correctly).
Examples of highly effective contraceptives include 
-user-independent methods:
implantable progestogen -only horm one contraception associated with 
inhibition of ovulation; intrauterine device (IUD); intrauterine 
horm one-releasing system (IUS); vasect omized partner; sexual 
abstinence (sexual abstinence is considered a highly effective method 
only if defined as refraining from heterosexual intercourse during the 
entire period of risk associated with the study drug. The reliability of 
sexual abstinence needs to be evaluated in relation to the duration of 
the study and the preferred and usual lifesty le of the subject.)
-user-dependent methods:
combined (estrogen -and progestogen -containing) horm onal 
contraception associated with inhibition of ovulation: oral, intravaginal, 
and transdermal; progestogen -only hormone contraception associated 
with inhibition of ovulation: oral and injectable
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3002 Amendment 2
Status: Approved , Date: 3 June 2016 19Applicable Section(s) Description of Change(s)
Typi[INVESTIGATOR_170439]. Use should be consistent with local regulations regarding the use 
of contraceptive methods for subjects participating in clin ical studies.
Hormonal contraception may be susceptible to interaction with the study 
drug, which may reduce the efficacy of the contraceptive method.
oagrees to usea highly effective method throughout the study and for at least 
[ADDRESS_508608] dose of study drug.
Note: If th e childbearing potential changes after start of the study or the risk of 
pregnancy changes (eg, a w oman who is not heterosexually active becomes active) ,a 
woman must begin a highly effective method of contraception, as described
throughout the inclusion criteria.
Rationale: Allow option for subjects who have in the past shown increased sensitivity towards SSRI/SNRIs to start 
at a 30 mg dose of duloxetine in the oral antidepressant titration schedule.
[IP_ADDRESS]. Duloxetine; 
Attachment 3,
Footnote ‘a’Deletion of text in Section [IP_ADDRESS]. stating: ‘Although not in the US prescribing 
information, an initial starting dose of 30 mg/day has also been evaluated’.
The follow ing text has been added, as the US prescribing information does indicate 
that:
“For some patients, it may be desirable to start at 30mg once daily for [ADDRESS_508609] to the medication before increasing to 60 mg once daily.”
“In the current study, subjects should be initiated with 60mg/day and that subjects 
who have in the past shown increased sensitivity towards SSRI/SNRIs can, at the 
discretion of the treating physician, be started on 30mg dose and up-titrated into the 
therapeutic range of 60mg by [CONTACT_154904] 2 of the screening/pros pective 
observational phase”.
Rationale: Update to align with ne w protocol template text regarding data being collected for medical resource 
utilization
9.6. Medical Resource 
UtilizationDeleted text that specified “including surgeries and other selected procedures; 
“number and character of diagnostic and therapeutic tests and procedures”, and 
“outpatient medical encounters and treatments (including physician or emergency 
room  visits, tests and procedures, and medications)”.
Rationale: Total bilirubin w as om itted in error from the serum chemistry panel in the prior protocol.
9.7. Safety Evaluations Total bilirubin was added to the serum chemistry panel.
Rationale: Clarify that in the event that an intranasal treatment session is postponed/de layed (within a visit window) 
due to a predose vital sign assessment (eg, blood pressure), on the actual day of the intranasal treatment session, 
specific assessments (including predose) must be performed/repeated, as specified in the T&E Schedule.
9.7. Safety Evaluations;
Time & Events ScheduleWhere a decision has been made to postpone/delay the intranasal treatment session 
within the visit window , all time points (including predose) of the following 
assessments listed in the Time & Events Schedule, must be repeated on the actual 
intranasal treatment session day : vital signs (ie, blood pressure, pulse, respi[INVESTIGATOR_697], 
and temperature), 12 -lead ECG, C -SSRS (since last visit), MOAA/S, pulse oximetry, 
BPRS+, and CADSS
A footnote ‘q’ was added to the follo wing assessments in the double -blind induction 
phase to indicate what needs to be performed/repeated for a postponed (w ithin the visit 
window ) intranasal dosing visit:
Vital signs, 12 -lead ECG, C -SSRS, MOAA/S, pulse oximetry, BPRS+, and CADSS.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3002 Amendment 2
Status: Approved , Date: 3 June 2016 20Applicable Section(s) Description of Change(s)
Rationale: Add recommendation for rescheduling smell test assessments if a subject has significant nasal 
congestion on the day of a scheduled smell test(s).
Time & Events Schedule;
9.7. Safety EvaluationsA footnote ‘o’ was added to UPSIT and Smell Threshold Test to note that the smell 
test assessment(s) should be rescheduled for the next clinic visit if the subject has nasal 
congestion.
Rationale: Update to include new template text for reporting abnormal pregnancy outcomes
12.3.3. Pregnancy Instructions for the reporting of abnormal pregnancy outcomes (eg, spontaneous 
abortion, fetal death, stillbirth, congenital anomalies, ectopic pregnancy) were added.
Rationale: Clarification that menstrual cycle tracking will be documented for w omen with a menstrual cycle only.
Time & Events Schedule;
9.8. Other EvaluationsA footnote ‘n’ was added to menstrual cycle tracking in the double -blind induction 
phase of the Time & Events Schedule to indicate it is only applicable to w omen with a 
menstrual cycle.
Rationale: Footnote corrected to specify at which clinic visit a predose and/or postdose 12 -lead ECG w ill be 
performed. 
Time & Events Schedule The footnote ‘f’ was corrected to indicate that:
Twelve-lead ECG will be performed at t = 1 h postdose “only (ie, no predose ECG 
required)” at Visits 2.4, 2.6, and 2.9. 
Rationale: The Time and Events Schedule row that provided the assessment windows for MADRS was removed 
due to misunderstandings it was creating relative to the clinic visit windows.
Time & Events Schedule The row for MADRS assessment windows was deleted and afootnote ‘p’ was added , 
with the same guidance as previously stated in the row, to indicate that the MADRS 
should be administered no more than [ADDRESS_508610]’s scheduled clinic 
visit, and that if performed on the day of the scheduled clinic visit for an intranasal 
treatment session, the MADRS must be performed prior to the intranasal treatment 
session.
Rationale: Clarify arterial oxygen saturation level that requires further monitoring.
9.7. Safety Evaluations The symbol “<” was added to this sentence to clarify that additional assessments are 
required w hen the level is < 93%: 
“If oxygen saturation levels are < 93% at any time during the 1.5 hour postdose 
interval, pulse oximetry will be recorded every 5 minutes until levels return to ≥ 93%.”
Rationale: Add an additional Sheehan Disability Scale (SDS) assessment between Day 1 and Day 28.
Time & Events Schedule An SDS assessment was added on Day 15 (Week 2) of the Double -blind Induction 
Phase, as indicated.
Rationale: The PWC -20 assessment is to be performed for all subjects on Day 25 of the Double- blind Induction 
Phase (last planned intranasal treatment session ) because sites will not know at that time whether or not a subject 
will be continuing into ESKETINTRD3003.
Time & Events Schedule Footnote “j” w as rem oved from the T&E schedule.
Rationale: The scoring of the PAQ assessment was revised.
9.8. Other Evaluations Text describing scoring of the PAQ was revised to indicate: 
The total score is  based on the response selected for Question 1 (previously 
stated it was calculated by [CONTACT_154907] 1c through 
1f), and
A score of 0 -1 = adherent (previously stated 0 = adherent) and 2 or more is 
nonadherent (previously stated 1 or more = nonadherent).
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3002 Amendment 2
Status: Approved , Date: 3 June 2016 21Applicable Section(s) Description of Change(s)
Rationale: Clarification of the description for the HVLT -R recall test.
9.7. Safety Evaluations Changes added to the description of the HVLT -R recall test:
Administration includes a delayed recall (20 minute) trial and a [ADDRESS_508611].
The test administrator reads instructions and w ord lists aloud, and records 
words recalled/recognized by [CONTACT_748]. 
Scores include learning, delayed recall, and recognition.
Additional text added stating that “All subjects will complete a practice 
session for the computerized cognitive battery during the 
screening/prospective observational phase. There is no practice session for the 
HVLT -R.”
Rationale : To alert site staff to ECG readings that would raise safety concerns and necessitate subject w ithdrawal 
and study discontinuation
9.7. Safety Evaluations; 
10.2. Withdraw al from the 
StudyThe follow ing text was added:
The subjects must be discontinued at any time point after baseline (Day1, predose), if:
QTcF change from baseline is ≥60 msec AND QTcF >480 msec, or
QTcF >500 msec
Rationale: Clarification on the mandatory use of oral antidepressant dosing titration schedule.
Synopsis, Dosage and 
Administration;
3.2.4. Treatment Groups 
and Dose Selection;
6.2. Double -Blind 
Induction Phase, 
Oral Antidepressant 
Medication;
9.1.3 Double- Blind 
Induction Phase-Use of the titration schedule provided in Attachment 3 is mandatory. 
-“Doses are not to exceed the maximum dose defined in the titration 
schedule.” w as added
Rationale: Indicate biomarkers will be protein and RNA and provide the rationale for recommendation of subject 
adherence to a low  fat diet on the day of sample collection.
3.2.10. Biomarker, 
Pharm acogenomic 
(DNA), and Expression 
(RNA) Evaluations;
SynopsisAdded text to indicate that biomarkers will be assessed at both the protein and RNA 
level.
Addition of sentence stating that ‘On the day of biomarker sample collection, i t is 
preferred that subjects adhere to a low  fat diet (as an alternative to fasting) to reduce 
the level of postprandial lipemia in blood samples, since moderately or grossly lipemic 
specimens may interfere with assay results.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3002 Amendment 2
Status: Approved , Date: 3 June 2016 22Applicable Section(s) Description of Change(s)
Rationale: Blood volume table updated to include tricyclic antidepressant and free thyroxine (FT4) blood level 
testing, if required , as w ell as changes in blood volumes for biomarker (protein/DNA) assessment.
9.1.1. Overview, Table 3 
legend d) and e)Table 3. 
Screening/Prospective Observational Phase :
-Row added to blood volume table to include:
-a single [ADDRESS_508612] for analysis of blood level s of FT4, if 
required.
-Addition of footnote ‘ d)’”for specific tricyclic antidepressants which are being taken 
at a dose below  the MGH -ATRQ minimum therapeutic dose, a blood level that is 
within the therapeutic (antidepressant) range, is acceptable to est ablish the adequacy of 
antidepressant treatment”.
-Addition of footnote ‘ e)’ “for any subject (regardless of thyroid history), if the TSH 
value is out of range, a free thyroxine (FT4) w ill be conducted”
Double blind Induction Phase:
-Merged the 2 rows f or ‘Biomarker protein visits’ to a single row , that now  states: 
“Biomarker protein (at Visits 2.1, 2.4, and 2.9). The volume of sample collected at 
each visit is [ADDRESS_508613] is now 3.
All study phases:
-Volume of blood sample for Biomarker: protein is now 10 mL
-Volume of blood sample for Biomarker: DNA is now 6 mL
Deleted old footnote ‘d)’ Blood volume listed under protein biomarkers represents the 
combined volume of several different collection tubes.
Total Volume of Bloo d to be collected per subject is now  116 mL. 
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3002 Amendment 2
Status: Approved , Date: 3 June 2016 23Applicable Section(s) Description of Change(s)
Rationale: Provide further clarification on how the current oral antidepressant treatment regimen should remain 
unchanged for the duration of the screening/prospective observational phase and provide the criterion for non -
response at the end of the screening/prospective observational phase (i.e., site investigators are no longer blinded .
Synopsis, Overview of 
Study Design;
Dosage and 
Administration;
Study Population;
3.1. Overview  Study 
Design;
3.2.1. Study Phases;
6.1.Screening/Prospective 
Observational Phase;
9.1.2. 
Screening/Prospective 
Observational PhaseSubject’s current oral antidepressant treatment regimen should remain unchanged and 
at the same dosage for the 4 -week screening/pro spective observational phase.
At the start of the screening/prospective observational phase. the subject must 
be taking one of the oral antidepressant treatment(s) with non-response 
(≤25% improvement) that will be documented on the MGH -ATRQ (ie, this 
oral antidepressant treatment must have been taken for at least 6 weeks at the 
minimum therapeutic dose with a lack of clinically meaningful 
improvement). This antidepressant treatment, as well as any other ongoing 
medications being taken for depression at screening (including adjunctive/ 
augmentation therapi[INVESTIGATOR_014]), will continue unchanged, at the same dosage, from 
the start of Week 1 through the end of Week 4 of the screening/prospective 
observational phase.
After 4 weeks, subjects who are non-responders to thecurrent oral antidepressant 
treatment may be eligible to proceed to the double- blind induction phase. Non-
response at the end of the screening/prospective observational phase is defined as ≤
25% improvement in the MADRS total score for 2 consecutive visits and a MADRS 
total score of ≥ 28 for 2 consecutive visits .
Eligible subjects who are entering the double- blind induction phase will discontinue 
all of their current medication (s), being used for depression treatment, including 
adjunctive/au gmentation the rapi[INVESTIGATOR_014]. 
-Subjects taking benzodiazepi[INVESTIGATOR_1651] (at dosages equal to or less than the 
equivalent of 6 mg/day of lorazepam) and/or permitted non -benzodiazepi[INVESTIGATOR_154815] (e.g., zolpi[INVESTIGATOR_6730], zaleplon) during the screening/prospective 
observational phase can co ntinue these medications.
-No dose increases beyond the equivalent of 6 mg/day of lorazepam or new 
benzodiazepi[INVESTIGATOR_154816]/prospective observational 
phase .
Eligible subjects who do not require a tapered discontinuation of their antidepressant 
treatment(s) can proceed immediately into the double- blind induction phase.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3002 Amendment 2
Status: Approved , Date: 3 June 2016 24Applicable Section(s) Description of Change(s)
Rationale: Clarification of guidance on blood p ressure monitoring on intranasal treatment session days.
6.2.1. Guidance on Blood 
Pressure Monitoring on 
Intranasal Treatment 
Session DaysClarification of guidance on blood pressure monitoring;
predose blood pressure monitoring :
If subsequent to fulfilling the inclusion and exclusion criteria on Day 1 “(ie,applicable 
to all other intranasal treatment session days after Day 1)”, a subject’s pre-dose 
systolic blood pressure “(SBP) is ˃140 mmHg and/or diastolic blood pressure 
(DBP) is ˃90mmHg ”, itis recommended to repeat the blood pressure measurement 
after subject rests in sitting or recumbent position.
-“If after rest and repeated measurements, pre -dose SBP is ˃140 mmHg and/or 
DBP is ˃90 mmH g”, then dosing should be postponed and the subject 
scheduled to return on the follow ing day or within the given visit window.
-If the blood pressure elevation still persists on the next visit, the subject w ill 
be scheduled for a consultation by [CONTACT_154908], “other specialist” or primary 
care physician, prior to further dosing”
postdose blood pressure monitoring :
If at any postdose time point on the dosing da y, the SBP is ≥180 mmHg but 
<200 mmHg and/or the DBP is ≥110 mmHg but <[ADDRESS_508614], “other 
specialist ”, or primary care physician for a follow -up assessment .”
-After the assessment by a cardiologist, “other specialist ” or primary care 
physician , “if recommended by [CONTACT_154909] ”for the subject to continue in 
the study, the subject may continue with intranasal dosing, if the predose 
blood pressure, at the next scheduled visit is within the acceptable range (see 
bullet point above).
If at any postdose time poin t on the dosing day the SBP is ≥200mmHg and/or the 
DBP is ≥[ADDRESS_508615] “mus t” discontinue from further dosing and the 
subject should be referred to a cardiologist, “other specialist ”, or primary care 
physician for a follow -up assessment .
Addition of the following criteria for discharge based on  post -dose blood pressure 
assessme nts during the double -blind induction phase:
theblood pressure is <160 mmHg SBP and <100 mmHg DBP, or
“in the investigator’s clinical judgment, the subject is clinically stable  and 
can be discharged from the study site”, or
thesubject is referred for appropriate medical care, if clinically indicated.
“If the blood pressure remains ≥ 180 mmHg SBP and/or / ≥[ADDRESS_508616] should be referred for immediate 
medical treatment”.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3002 Amendment 2
Status: Approved , Date: 3 June 2016 25Applicable Section(s) Description of Change(s)
Rationale: Clarificat ion of the language regarding subjects meeting blood pressure criteria on intranasal treatment 
session days for discontinuation from further dosing, to indicate that the discontinuation of such subjects is 
mandatory.
6.2.1. Guidance for Blood 
pressure Monitoring on 
Intranasal Treatment 
Session Days Updated the text in the section “Guidance for Blood Pressure Monitoring on Intranasal 
Treatment Session Days” to indicate that:
If at any postdose time point on the dosing day the SBP is ≥200 mmHg 
and/or the DBP is ≥[ADDRESS_508617] “must ” discontinue from further 
dosing (rather than ‘should’ discontinue), and the subject should be referred 
to a cardiologist, “other specialist”, or primary care physician for a follow -up
assessment..
Rationale: Clarifications for the use of prestudy and concomitant therapi[INVESTIGATOR_014].
4.3. Prohibitions and 
Restrictions ;8. Prestudy 
and Concomitant 
Therapy;Clarification of the following:
Concom itant Therapy
Antidepressant treatments which are not listed on the MGH -ATRQ, but were used, or 
are currently being used, as antidepressant treatments in the current depressive epi[INVESTIGATOR_403363] ‘Concomitant Therapy ’ eCRF .
Concomitant therapi[INVESTIGATOR_403364].
If a subject routinely takes his/her oral antihypertensive medications in the morning, 
on dosing days, the morning dose should be taken prior to intranasal dosing.
Subjects receiving psychotherapy (includin g cognitive behavioral therapy, CBT) can 
continue receiving psychotherapy; however, CBT must have been ongoing for the last 
3 months prior to the start of the screening/prospective observational phase.
With the exception of new CBT, w hich is prohibited, ne w psychotherapy is allowed 
during the study. Any change in existing therapy or new therapy must be documented 
on the concomitant therapi[INVESTIGATOR_77235].
Rescue Medications
Clarification of text: “Unless clinically indicated” it is recommended that transient 
incre ases in blood pressure not be treated, as the blood pressure “typi[INVESTIGATOR_897]” returns to 
predose values in 2 hours.
Rationale: Clarification of the language regarding subjects who develop treatment emergent ulcerative cystitis to 
indicate the discontinuation of such subjects is mandatory.
3.2.6. Safety Evaluations;
9.7. Safety EvaluationsUpdated/ added the text in these sections describing the BPIC -SS and instructions for 
discontinuing due to ulcerative cystitis, to read as follows,: “If a subject is determi ned 
to have a diagnosis of ulcerative cystitis the subject must be discontinued from the 
study and followed up with appropriate medical care.”
Rationale: Clarification that further clinical/standard of care for the treatment of depression will be perm itted for 
the remainder of the follow -up phase
Synopsis, Overview of 
Study Design;
3.1. Overview  of Study 
Design;
3.2.2. Study Phases;
6.3. Follow -up Phase;
9.1.4. Follow -up PhaseFurther clinical/standard of care for the treatment of depression will be arranged by [CONTACT_403380]/or the subject’s treating physician and medication changes are 
permitted.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3002 Amendment 2
Status: Approved , Date: 3 June 2016 26Applicable Section(s) Description of Change(s)
Rationale: Provide further clarification to site staff requirements for intranasal treatment sessions. 
Synopsis , Dosage and 
Administration ;
6.2. Double -blind 
Induction Phase, 
Intranasal Study DrugThe text now states: On all intranasal treatment session days, a site staff member 
with training in cardiopulmonary resuscitation (eg, Basic Life Support course or 
equivalent courses) that is up to date per local regulations must be present with the 
subject during the intranasal treatment sessions and the postdose observation 
period. 
Rationale: Inclusion of tests for measuring free thyroxine (FT4) and for determining rates of creatinine clearance
9.7. Safety Evaluations Inclusion of the following tests at time points specified in the Time & Events 
Schedule:
Free thyroxine (FT4), if applicable
Calculation of creatinine clearance
Rationale: Changes to Attachment 1, including the table listing of Prohibited Concomitant Medications:
Attachment 1 Inclusion of the following statement proceeding the table listing prohibited 
medications: “Note: If a medication is part of the antidepressant treatment regimen 
being taken at the time of signing the ICF (i.e., start of screening/prospective 
observational phase), itmust be continued unchanged until the end of Week 4 of the 
screening/prospective observational phase, therefore this requirement is not applicable. 
In such cases the investigator may choose to taper the relevant medication during the 
3-week taper period b ased on their clinical judgment”.
-Deletion of row referring to CYP3A4 inhibitors as prohibited concomitant 
medication.
-Additional example of anorexiants (eg, phendimetrazine) that are prohibited as 
concomitant medication for reasons of safety.
-An addition al example of anticonvulsants (eg, pregabalin) that are permitted as 
concomitant medication when used for indications other that seizures was added.
-Methylphenidate, modafinil, and armodafinil, were added as additional examples 
of prohibited psychostimulan ts. 
-A new row  was added for prohibited non -stimulant ADHD medications (eg, 
.atomoxetine, guanfacine).
-Addition of new text to comments on the use of antidepressants in this study, 
stating that ”Even if used primarily for sleep, trazodone use is not permitted 
during the treatment phase”.
-Deletion of text in comments on the use of Non -benzodiazepi[INVESTIGATOR_154819].
-Clarification that benzodiazepi[INVESTIGATOR_403365] 6mg/day of lorazepam.
-Additi on of new text to comments on the use of Cough/cold preparations/nasal 
solutions containing vasoconstrictors, decongestants “pseudoephedrine –
containing products should not be used w ithin 12 hours prior to an intranasal 
treatment session”. This is for rea sons of safety and due to potential PD 
interactions.
-Added row  for non -vitamin K antagonist oral anticoagulant agents (eg, 
dabigatran, rivaroxaban, api[INVESTIGATOR_3822]).
-Deletion of text in comments on the use of thyroid hormone supplements
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3002 Amendment 2
Status: Approved , Date: 3 June 2016 27Applicable Section(s) Description of Change(s)
Rationale: Clarification of procedures that need to be followed with respect sample collection and handling, on 
withdrawal of a subject from the study.
10.2. Withdraw al from the 
StudyAddition of new text specifying that:
When a subject w ithdraws before completing the study, the reason for 
withdrawal must be documented in the CRF and in the source document.
Subjects who withdraw  will not be replaced.
If a subject w ithdraws before the end of the double- blind induction phase, an 
Early Withdrawal visit is to be performed. .
Deletion of the following text:
Study drug assigned to the withdrawn subject may not be assigned to another 
subject.
Rationale: Update and clarification to prohibited medications and substances and restrictions during the double -
blind induction phase.
Synopsis, Overview of 
Study Design,
Double -Blind Induction 
Phase;
3.1. Overview  Study 
Design;
4.3. Prohibitions and 
RestrictionsRestrictions on the use of benzodiazepi[INVESTIGATOR_154821] -blind induction phase:
-Subjects who were taking benzodiazepi[INVESTIGATOR_1651] “(at dosages equal to or less than 
the equivalent of 6 mg/day of lorazepam)” and/or perm itted non-
benzodiazepi[INVESTIGATOR_154822] (eg, zolpi[INVESTIGATOR_6730], zaleplon) “during the 
screening/prospective observational phase” can continue these medications 
during the induction phase. 
-No dose increases “beyond the equivalent of 6 mg/day of lorazepam” or new 
benzodiazepi[INVESTIGATOR_154823], with 
the exception of the use of permitted benzodiazepi[INVESTIGATOR_154824].
-Benzodiazepi[INVESTIGATOR_92650]-benzodiazepi[INVESTIGATOR_154825] (eg, zolpi[INVESTIGATOR_6730], 
zaleplon, eszopi[INVESTIGATOR_11123], and ramelteon) are prohibited within 12 hours prior to 
the start of each intranasal treatment session or cognition testing.
Removal of the following restriction: ‘Subjects should not ingest grapefruit juice, 
Seville oranges, or quinine for 24 hours before an intranasal dose of study medication 
is to be administered.
An additional criterion has been added: A positive urine drug test for “lys ergic acid 
diethylamide (LSD)” from Day 1 through to the final visit in the double- blind 
induction phase will lead to discontinuation.
Rationale: Provide clarification that all medication(s) being used for depression must be discontinued after 
completion of the 4 -week prospective observational phase
Synopsis, Dosage and 
AdministrationText w as clarified to indicate that “all medication(s) being used for depression” w ill be 
discontinued for subjects eligible to enter the double -blind induction phase.
Rationale: A diary has been added to record oral antidepressant use.  
Time & Events Schedule;
Synopsis, Dosage and 
Administration;
6.2. Double -Blind 
Induction Phase;
7. Treatment Compliance;
15. Study -Specific 
MaterialsText added to indicate that a diary will be provided for subjects to keep a record of 
oral antidepressant study medication use, to be review ed and updated (if applicable), 
and returned at the end of the double- blind induction phase, in the event of an early 
withdrawal, or at the end of the f ollow -up phase.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3002 Amendment 2
Status: Approved , Date: 3 June 2016 28Applicable Section(s) Description of Change(s)
Rationale: Drug accountability (oral antidepressant) , to be performed on visit 3.7 of the Follow -up Phase
Time & Event Schedule Drug accountability for oral study medication is to be performed on visit 3.7 (Week [ADDRESS_508618] intranasal dose) of the Follow -up Phase.
Footnote ‘e)’, which is applicable to this assessment was added:
e) For any remaining oral antidepressant study medication.
Rationale: Indicate that there is a required order of administration for intranasal devices.
6.2. Double -blind 
Induction Phase, Table 2A footnote ‘c)’ added, w hich states that ‘The 3 intranasal devices for each intranasal 
treatment session should be administered in the medication kit order provided by [CONTACT_129212].”
Rationale: Update list of study -specific materials
15. Study -Specific 
MaterialsGuidance document for the use of the MGH -ATRQ and subject diary have been 
added.
Rationale: Clarification of criteria for w ithdrawal of consent.
10.2. Withdraw al from the 
StudyFor clarification the following additions to the text were made:
Withdrawal of consent :
Should only be selected as a reason for withdraw al if the subject does not agree to any 
further study assessments or procedures. If the subject is agreeable to participating in 
the Early Wi thdraw al visit and the follow -up phase, another reason for withdraw al 
should be selected.
If the subject w ithdraws from the study before the end of the double -blind induction 
phase, an Early Withdr awal visit is to be performed. 
If the subject is lost to follow -up, every reasonable effort must be made by [CONTACT_403381]/withdrawal. This should include at least [ADDRESS_508619] 
numbers (eg, home, work, and mobile numbers), as well as other contact [CONTACT_3031] 
(eg, email addresses) from subjects before randomi zation. In addition, the study site 
should emphasize the importance of follow -up information to the subject before 
randomization. The measures taken to follow  up must be documented.
Subjects who withdraw  will not be replaced.
Every effort will be made in the study to ensure withdrawal of consent is not selected 
as a reason for discontinuation when in fact the subject w ithdrew  for an identifiable 
reason (e.g due to an adverse event or withdrew  due to lack of efficacy).
Subjects who wish to withdraw from the study should be asked if they are agreeable to 
be contact[CONTACT_107810] -up information. Subjects who are not agreeable to follow -up 
contact [CONTACT_154911] “withdrawal of consent.” Subjects who no 
longer wish to take study drug but agree to provide follow -up information will be 
withdrawn from the study with the reason noted as “Other” and will specify the reason 
why.For a subject who “withdraw sconsent ”, it is recommended that the subject 
withdraw consent in writing; if the subject refus es or is physically unavailable, the 
study site should document and sign the reason for the subject’s failure to w ithdraw 
consent in writing and maintain it with the subjects source records.
-The investigator will be responsible for making all required noti fications to 
the Institutional Review Board (IRB) or Independent Ethics Committee 
(IEC).
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3002 Amendment 2
Status: Approved , Date: 3 June 2016 29Applicable Section(s) Description of Change(s)
Rationale: Clarification of study site personnel availability for on -site monitoring visits.
17.8. Monitoring Revision of text, which now states that;
‘It is expected that study -site personnel will be available to provide an update on the 
progress of the study at the study site’
Rationale: Clarification of the content of electronic case report form(s) (eCRF)
17.11. Use of Information 
and PublicationIt is now stipulated that the Clinical Study Report generated by [CONTACT_456] w ill 
contain eCRF data from all study sites that participated in the study and w ill represent 
uploaded data transferred from external service providers into the sponsor’s database.
Rationale: Clarification of procedures for correcting data entries in the eCRF
17.5. Case Report Form 
Com pletionClarification that: “All data relating to the study must be recorded in CRF. All CRF 
entries, corrections, and alterations must be made by [CONTACT_170191] -site personnel. The investigator must verify that all data entries in the CRF are 
accurate and correct ”.
If corrections to an eCRF are needed after the initial entry into the eCRF, this can be 
done in either of the followi ng w ays:
Investigator and study site personnel can make corrections in the eDC tool at 
their own initiative or as a response to an auto query (generated by [CONTACT_154914]).
Sponsor or sponsor delegate can generate a query for resolution by [CONTACT_154915] -site personnel.
Deletion of the following text: ‘Clinical data manager can generate a query for 
resolution by [CONTACT_3991]’.
Rationale: Include published data 
[IP_ADDRESS]. Safety and 
Tolerability, Adverse 
events associated w ith 
short -term use of 
intranasal esketamine in 
patients with MDDSummary introduction paragraph: Additional text added to include published data 
relating summarize to adverse events associated w ith short -term use of intranasal 
esketamine in patients with MDD.
Rationale: Minor errors and clarification were noted .
Throughout the protocol Grammatical, formatting, or spelling changes were made.
10.3. Withdraw al from the 
use of Samples in Future 
ResearchNew  section 10.3. designated.
Attachment 3 Global titration schedule: list of countries that are exempt (ie, Japan, Taiw an, South 
Korea, and Malaysia) is no longer applicable.
Time & Events Schedule Changes to the text:
Study Drug: distinguish betw een study visits during the double- blind 
induction phase in which the subject diary is to be dispensed, review ed, and 
returned to the subject. 
Cognition tests: clarification that the “practice sessions for computerized test 
battery” are distinct from the actual sessions in which the “Computerized test 
battery and the HVLT -R” recall cognition tests are performed.
Added foonote “r” to Visit 2.1 C-SSRS (Since Last Visit) assessment to 
indicate this is only performed for subjects who do not have Visit 1.3 and 2.1 
occur on the same day.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3002 Amendment 2
Status: Approved , Date: 3 June 2016 30Applicable Section(s) Description of Change(s)
Synopsis, Oral 
Antidepressant Study 
Medication ; 3.2.4. 
Treatment Groups and 
Dose Selection; 6.2. 
Double -blind Induction 
PhaseText added to clarify that:
The subjects maximum tolerated dose of oral an tidepressant, should not be low er than 
the minimum therapeutic dose “at the end of the induction phase”
9.3. Pharmacokinetics The follow ing text was added:
“Whole blood samples will be used to evaluate the PK of esketamine. Serum collected 
for PK may additionally be used to evaluate safety or efficacy aspects that address 
concerns arising during or after the study period. Genetic analyses will not be 
performed on these serum samples. Subject confidentiality will be maintained. ”
[IP_ADDRESS] Primary Efficacy 
EvaluationText w as added to indicate that the MADRS will be administered using t he structured 
interview guide for the MADRS (SIGMA) .
[IP_ADDRESS]. Primary Efficacy
Evaluation“(interest level)” was added after the MADRS item description of “inability to feel ” to 
describe w hat this item will be assessing .
Synopsis, Primary and 
Key Secondary Efficacy 
Analyses;
11.4. Efficacy AnalysesThe third key secondary efficacy endpoint, change from baseline in SDS total score at 
Week 4 in the double -blind -induction -phase, will be analyzed using the same models 
described for the MADRS total score, and not using the AN COVA, as originally 
stated.
9.7. Safety Evaluations Administrative error corrected to lipid panel w hich previously listed lowdensity 
lipoprotein ( LDL)-cholesterol tw ice. Text was updated to clarify it includes low 
density lipoprotein (LDL) and high density lipoprotein (HDL) -cholester ol. 
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3002 Amendment 2
Status: Approved , Date: 3 June 2016 31SYNOPSIS
A Randomized, Double -blind, Multicenter, Active -controlled Study to Evaluate the Efficacy, Safety, 
and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult 
Subjects with Treatment -resistant Depression
Study Acronym: TRANSFORM -2
Major depressive disorder (MDD) ,a serious, recurrent, and disabling psychiatric illness ,is the second 
leading cause of years lost to disability worldwide . MDD is associated with excess mortality, and with 
years of potential life lost. About 30% of patients fail to achieve remission despi[INVESTIGATOR_154826], and are considered to have treatment -resistant depression (TRD). There is a 
significant need to develop novel treatments based upon relevant pathophysiologic pathways underlying 
MDD for the rapid relief of symptoms of depression, especially in patients with TRD.
Ketamine and esketamine (S-ketamine, the Senantiomer of ketamine) are approved and widely used for 
the induction and maintenance of anesthesia via intramuscular (IM) or intravenous (IV) administration. 
The desired analgesic -anesthetic effects of ketamine and esketamine are attributed to the blockade of 
ionotropic N -methyl -D-aspartate (NMDA) glutamate receptors. The mechanism of action of ketamine and 
esketamine is distinct from conventional monoaminergic antidepressant treatments and ketamine 
profoundly affects fast excitatory glutamate transmission, increases brain -derived neurotrophic factor 
(BDNF) release, and stimulates synaptogenesis.
Janssen Research & Development (JRD) is developi[INVESTIGATOR_154827] .A higher NMDA receptor affinity of esketamine allows a lower volume of medication to be 
administered via the non- invasive, rapi[INVESTIGATOR_154828].
The current study is being conducted to evaluate the efficacy, safety, and tolerability of flexibly dosed 
intranasal esketamine plus a newly initiated oral antidepressant in adult subjects with TRD. The study 
will serve as a pi[INVESTIGATOR_9205] [ADDRESS_508620] from  
a prior antidepressant treatment (to which they have not responded ) to flexibly dosed intranasal 
esketamine (56 mg or 84mg) plus a newlyinitiated oral antidepressant compared with switching to a 
newlyinitiated oral antidepressant (active comparator) plus intranasal placebo, in improving depressive 
symptoms, as assessed by [CONTACT_154916] -Asberg Depression Rating Scale 
(MADRS )total score from Day 1 (pre- randomization )to the end of the 4-week double -blind induction 
phase.
Key Secondary Objective s
 The key secondary objective s are to assess the effect of intranasal esketamine plus a newly initiated 
oral antidepressant compared with a newly initiated oral antidepressant (active comparator) plus 
intranasal placebo on the following parameters in adult subjects with TRD :
 Onset of clinical response by [CONTACT_2006] 2
 Function ingand associated disability
 Depressive symptoms (subject -reported)
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3002 Amendment 2
Status: Approved , Date: 3 June 2016 32Other Secondary Objectives
 To assess the effect of intranasal esketamine plus a newly initiated oral antidepressant compared 
with a newly initiated oral antidepressant (active comparator) plus intranasal placebo onthe 
following parameters in adult subjects with TRD :
 Depression response rates
 Depression remission rates
 Overall severity of depressive illness
 Anxiety symptoms
 Health- related quality of life and health status
 To investigate the safety and tolerability of intranasal esketamine plus a newly initiated oral 
antidepressan t compared with a newly initiated oral antidepressant (active comparator) plus 
intranasal placebo in adult subjects with TRD, including the following :
 Treatment -emergent adverse events (TEAEs) , including AEs of special interest
 Local nasal tolerability
 Effects on heart rate, blood pressure, respi[INVESTIGATOR_697], and blood oxygen saturation
 Effects on alertness and sedation
 Potential psychosis -like effects
 Dissociative symptoms 
 Potential e ffects on cognitive function
 Potential e ffects on suicidal ideation/behav ior
 Potential t reatment -emergent symptoms of cystitis and/or lower urinary tract symptoms
 Potential withdrawal and/or rebound symptoms following cessation of intranasal esketamine 
treatment
 Potential e ffects on sense of smell
 To assess the pharmacokinetic s(PK) of intranasal esketamine in adult subjects with TRD receiving 
intranasal esketamine plus a newl y-initiated oral antidepressant
Exploratory Objectives
 To assess the PK/pharmacodynamic (PK/PD) relationship of intranasal esketamine and MADRS 
total score in adult subjects with TRD
 To assess the potential relationship of biomarkers with response/non -response to intranasal 
esketamine or oral antidepressants in adult subjects with TRD
 To assess medical resource utilizatio n
Hypothesis
The hypothesis for this study is that,in adult subjects with TRD ,switching from a failed antidepressant 
treatment to intranasal esketamine plus a newly initiated oral antidepressant is superior toswitching toa
newly initiated oral antidepressant treatment (active comparator) plus intranasal placebo in improving 
depressive symptoms.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3002 Amendment 2
Status: Approved , Date: [ADDRESS_508621] to assess the efficacy, safety, and tolerability of flexibly dosed intranasal esketamine (56 mg or 
84mg) plus a newly initiated oral antidepressant compared with a newly initiated oral antidepressant 
(active comparator) plus intranasal placebo. 
The study has3 phases which are briefly described below .
Screening/prospective observational phase (4-week duration + optional 3 -week taper period )
This phase will prospectively assess treatment response to the subject’s current oral antidepressant 
treatment regimen.
At the start of the screening/prospective ob servational phase, the subject must have had documented non -
response to at least 1 antidepressant treatment (based on MGH -ATRQ criteria) in the current epi[INVESTIGATOR_154807], and the subject is taking a different oral antidepressant treatment (on the MGH -ATRQ ) for at 
least the previous 2 weeks at or above the minimum therapeutic dose. This antidepressant treatment, as 
well as any other ongoing medications being taken for depression at screening (including 
adjunctive/augmentation therapi[INVESTIGATOR_014]), will contin ue from the start of Week 1 through the end of Week 4 of 
the screening/prospective observational phase. Dose adjustment is permitted per clinical judgment, but the 
oral antidepressant treatment is to remain at or abov e the minimum therapeutic dose (per theMGH -
ATRQ) through the end of Week 4.
After 4 weeks , subjects who are non-responders to the current oral antidepressant treatment may be 
eligible to proceed to the double -blind induction phase . Non-response at the end of the 
screening/prospective observati onal phase is defined as ≤ 25% improvement in the MADRS total score 
from Week 1 to Week 4 and a MADRS total score of ≥ 28 on Week 2 and Week 4 .
Eligible subjects who are entering the double -blind induction phase will discontinue all of their current 
medication(s) being used for depression treatment, including adjunctive/augmentation therapi[INVESTIGATOR_014] . Of note, 
subjects taking benzodiazepi[INVESTIGATOR_1651] (at dosages equal to or less than the equivalent of 6mg/day of 
lorazepam ) and/or permitted non-benzodiazepi[INVESTIGATOR_154822] (eg, zolpi[INVESTIGATOR_6730], zaleplon) during the 
screening/prospective observational phase, can continue these medications, but no dose increases beyond 
the equivalent of 6 mg/day of lorazepam or new benzodiazepi[INVESTIGATOR_403366]/prospective observational phase . If clinically indicated, asubject’s current antidepressant 
treatment s)may be tapered and d iscontinued over an additional, optional period of up to 3 weeks per the 
local prescribing information or clinical judgment.
Asa new oral antidepressant will be initiated on Day 1 of the double -blind induction phase, eligible 
subjects who do not require a tapered discontinuation of their antidepressant treatment (s) can proceed 
immediately into the double -blind induction phase .
Double -blind induction phase (4-week duration )
Approximately 196 subjects will be randomly assigned at a 1:1 ratio (n=98 per treatment arm) to receive 
double -blind treatment with either intranasal esketamine or intranasal placebo. The intranasal treatment 
sessions (esketamine or placebo) will occur twice weekly. In addition, all subjects will initiate anew
open -label oral antidepressant on Day 1 that will be taken daily for the duration of this phase. The 
assigned oral antidepressant will be 1 of 4 oral antidepressant medications (duloxetine, escitalopram, 
sertraline, or venlafaxine extended release [XR]) , that the subject has not previously had a non-response 
to in the current depressive epi[INVESTIGATOR_1865], has not been previously intolerant to (lifetime), and is avai lable in the 
participating country.
Subjects who were taking benzodiazepi[INVESTIGATOR_1651] (at dosages equal to or less than the equivalent of 6 mg/day of 
lorazepam) and/or permitted non-benzodiazepi[INVESTIGATOR_154822] (eg, zolpi[INVESTIGATOR_6730], zaleplon) during the 
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3002 Amendment 2
Status: Approved , Date: 3 June 2016 34screening/pros pective observational phase can continue these medications during the induction phase. No 
dose increases beyond the equivalent of 6 mg/day of lorazepam or new benzodiazepi[INVESTIGATOR_403367], with the exception of the use of permitted benzodiazepi[INVESTIGATOR_154830].
At the end of the induction phase, subjects who are responders (defined as ≥50% reduction in the ≥total 
score from baseline [Day 1 pre-randomization] to the end of the 4-week double -blind induction phase) 
may be eligible to participate in the subsequent study ESKETINTRD3003 if they meet all other study 
entry criteria (ESKETINTRD3003 is alonger -term efficacy maintenance study involving repeate d 
treatment sessions of intranasal esketamine) .
If a subject withdraws from the study before the end of the double -blind induction phase for reasons other 
than withdrawal of consent, an Early Withdrawal visit should be conducted within 1 week of the date of 
discontinuation, followed by [CONTACT_6591] -up phase.
Follow -up pha se (24-week duration )
This phase will include all subjects who are not eligible or who choose to not participate in the 
maintenance of effect study ESKETINTRD3003 and have receive dat least 1 dose of intranasal study 
medication in the double -blind inductio n phase. There will be no intranasal treatment sessions 
administered during this phase.
At the start of the follow -up phase, further clinical/standard of care for the treatment of depression will be 
arranged by [CONTACT_63789]/or the subject’s treating physician, and changes to medication 
treatment are permitted. The decision to continue the oral antidepressant in this phase will be at the 
discretion of the investigator, however, in order to better assess potential withdrawal symptoms from 
intranasal study medication ,the oral antidepressant medication should be con tinued for at least the first 
2weeks of the follow -up phase unless determined as not clinically appropriate.
The follow -up phase will also allow collection of additional informative data to assess the course of the 
subject’s major depressive epi[INVESTIGATOR_81633] a 6- month period.
An open -label safety extension study, 54135419TRD3008, may be available (pending country and site 
approval) for eligible subjects participating in the ESKETINTRD3002 study. Please refer to the 
54135419TRD3008 protocol for full details when available.
Taking into consideration the optional taper period of up to [ADDRESS_508622]’s 
study participation in the current study will be 11 weeks (for subjects continuing into 
ESKETINTRD3003) or 35 weeks (for subjects completing the follow -up phase).
An Independent Data Monitoring Committee (IDMC) will be commissioned for this study.
STUDY POPULATION
The study population will include adult men and women, 18 (or older if the minimum legal age of consent 
in the country in which the study is taking place is >18) to 64 years of age (inclusive), who meet the 
Diagnostic and Statistical Manual of Mental Disorders (5th Edition; DSM -5)diagnostic criteria for 
single -epi[INVESTIGATOR_154831] (if single -epi[INVESTIGATOR_154831], the duration of the epi[INVESTIGATOR_154832] 2years) or recurrent 
MDD without psychotic features, based upon clinical assessment, and confirmed by [CONTACT_154917] -International Neuropsychiatric Interview (MINI ).In addition, th e subject must have an Inventory of 
Depressive Symptomatology- Clinician rated, 30-item (IDS-C30) total score of 34, which corresponds to 
moderate to severe depression.
At the start of the screening/prospective observational phase, subjects must have had non-response (ie, 
lack of clinically meaningful improvement, defined as ≤25% improvement) to 1but ≤5(if current 
epi[INVESTIGATOR_154806] >[ADDRESS_508623] 2 years) oral antidepressant treatment staken 
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3002 Amendment 2
Status: Approved , Date: 3 June 2016 35at adequate dosage and for adequate duration, as assessed using the [LOCATION_005] General Hospi[INVESTIGATOR_307] –
Antidepressant Treatment Response Questionnaire (MGH -ATRQ) and documented by [CONTACT_154918] (eg, 
medical /pharmacy/prescription records or a letter from treating physician, etc. ), for the current epi[INVESTIGATOR_154807]. In addition , the subject must currently be taking a different oral antidepressant treatment (on 
the MGH -ATRQ) for at least the previous 2 weeks at or above the minimum therapeutic dose.This 
antidepressant treatment, as well as any other medications being used for depression treatment (including 
adjunctive/augmentation therapi[INVESTIGATOR_014]), will continue from the start of Week 1 through the end of Week 4 of 
the screening/prospective observational phase. Dose adjustment is permitted per clinical judgment, but the 
oral antidepressant treatment is toremain at or abov e the minimum therapeutic dose (per the MGH -
ATRQ) through the end of Week 4.
Non-response at the end of the screening/prospective observational phase is defined as ≤ 25% 
improvement from Week 1 to Week 4 in the MADRS total score and a MADRS total score of≥ [ADDRESS_508624]’s current major depressive epi[INVESTIGATOR_1865] , depression symptom severity (Week 1MADRS total 
score ≥28 required), and antidepressant treatment response in theircurrent depressive epi[INVESTIGATOR_1865] 
(retrospectively assessed) must be deemed valid for participation in the clinical study based on a Site-
Independent Qualification Assessment. The Site Independent Qualification Assessment is a tool to 
facilitate subject selection for MDD clinical studies, with a goal to ensure enrollment of subjects who 
have symptoms that reflect the current state of illness and that these symptoms can be reliably measured 
with a ppropriate measurement tools .
Potential subjects will be excluded from participating in the study if they have previously demonstrated 
non-response of depressive symptoms to esketamine or ketamine in the current major depressive epi[INVESTIGATOR_1865] ,
or to all 4 of the oral antidepressant treatment options available for the double -blind induction phase 
(ie,duloxetine, escitalopram, sertraline, and venlafaxine XR) in the current major depressive epi[INVESTIGATOR_1865] 
(based on MGH -ATRQ) ,or an adequate course of treatment with electroconvulsive therapy (ECT) in the 
current major depressive epi[INVESTIGATOR_1865], defined as at least 7 treatments with unilateral / bilateral ECT. Subjects,
who in the current depressive epi[INVESTIGATOR_154833] (VNS) or who have received 
deep brain stimulation (DBS) ,in the current depressive epi[INVESTIGATOR_403368]. Subjects will also be 
excluded if they have a current or prior DSM- 5 diagnosis of a psychotic disorder or MDD with psychotic 
features , bipolar or related disorders (confirmed by [CONTACT_42145]), obsessive compulsive disorder (current 
only) , intellectual disability (DSM -5 diagnostic codes 317, 318.0, 318.1, 318.2, 315.8, and319), autism  
spectrum disorder, borderline personality disorder, antisocial personality disorder, histrionic personality 
disorder, or narcissistic personality disorder; ifthey have homicidal ideation/intent or suicidal ideation 
with some intent to act within 6 months prior to the start of the screening/prospective observational phase
per the investigator’s clinical judgment and/or based on the Columbia Suicide Severity Rating Scale 
(C-SSRS) ; or if they have a history of moderate or severe substance or alcohol use disorder according to 
DSM -5 criteria.
DOSAGE AND ADMINISTRATION
Screening/ prospective observational phase
At the start of the screening/prospective observational phase, the subject must have had documented non -
response to at least 1 antidepressant treatment (based on MGH -ATRQ criteria) in the current epi[INVESTIGATOR_154807], and the subject istaking a different oral antidepressant treatment (on the MGH -ATRQ ) for at 
least the previous 2 weeks at or above the minimum therapeutic dose. This antidepressant treatment, as 
well as any other ongoing medications being taken for depression at screening (including 
adjunctive/augmentation therapi[INVESTIGATOR_014]), will continue from the start of Week 1 through the end of Week 4 of 
the screening/prospective observational phase for prospective observation of response or non-response.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3002 Amendment 2
Status: Approved , Date: 3 June 2016 36Dose adjustment is permitted per clinical judgment, but the oral antidepressant treatment is to remain at or 
above the minimum therapeutic dose (per the MGH -ATRQ) through the end of Week 4.The sponsor will 
not supply these antidepressant medication s. Antidepressant treatment adherence during this phase will be 
assessed using the Patient Adherence Questionnaire (PAQ).
Eligible subjects who are enter ingthe double -blind induction phase ,after completion of 4weeks of 
prospective antidepressant treatment and assessment of the antidepressant treatment response, will 
discontinue all of their current medication(s) being used for depression treatment , including 
adjunctive/augmentation therapi[INVESTIGATOR_014]. Subjects taking benzodiazepi[INVESTIGATOR_1651] (at dosages equal to or less than the 
equivalent of 6 mg/day of lorazepam) and/or permitted non-benzodiazepi[INVESTIGATOR_154822] (eg, 
zolpi[INVESTIGATOR_6730], zaleplon) during the screening/prospective observational phase can continue these medications, 
but no dose increases beyond the equivalent of 6 mg/day of lorazepam or new benzodiazepi[INVESTIGATOR_403369]/prospective observational phase .If clinica lly indicated (eg, antidepressant
treatme nts with short half-lives, such as paroxetine and venlafaxine XR; or tolerability concerns ), the 
antidepressant medication (s)may be tapered off and discontinued over a period of up to 3weeks per the 
local prescribing information or clinical judgment .
As a new oral antidepressant will be initiated on Day 1 of the double -blind induction phase, eligible 
subjects who do not require a tapered discontinuation of their antidepressant treatment (s) can proceed 
imme diately into the double -blind induction phase .
Double -blind induction p hase
During this phase, subjects will be randomized to receive double -blind intranasal treatment with 
esketamine or placebo . In addition, subjects will simultaneously initiate a new, open -label oral 
antidepressant on Day 1 that will be continued for the duration of this phase.
Intranasal Study Medication
All subjects will self-administer the intranasal study drug (esketamine or placebo) at treatment sessions 
twice a week for [ADDRESS_508625] intranasal dose on Day 1, subjects will practice spraying (into the air, not intranasally) a 
demons tration intranasal device that is filled with placebo solution.
On Day 1, subjects randomized to intranasal esketamine will start with a dose of 56 mg. On Day 4, the 
dose may be increased to 84 mg or remain at 56 mg, as determined by [CONTACT_403382]. On Day 8, the dose may be increased to 84 mg (if Day 4dose was 56 mg), remain the 
same, or be reduced to 56 mg (if Day 4dose was 84 mg), as determined by [CONTACT_403383]. On Day 11, the dose may be increased to 84 mg (if Day 8 dose was 56 mg), 
remain the same, or be reduced to 56 mg (if Day 8 dose was 84 mg), as determined by [CONTACT_403384]. On Day 15, a dose reduction from 84 mg to 56 mg is permitted, if 
required for tolerability; no dose increase is permitted on Day 15. After Day 15, the dose must remain 
stable (unchanged). If there is no intranasal treatment session on Day 15 (eg, visit is missed), a dose 
reduction from 84 mg to 56 mg is permitted on Day 18 if required for tolerability; no dose increase is 
permitted.
On all intranasal treatment session days, a site staff member with training in cardiopulmonary 
resuscitation (eg, Basic Life Support course or equivalent course) that is up to date per local regulations ,
must be present with the subject during the intranasal treatment session sand the postdose observation 
period. In addition, equipment for supportive ventilation and resuscitation needs to be present. Subjects 
must remain at the site until s tudy procedures have been completed and the subject is ready for discharge . 
At the time of discharge, subjects should be accompanied by a responsible adult when released from the 
clinical site. Subjects must not drive a car or work with machines for 24hours after receiving intranasal 
study drug.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3002 Amendment 2
Status: Approved , Date: 3 June 2016 37Oral Antidepressant Study Medication
Starting on Day 1, a new, open -label oral antidepressant treatment will be initiated in all subjects. The 
oral antidepressant will be 1 of 4 oral antidepressant medications (duloxetine, escitalopram, sertraline, or 
venlafaxine XR). The antidepressant medic ation will be assigned by [CONTACT_154920] -ATRQ and relevant prior antidepressant medication information , and will be one that the subject 
has not previously had a non-response to in the current depressive epi[INVESTIGATOR_1865], has not been previ ously 
intolerant to (lifetime), and is available in the participating country.
Dosing of the oral antidepressant will begin on Day 1and will follow a protocol specific titration 
schedule (Attachment 3 of protocol) .The use of thetitration schedule provided in the protocol is 
mandatory . Doses are not to exceed the maximum dose defined in the titration schedule .If higher doses 
are not tolerated, a down -titration is permitted based on clinical judgment. However, the subject’s dose 
should not be lower than the follo wing minimum therapeutic doses at the end of the induction phase : 
Sertraline (50 mg/day), venlafaxine XR (150 mg/day), escitalopram (10mg/day), and duloxetine 
(60mg/day). While subjects requiring lower doses can continue in the study and complete the double -
blind induction phase, such subjects will not be eligible to participate in the maintenance of effect study 
ESKETINTRD3003 and will proceed to the follow -up phase after completion of the induction phase .
All subjects will be provided with an additional 4-week supply of the oral antidepressant medication to 
ensure that there is no interruption of oral antidepressant therapy during the transition to 
ESKETINTRD3003 or to further clinical/standard of care in the follow -up phase.
Study -site personnel will instruct subjects on how to store and take the oral antidepressant treatment
supplied during this study for at -home use. A subject diary w ill be provided to capture oral antidepressant 
study medication use.
On intranasal dosing days, it is recommended that the oral antidepressant not be taken until at least 3 
hours after the intranasal treatment session .
Follow -up phase
At the start of the f ollow -up phase, further clinical/standard of care for the treatment of depression will be 
arranged by [CONTACT_63789]/or the subject’s treating physician and medication changes are 
permitted.
No intranasal study medication will be administered during this phase.
The decision to continue the oral antidepressant medication in this phase will be at the discretion of the 
investigator, however, in order to better assess potential withdrawal symptoms from intranasal study  
medication, it is recommended that the oral antidepressant medication should be continued for at least the 
first 2 weeks of the follow -up phase unless determined as not clinically appropriate.
EFFICACY EVALUATIONS/ENDPOINTS
Primary Efficacy Evaluation and Endpoint
The primary efficacy evaluation will be the MADRS total score. The MADRS will be performed by 
[CONTACT_154921]. The MADRS is a clinician- rated scale designed to measure 
depression severity and detects changes due to antidepre ssant treatment.
The primary efficacy endpoint will be change from baseline in MADRS total score from Day 1 
pre-randomization to the end of the 4- week double -blind induction phase.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3002 Amendment 2
Status: Approved , Date: 3 June 2016 38Key Secondary Efficacy Evaluation sand Endpoints
1. MADRS: The first key secondary endpoint is the onset of clinical response by [CONTACT_2006] 2 that is 
maintained for the duration of the double -blind induction phase (≥50% improvement in MADRS 
total score by [CONTACT_154922] [ie,Day 2] of double- blind intranasal medication that 
continued through the end of the 4-week double -blind induction phase with one excursion allowed ).
Subjects who discontinue the study prior to end of the double -blind induction phase will not be 
considered to have maintained clinical response.
2. Sheehan Disability Scale (SDS): The SDS is a subject -report ed outcome measure that will be used to 
assess functional impairment and associated disability. The second key secondary endpoint is the 
change in SDS total score as measured by [CONTACT_7159] (Day 1 prior to randomization) 
to the end of the 4- week double -blind induction phase.
3. Patient Health Questionnaire 9-item (PHQ -9): The PHQ -[ADDRESS_508626] key secondary endpoint is the change from baseline (Day 1 prior 
to randomization) to the end of the [ADDRESS_508627] -reported 
depressive symptoms, using the PHQ -9 total score.
Other Secondary Efficacy Evaluations and Endpoints
 Proportion of responders (≥50% reduction from baseline in MADRS total score) at the end of the 
4-week double -blind induction phase
 Proportion of subjects in remission (MADRS ≤12) at the end of the 4-week double -blind induction 
phase
 Change from baseline (Day 1 prior to randomization) to the end of the 4-week double -blind 
induction phase in:
 Severity of depressive illness, using the Clinical Global Impression –Severity (CGI -S);
 Anxiety symptoms, using the Generalized Anxiety Disorder (GAD -7), and 
 Health- related quality of life and health status, as assessed by [CONTACT_43433] -5 dimension -5 level
(EQ-5D-5L).
PHARMACOKINETIC EVALUATIONS
Plasma samples will be analyzed to determine concentrations of esketamine (and noresketamine , if 
warranted) using a validated, specific, achiral, and sensitive liquid chromatography -tandem mass 
spectrometry (LC-MS/MS )method by [CONTACT_43754]. Plasma samples may be 
analyzed to document the presence of circulating metabolites using a qualified research method. In 
addition, plasma PK samples may be stored for future analysis of the metab olite profile.
BIOMARKER, PHARMACOGENOMIC (DNA), AND EX PRESSION (RNA) EVALU ATIONS
Assessment of biomarkers and their potential relationship to intranasal esketamine plus a newly initiated
oral antidepressant and to maintenance/stabilization of response, non-response, and relapse will be 
explored. Blood samples will be collected to measure genetic and epi[INVESTIGATOR_27787] (including but not 
limited to BDNF allelic variants) and protein markers (including but not limited to growth factors, 
inflammation, endocri ne, or metabolic markers ). Samples of deoxyribonucleic acid (DNA) and 
biomarker s(protein and RNA) may be used to help address emerging issues and to enable the 
development of safer, more effective, and ultimately individualized therapi[INVESTIGATOR_014].
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3002 Amendment 2
Status: Approved , Date: 3 June 2016 39MEDICAL RESOURCE UTILIZATION
Medical resource utilization data, associated with medical encounters, will be collected using the 
Healthcare Resource Use Questionnaire (HRUQ) during the follow -up phase. The HRUQ includes 
information regarding utilization of healthcare servi ces (including the timing and type of services), 
enabling changes in level and quantity of services to be considered as a variable in economic models.
SAFETY EVALUATIONS
Safety evaluations will include:
 Monitoring of TEAEs , including TEAEs of special interest, clinical laboratory tests (including 
hematology, serum chemistry, and urinalysis ), pregnancy testing (for women of childbearing 
potential ), urine drug screen, 12- lead electrocardiogram , vital signs , pulse oximetry , physical 
examination, and body weight measurements
 Nasal examinations and nasal symptom questionnaire
 Columbia Suicide Severity Rating Scale ( C-SSRS ), to assess potential suicidal ideation and behavior
 Clinician Administered Dissociative States Scale (CADSS ), to assess treatment -emergen t 
dissociative symptoms
 Four -item positive symptom subscale of the Brief Psychiatric Rating Scale (BPRS+ ), to assess 
potential treatment -emergent psychotic symptoms
 Modified Observer’s Assessment of Alertness/Sedation (MOAA/S ), to measure treatment -emergent 
sedation
 Clinical Global Assessment of Discharge Readiness (CGADR ), to document the subject’s current 
clinical status and is the clinician's assessment of the readiness to be discharged from the study site
 Physician Withdrawal Checklist (20 items; PWC- 20) to assess potential withdrawal symptoms 
following cessation of intranasal esketamine treatment
 Bladder Pain/ Interstitial Cystitis Symptom Score (BPIC -SS), to monitor subjects for potential 
symptoms of cystitis, bladder pain, and interstitial cystitis
 Computerized cognitive battery and Hopkins Verbal Learning Test-Revised ( HVLT -R),to assess the 
effect of intranasal esketamine on cognition
 University of Pennsylvania Smell Identification Test (UPSIT )and Smell Threshold Test to assess 
any potential treatme nt-emergent effects on the sense of smell
STATISTICAL METHODS
Subject Information
The primary efficacy and safety analysis sets are defined below:
 Full Analysis Set: All randomized subjects who receive at least 1 dose of intranasal study 
medication and 1 dose of oral antidepressant medication in the double -blind induction phase. 
 Safety Analysis Set: All randomized subjects who receive at least 1 dose of intranasal study 
medication or 1 dose of oral antidepressant medication in the double -blind induction phase.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3002 Amendment 2
Status: Approved , Date: [ADDRESS_508628] deviation of 12, a 1 -sided significance level of 0.025 , and a drop- out rate of 
25%. Atotal of about 98subjects will need to be randomized to each treatment group to achieve 90% 
power for treatment comparison .The treatment difference and standard deviation used in this calculation 
were based on results from Panel A of the ESKETINTRD2003 study and onclinical judgment.
Primary and Key Secondary Efficacy Analyses
With the exception of the European Union (EU) dossier, the primary efficacy  variable, change from 
baseline in MADRS total score at Week 4 in the double -blind induction phase, will be analyzed using 
mixed -effects model for repeated measures (MMRM ). The model will include baseline MADRS total 
score as a covariate, and treatment, country, class of antidepressant (Serotonin and Norepi[INVESTIGATOR_154837] [SNRI] or Selective Serotonin Reuptake Inhibitors [SSRI]) , day, and 
day-by-treatment interaction as fixed effects, and a random subject effect. Comparison of theesketamine 
plus oral antid epressant arm versus oral antidepressant plus intranasal placebo will be performed using the 
appropriate contrast.
For the EU dossier, the primary efficacy analysis will be based on an analysis of covariance (ANCOVA) 
model using last observation carried forward (LOCF) data. The model will include factors for treatment, 
country, and class of oral antidepressant (SNRI or SSRI) and baseline MADRS total score as a covariate. 
Comparison of theesketamine plus oral antidepressant arm versus intranasal placebo plus oral 
antidepressant will be performed using the appropriate contrast.
For the analysis of the first of 3key secondary efficacy endpoints, the proportion of subjects showing 
onset of clinical response (by [CONTACT_2006] 2 that is maintained for the duration of the double -blind induction 
phase )in the esketamine plus oral antidepressant arm will be compared with the oral antidepressant plus 
intranasal placebo arm using a Cochran -Mantel- Haenszel chi-square test adjusting for country and class 
of antidepressant (SNRI or SSRI). Clinical response is defined as 50% improvement in MADRS total 
score by [CONTACT_2006] 2 (ie, the day after taking the first dose of double -blind intranasal medication ) that continues
through the end of the double -blind phase with one excursion allowed . Subjects who discontinue the 
study prior to end of the double -blind induction phase will not be considered to have maintained clinical 
response.
The second and third key secondary efficacy endp oints,change from baseline in SDS total score at Week  
4 and chang e from baseline in PHQ -9 total score at Week 4 (subject to regulatory acceptance of PHQ -9) 
in the double -blind induction phase, will be analyzed using the same models described above for the 
MADRS total score .
A serial gatekeepi[INVESTIGATOR_007] (fixed sequence) approach will be applied to adjust for multip licity and to strongly 
control Type I error across the primary and the 3 key secondary efficacy endpoints (onset of clinical 
response, change in SDS total score , andchange in PHQ -9 total score ). Further details of this approach 
will be provided in the statistical analysis plan (SAP).
Response and remission rates wil l be summarized at each visit.
Change from baseline in GAD -7 total scores and ranks of change from baseline in CGI-S scores at the 
end of the double -blind induction phase will be analyzed based on LOCF data using an ANCOVA model, 
with country and class of antidepressant (SNRI or SSRI) as factors, and the respective baseline score 
(unranked score in the case of CGI -S) as the covariate. 
Dimension scores of the EQ-5D-5L descriptive system, the health status index, and the EQ visual 
analog uescale (EQ-VAS) scores will be summarized over time.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3002 Amendment 2
Status: Approved , Date: [ADDRESS_508629] among relevant subgroups 
(eg, antidepressant class: SNR I and S SRI).
PKAnalyses
Plasma esketamine (and noresketamine , if warranted )concentrations will be listed for all subjects. The 
plasma concentration- time data of esketamine (and noresketamine , if warranted) will be analyzed using  
population PK modeling. Data may be combined with those of other selected studies to support a relevant 
structural model. Typi[INVESTIGATOR_403370]-individual variability. Effects of subject demographics, laboratory parameter values, and other 
covariates on the PKof esketamine will be explored. The results of the population PK analyses may be 
reported separately.
PK/PD Analyses
The relationship between MADRS total score (and possibly selected adverse events as additional PD
parameters) and PKmetrics of esketamine may be evaluated. If there is any visual trend in graphical 
analysis, suitab le models will be applied to describe the exposure -effect relationships. The results of the 
PK/PDanalyses may be reported separately.
Biomarker, Pharmacogenomic (DNA), and Expression (RNA) Analyses
Baseline biomarker values and c hanges from baseline biomarker values to the time points specified in the 
Time and Events Schedule will be summarized. Exploratory biomarker analyses may include comparison 
of biomarker measures between the treatment groups, correlation with efficacy and other measures , and 
relationship with clinical response, relapse, and non -response.
The analysis plan and summarized results from both biomarker and pharmacogenomics analyses will be 
reported separately .
Medical Resource Utilization Analyses
Medical resource utilization data will be descriptively summarized.
Safety Analyses
All safety data will be analyzed separately for the double -blind induction phase and the follow -up phase.
The verbatim terms used in the electronic case report form (eCRF )by [CONTACT_403385] (MedDRA). All reported 
adverse events with onset during the double -blind induction phase (ie, TEAEs , and adverse events that 
have worsened since baseline) will be included in the analysis. For each adverse event, the percentage of 
subjects who experience at least [ADDRESS_508630] will be examined separately groupe d in the following categories: Drug abuse, 
dependence and withdrawal (standardized MedDRA  queries [SMQ]), increased blood pressure, increased 
heart rate, transient dizziness/vertigo , impaired cognition , anxiety ,and cystitis. AEs of special interest 
will be further listed in the SAP.
Subjects who die, who discontinue treatment due to an adverse event, or who experience a severe or a 
serious adverse event will be summarized separately .
Laboratory data will be summarized by [CONTACT_154924]. Reference ranges and markedly abnormal 
results (specified in the SAP) will be used in the summary of laboratory data. Descriptive statistics will be 
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3002 Amendment 2
Status: Approved , Date: 3 June 2016 42calculated for each laboratory analyte at baseline and at each scheduled time point in each phase of the 
study. Changes from baseline results will be presented. Frequency tabulations of the abnormalities will be 
provided. Listings of subjects with laboratory results outside the reference ranges and markedly abnormal 
results will also be provided.
Electrocardiogram (ECG) data will be summarized by [CONTACT_105292] . Descriptive statistics will be 
calculated at baseline and for observed values and changes from baseline at each scheduled time point. 
Frequency tabulations of the abnormalities will be made. The ECG variables that will be analyzed are 
heart rate, PR interval, QRS interval, QT interval, and corrected QT (QTc) interval using the following 
correction methods: QT corrected according to Bazett’ s formula (QTcB) and QT corrected according to 
Fridericia’ s formula (QT cF).
Descriptive statistics of QT c intervals and changes from double -blind baseline will be summarized at each 
scheduled time point. The percentage of subjects with QTc interval >450 msec, >480 msec, or >500 msec
will be summarized as will the percentage of subjects with QTc interval increases from baseline 
<30msec, 30 -60 msec, or >60 msec.
Descriptive statistics of temperature, pulse/heart rate, respi[INVESTIGATOR_697], pulse oximetry, and blood pressure 
(systolic and diastolic) (supi[INVESTIGATOR_050]) values and changes from baseline will be summarized at each scheduled 
time point. The percentage of subjects with values beyond clinically important limits will be summarized.
Changes in findings from the baseline nasal examination (inc luding the upper respi[INVESTIGATOR_4352]/throat) will 
be listed by [CONTACT_1570]. Examinations will provide ratings (absent , mild, moderate, or severe) that 
are based on a visual inspection of the nostrils, nasal mucosa, and throat for nasal erythema, rhinorrh ea, 
rhinitis, capi[INVESTIGATOR_1396]/blood vessel disruption and epi[INVESTIGATOR_3940]. A shift table for changes from double -blind 
baseline in ratings for each examination will be presented by [CONTACT_1570].
Scoring from the nasal symptom questionnaire will be summarized descri ptively for each scheduled time 
point by [CONTACT_1570].
Suicide -related thoughts and behaviors based on the C-SSRS will be summarized by [CONTACT_154925]. Separate endpoints for suicidal ideation and suicidal behavior will bedefined 
and summarized descriptively by [CONTACT_1570].
Descriptive statistics of the CADSS, BPRS+, and MOAA/S scores and changes from predose will be 
summarized at each scheduled time point.
Descriptive statistics of the CGADR , PWC-20, BPIC -SS, UPSIT, and Smell Threshold Test scores and 
changes and/or percent changes from baseline will be summarized at each scheduled time point.
Descriptive statistics of each cognitive domain scoreand changes from baseline will be summarized at 
each scheduled ti me point.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3002 Amendment 2
Status: Approved , Date: 3 June 2016 43TIME A ND EVENTS SCHED ULE (Screening/Prospective Observational Phase and Double -blind Induction Phase)
Screening/ Prospective 
Observational Phase Double -blind Induction Phase
Visit number 1.1 1.2 1.3a2.1a2.2 2.3 2.4 2.5 2.6 2.7 2.8 2.9 2.10 EW b
Week Week 1End of 
Week 2End of 
Week 4 1 2 3 4 —
Study day — — —1
(baseline) 2 4 8 11 15 18 22 25 28 EW
Clinic visit window (in days) — ±2 ±2 — — ±1 ±1 ±1 ±1 ±1 ±1 ±1 ±1 —
Clinic visit ( C) or rem ote MADRS 
interview only (R M) C C C C RM C C C C C C C C C
Screening/Administrative
Informed consent (ICF) X
Medical hi story, psychiatric 
history, demographics , 
employment statusX
MINI X
MGH- ATRQ X
Site Indep endent Qualification 
AssessmentX
Height X
Inclusion/exclusion criteria X X
Prestudy therapy X
Preplanned surgery/procedures X
STOP -Bang q uestionnaire 
(including assessment of BMI 
and neck circumference)X
MGH- FemaleRLHQ: Module I X
IDS-C30 X
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3002 Amendment 2
Status: Approved , Date: 3 June 2016 44Screening/ Prospective 
Observational Phase Double -blind Induction Phase
Visit number 1.1 1.2 1.3a2.1a2.2 2.3 2.4 2.5 2.6 2.7 2.8 2.9 2.10 EW b
Week Week 1End of 
Week 2End of 
Week 4 1 2 3 4 —
Study day — — —1
(baseline) 2 4 8 11 15 18 22 25 28 EW
Clinic visit window (in days) — ±2 ±2 — — ±1 ±1 ±1 ±1 ±1 ±1 ±1 ±1 —
Clinic visit ( C) or rem ote MADRS 
interview only (R M) C C C C RM C C C C C C C C C
Study Drug
Rand omization X
Dispensing of new oral 
antidepressant (duloxetine, 
escitalopram, sertraline, or 
venlafaxine XR)X XjX
Practice session for use of 
intranasal deviceXc
Intranasal esketamine or placebo X X X X X X X X
Drug accountability
(intranasal study medication)X X X X X X X X X
Drug accountability (oral 
antidepressant study medication)X X X
Dispense subject diary for oral 
antidepressantX
Revie w subject diary and update 
(if applicable)X X X X X X X X X
Oral antidepressant compliance 
checkX X X X X
Return of subject diary if not 
entering follow -up phaseX
Safety Assessments (Clinician)
Physical examination X X X X
Nasal examinationcX X X X
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3002 Amendment 2
Status: Approved , Date: 3 June 2016 45Screening/ Prospective 
Observational Phase Double -blind Induction Phase
Visit number 1.1 1.2 1.3a2.1a2.2 2.3 2.4 2.5 2.6 2.7 2.8 2.9 2.10 EW b
Week Week 1End of 
Week 2End of 
Week 4 1 2 3 4 —
Study day — — —1
(baseline) 2 4 8 11 15 18 22 25 28 EW
Clinic visit window (in days) — ±2 ±2 — — ±1 ±1 ±1 ±1 ±1 ±1 ±1 ±1 —
Clinic visit ( C) or rem ote MADRS 
interview only (R M) C C C C RM C C C C C C C C C
Vital signs: blood pressure, pulse, 
respi[INVESTIGATOR_697], temperaturec,q X X X X X X X X X X
Vital signs (postdose): blood 
pressure, pulse, respi[INVESTIGATOR_154839],q X X X X X X X X
Weight X X X X
12-lead ECGf,qX X X X X X
C-SSRS: Baseline/Screening 
versionX
C-SSRS: Since last visit versionqX X XrX X X X X X X X X
MOAA/S and pulse oximetryg,qX X X X X X X X X
BPRS+ h,qX X X X X X X X
CADSSh,qX X X X X X X X
CGADRiX X X X X X X X
PWC -20 X X
Safety Assessments (Subject -completed)
Nasal symptom questionnairekX X X X X
BPIC -SScX X X X
Assessment of Sense of Sm ell
UPSITc,oX X X X
Smell Threshold Testc,oX X X
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3002 Amendment 2
Status: Approved , Date: 3 June 2016 46Screening/ Prospective 
Observational Phase Double -blind Induction Phase
Visit number 1.1 1.2 1.3a2.1a2.2 2.3 2.4 2.5 2.6 2.7 2.8 2.9 2.10 EW b
Week Week 1End of 
Week 2End of 
Week 4 1 2 3 4 —
Study day — — —1
(baseline) 2 4 8 11 15 18 22 25 28 EW
Clinic visit window (in days) — ±2 ±2 — — ±1 ±1 ±1 ±1 ±1 ±1 ±1 ±1 —
Clinic visit ( C) or rem ote MADRS 
interview only (R M) C C C C RM C C C C C C C C C
Efficacy Assessments (Clinician)
MADRS (7 -day recall ; performed 
by [CONTACT_6222], remote raters )X XpXpXdXpXpXpXpX
MADRS (24 -hr recall ; performed 
by [CONTACT_6222], remote raters )X
CGI-S cX X X X X X X X X
Subject -completed Assessments
PAQ X X X
PHQ -9cX X X X X
SDScX X X X X
GAD -7cX X X X
EQ-5D-5LcX X X X X
Cognition Testing
Practice sessions for computerized 
test batteryX
Com puterized test battery and 
HVLT -R X X X
Clinical Laboratory Assessments
TSH, HbA1c X
Lipid panel (fasting) X
Hem atology, chemistrycX X X X
Urine drug screencX X X X
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3002 Amendment 2
Status: Approved , Date: 3 June 2016 47Screening/ Prospective 
Observational Phase Double -blind Induction Phase
Visit number 1.1 1.2 1.3a2.1a2.2 2.3 2.4 2.5 2.6 2.7 2.8 2.9 2.10 EW b
Week Week 1End of 
Week 2End of 
Week 4 1 2 3 4 —
Study day — — —1
(baseline) 2 4 8 11 15 18 22 25 28 EW
Clinic visit window (in days) — ±2 ±2 — — ±1 ±1 ±1 ±1 ±1 ±1 ±1 ±1 —
Clinic visit ( C) or rem ote MADRS 
interview only (R M) C C C C RM C C C C C C C C C
Alcohol breath test X X
UrinalysiscX X X X X
Serum pregnancy test X
Urine pregnancy testcX X X X
Pharm acokinetics
Blood collectionlX X
Biom arker, Pharmacogenomic (DNA), and Expression (RNA) Evaluations
Blood sample collection 
(protein )c, m X X X X X
Blood sample collection 
(DNA) c, m X X X
Blood sample collection 
(RNA) c, m X X X X X
Ongoing Subject Review
Concomitant therapy Ongoing
Adverse events Ongoing
Other
Menstrual cycle tracking
(start date of last menstrual period 
prior to study v isit)XnXn
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3002 Amendment 2
Status: Approved , Date: 3 June 2016 48Footnotes:
Abbreviations: BMI, body mass index; BPIC -SS, Bladder Pain/Interstitial Cystitis Symptom Score; BPRS +, 4-item positive symptom s ubscale of the Brief Psychiatric 
Rating Scale; C, clinic visit; CADSS, Clinician Administered Dissociative States Scale; CGADR, Clinical Global Assessment of Discharge Readiness; CGI -S,Clinical 
Global Impression –Severity; C -SSRS, Columbia Suicide Severity Rating Scale; DNA, deoxyribonucleic acid; ECG, electrocardiogram; EQ-5D-5L,EuroQol -5
dimension - 5-level; EW, e arly w ithdrawal; GAD -7, Generalized Anxiety Disorder , 7-item scale; HbA1 c test, glyc ated hemoglobin test; HVLT -R, Hopkins Verbal 
Learning Test -Revised; IDS -C30, Inventory of Depressive Symptomatology Clinician -rated , 30-item scale ; MADRS, Montgomery -Asberg Depression Rating Scale; 
MGH- ATRQ, [LOCATION_005] General Hospi[INVESTIGATOR_307] -Antidepressant Treat ment History Questionnaire; MGH -Female RLHQ, [LOCATION_005] General Hospi[INVESTIGATOR_307] -Female 
Reproductive Lifecycle and Ho rmones Questionnaire; MINI ,Mini -International Neurop sychiatric Interview; MOAA /S, Modified Observer ’s Assessment of 
Alertness/Sedation; PAQ, Patient Adherence Questionnaire; PHQ -9,Patient Health Questionnaire –9; PWC -20, Physician Withdrawal Checklist , 20-item scale ; 
RNA, ribonucleic acid; SDS, Sheehan Di sability Scale; STOP -Bang, Snoring, Tired, O bserved Apnea, High Blood Pressure, Body mass index, Age, Neck Size, Gender 
(a questionnaire); TSH, thyroid -stimulating hormone
Note: On intranasal dosing days, time [ADDRESS_508631] intranasal spray. Therefore, postdose time points are referenced from this.
a)An additional, optional period of up to 3 weeks is permitted to taper and discontinue current antidepressant treatment (s) after completion of the Week 
4 (Visit 1.3) assessments, pe r the local prescribing information or clinical judgment. Subjects who do not require a taper and are thus eligible to 
immediately proceed to the double- blind induction phase can have Visit 1.3 and Visit 2.1 occur on the same day or within 1 week of each other ( if not 
occurring the same day, the antidepressant treatment regimen should be cont inued and discontinued prior to Visit 2.1) . 
b)If a subject withdraws before the end of the double -blind induction phase (ie, before completing Visit 2.10/Day 28) for rea sons other than withdrawal 
of consent, an early withdrawal visit should be conducted within 1 week of the date of discontinuation, followed by [CONTACT_6591] -up phase. If the early 
withdrawal visit is conducted on the same day as a scheduled visit, duplicate a ssessments are not required.
c)Predose ( if/when performed on intranasal dosing days). Predose subject -reported outcome assessments should be administered before all other study -
related procedures during a clinic visit .
d)Performed for subjects requiring a taper period during the screening/pros pective observational phase; the result will be considered as the subject’s 
baseline MADRS for the double -blind induction phase. For all other subjects, the baseline MADRS for the double -blind induction phase will be t he 
MADRS performed at the end of Week4 of the screening/prospective observational phase.
e)Postdose vital signs will be performed at 40 minutes, 1 hour, and 1.5 hours postdose. Please refer to Section 6.2.1 for guidance for blood pressure 
monitoring on intranasal dosing days.
f)Twelve -lead ECG will be performed predose and at t=1 hour postdose at Visit 2.1 . Twelve -lead ECG will be p erformed at t=1 hour po stdose only (ie, 
no predose ECG required) at Visits 2.4, 2.6, and2.9. A time window of ±15 minutes is permitted.
g)The MOAA/S will not be performed at Visit 1.1 (pulse oximetry only). The MOAA/S will be performed every 15 minutes from predo se to 
t=+1.5 hours postdose (please refer to Section 9.7 for further guidance on MOAA/S assessments). Pulse oximetry will be performed every 15 minutes 
from predose to t=1.5 hours postdose (please refer to Section 9.7for further guidance on timing of pulse oximetry assessments).
h)The BPRS+ and CADSS to be performed predose and at 40 minutes and 1.5 hours postdose. 
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3002 Amendment 2
Status: Approved , Date: 3 June 2016 49i)CGADR to be performed at 1 hour and 1.5 hour postdose; if the response is not “Yes” at 1 .5hour postdose, the asses sment will be repeated every 
15minutes until a “Yes” response i s achieved or until the subject is referred for appropriate medical care if clinically indicated. A subject should not 
be discharged prior to the 1.5 hour time point.
j)Performed only if the subject is not continuing into Study ESKETINT RD3003.
k)Nasal symptom questionnaire will be performed predose and at 1 hour postdose.
l)PK blood collection will be performed at t=40 minutes and t=2 hours postdose (where time=0 is defined as the time of the firs t intranasal spray). 
m)Blood samples should be collected prior to d osing .It is preferred that subjects adhere to a low fat diet on the day of sample collection .
n)Only applicable to women with a menstrual cycle.
o)If the subject has significant nasal congestion on the day of a scheduled assessment, the site should consider p ostponing the smell test assessment(s) to 
the next scheduled clinic visit.
p)The MADRS should be administered no more than [ADDRESS_508632]’s targeted (not actual) clinic visit date (except Visit 2.10, which is 
within 1 day prior ). If performed on the day of the scheduled clinic visit for an intranasal treatment session, the MADRS must be performed prior to 
the intranasal treatment session.
q)If intranasal dosing is postponed (but occurs within visit window) due to vital sign results (eg, blood pressure elevation), all assessment time points 
(including predose) must be performed on the actual intranasal dosing day.
r)Performed only if Visit 1.3 and Visit 2.1 do not occur on the same day.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3002 Amendment 2
Status: Approved , Date: 3 June 2016 50TIME A ND EVENTS SCHE DULE (Follow -up Phase)
Follow -up Phase
Visit number 3.[ADDRESS_508633] intranasal dose 1 2 4 6 8 10 12 14 16 18 20 22 24
Visit window for clinic visit or rem ote assessments only (days) ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3
Clinic visit (C)or rem ote assessments only (RA) RAfC RAfRAfRAfRAfC RAfRAfRAfRAfRAfC
Oral antidepressant compliance a 
Oral antidepressant compliance check X
Drug accountability
Drug accountability (oral antidepressant study medication) X Xe
Return of subject diary X
Safety Assessments (Clinician -completed)
Physical examination X X
Nasal examination X
Vital signs: B lood pressure, pulse, respi[INVESTIGATOR_697], temperature X X
12-lead ECG X
C-SSRS: Since last visit version X X X
PWC -20 X cX
Safety Assessments (Subject -completed)
BPIC -SS X
Efficacy Assessments (Clinician -completed)
MADRS (performed by [CONTACT_6222], remote raters) X X
CGI-S X X X
Efficacy Assessments (Subject -completed)
PHQ -9 X X X X X X X
SDS X X X X X X X
GAD -7 X X X X X X X
EQ-5D-5L X X X X X X X
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3002 Amendment 2
Status: Approved , Date: [ADDRESS_508634] intranasal dose 1 2 4 6 8 10 12 14 16 18 20 22 24
Visit window for clinic visit or rem ote assessments only (days) ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3
Clinic visit (C)or rem ote assessments only (RA) RAfC RAfRAfRAfRAfC RAfRAfRAfRAfRAfC
Cognition testing
Com puterized test battery and HVLT -R X
Medical Resource Utilization
HRUQ bX X X X X X X X X X X X
Clinical Laboratory Assessments
Hem atology, chemistry X
Urinalysis X
Serum pregnancy test X
Urine pregnancy test X X
Biom arker and Expression (RNA) Evaluations
Blood sample collection (protein) dX
Blood sample collection ( RNA ) dX
Ongoing Subject Review
Concomitant therapy Ongoing
Adverse events Ongoing
Footnotes:
Abbreviations: BPIC -SS, Bladder Pain/Interstitial Cystitis Symptom Score; C, clinic visit; CGI -S, Clinical Global Impression –Severity; C -SSRS, 
Columbia Suicide Severity Rating Scale; ECG, electrocardiogram; EQ -5D-5L, EuroQol -5D, 5 -level; GAD -7, Generalized Anxiety Disorder , 7-item 
scale; HRUQ, Healthcare Resource Use Questionnaire; HVLT -R, Hopkins Ve rbal Learning Test -Revised; PHQ -9, Patient Health Questionnaire – 9; 
PWC- 20, Physician Withdrawal Checklist , 20-item scale ; RA, remote assessments only; RNA, ribonucleic acid; SDS, Sheehan Disability Scale.
Note: No intranasal study medication will be administered during the follow -up phase.
a)In order to better assess potential withdrawal symptoms from intranasal study medication, the oral antidepressant medication should be continued for 
at least the first 2 weeks of the follow -up phase unless determine d to be not clinically appropriate.
b)For the HRUQ, a clinician- completed assessment may be required (based on subject -responses).
c)Performed by [CONTACT_154927].
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3002 Amendment 2
Status: Approved , Date: 3 June 2016 52d)It is preferred that subjects adhere to a low fat diet the day of sample collec tion.
e)For any remaining oral antidepressant study medication.
f)At each “Remote Assessment ” visit, site staff will contact [CONTACT_403386][INVESTIGATOR_014].
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3002 Amendment 2
Status: Approved , Date: 3 June 2016 53ABBREVIA TIONS
AHI apnea -hypopnea index
ANCOVA analysis of covariance
ASA American Society of Anesthesiologists
AUC area under the plasma concentration -time curve
BDNF brain -derived neurotrophic factor
BMI body mass index
BPIC -SS Bladder Pain/ Interstitial Cystitis Symptom Score 
BPRS Brief Psychiatric Rating Scale
BPRS+ 4-item positive symptom s ubscale of the Brief P sychiatric Rating Scale
C clinic visit
CADSS Clinician Administered Dissociative States S cale
CGADR Clinical Global Assessment of Discharge Readiness
CGI-S Clinical Global I mpression – Severity
Cmax maximum plasma concentration
CRF case report form
C-SSRS Columbia Suicide Severity Rating S cale
CYP cytochrome P450 , with any appended letters (2B6, 3A4, etc) indicating subtypes
DBP diastolic blood pressure
DBS deep brain stimulation
DNA deoxyribonucleic acid
DSM -5 Diagnostic and Statistical Manual of Mental Disorders (5thEdition)
ECG electrocardiogram
eCRF electronic case report form
ECT electroconvulsive therapy
eDC Electronic Data C apture
EQ-5D-5L European Quality of Life ( EuroQol -5)dimension -5 level
EQ-VAS EuroQol g roup: Visual Analogue Scale
EU European Union
EW Early Withdrawal
FDA [LOCATION_002] Food and Drug Administration
FT4 free thyroxine
GAD -[ADDRESS_508635]
MADRS Montgomery -Asberg Depression Rating Scale
MAO I monoamine oxidase inhibitor
MDD major depressive disorder
MedDRA Medical Dictionary for Regulatory Activities
MGH- ATRQ [LOCATION_005] General Hospi[INVESTIGATOR_307] -Antidepressant Treatment Response Questionnaire
MGH- Female RLHQ [LOCATION_005] General Hospi[INVESTIGATOR_307] -Female Reproductive Lifecycle and Hormones 
Questionnaire
MINI Mini -International Neuropsychiatric Interview (mental status questionnaire)
MOAA/ S Modified Obs erver’s Assessment of Al ertness/ Sedation
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3002 Amendment 2
Status: Approved , Date: 3 June 2016 54MMRM mixed -effects model for repeated measures
NMDA N-Methyl -D-Aspartate
PAQ Patient Adherence Questionnaire
PCP phencyclidine
PD pharmacodynamics
PHQ -9 Patient Health Questionnaire – [ADDRESS_508636] ; 20-item
QTc QT interval corrected
QTcB QT interval corrected according to Bazett's formula
QTcF QT interval corrected according to Fridericia's formula
RA remote assessments only
RNA ribonucleic acid
SAP statistical analysis plan
SDS Sheehan Disability Scale
SmPC Summary of Product Characteristics
SMQ standardized MedDRA queries
SNRI Serotonin and Norepi[INVESTIGATOR_154840] -Bang snoring, tired, o bserved apnea, high blood pressure, body mass index, age, neck size, 
gender (questionnaire)
S[LOCATION_003]Rs suspected unexpected serious adverse reactions
SBP systolic blood pressure
TEAEs treatment -emergent adverse events
TRD treatment -resistant depress ion
TSH thyroid -stimulating hormone
UPSIT University of Pennsylvania Smell Identification Test
US [LOCATION_002]
US FDA [LOCATION_002] Food and Drug Administration
VNS vagalnerve stimulation
XR extended release 
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3002 Amendment 2
Status: Approved , Date: 3 June 2016 551. INTRODUCTION
Major depressive disorder (MDD) is a serious, recurrent, and disabling psychiatric illness.[ADDRESS_508637] to disability  worldwide and is associated with 
excess mortality ;and the estimated median years of potential life lost is 10 y ears.91,94About 30% 
of patients fail to achieve remission despi[INVESTIGATOR_154841],
and are considered to have treatment -resistant depression (TRD).31,75In patients who respond to 
antide pressant treatment s, the time to onset of effect is ty pi[INVESTIGATOR_897]  [ADDRESS_508638].16,24
Ketamine and esketamine (S-ketamine, the Senantiomer of ketamine) are approved and widel y 
used forthe induction and maintenance of anesthesia via intramuscular (IM) or intravenous (IV) 
administration.45The desired analgesic -anesthetic effects of ketamine and esketamine are 
attributed to the blockade of ionotropic N-methy l-D-aspartate (NMDA) glutamate 
receptors.52,66,97
Monoamines (serotonin, norepi[INVESTIGATOR_238], and/or dopamine) are only modulatory  transmitters.
Therefore , conventional monoaminergic antidepressant treatment s would not be expected to 
robustly  affect synaptic transmission, activity -dependent release of brain -derived neurotrophic 
factor (BDNF), or synaptogenesis.24In contrast, the mechanism of action of ketamine and 
esketamine is distinct from conventional antidepressant treatment s because both ketamine and 
esketamine profoundl y affect fast excitatory  glutamate transmission, increases BDNF release, 
and stimulates sy naptogenesis.[ADDRESS_508639] literature repor ts of the antidepressant effects of ketamine describe studies using IV 
administration of the racemate, with a few exceptions.14,60Janssen Research & Development 
(JRD) is developi[INVESTIGATOR_403371] y which allows a lower volume to be administered via the intranasal 
route .51,62,[ADDRESS_508640] comprehensive nonclinical and clinical information regarding esket amine (JNJ-
54135419), please refer to the latest edition of the Investigator's Brochure .42
The term “sponsor ”used throughout this document refers to the entities listed in the Contact 
[CONTACT_23774](s), which will be provided as a separate document.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3002 Amendment 2
Status: Approved , Date: 3 June 2016 561.1. Background
1.1.1. Summary  of Nonclinical Findings
Safety Pharmacology
The following text is quoted from the [LOCATION_002] (US)prescribing information for anesthetic 
Ketalar®(ketamine hydrochloride injection )45is provided below: Intravenous Ketalar produces a 
fall in arterial blood pressure in the Rhesus monkey  and a rise in arterial blood pressure in the 
dog. In this respect the dog mimics the cardiovascular effect observed in man. The pressor 
response to Ketalar injected into intact, unanesthetized dogs is accompanied by a tachycardia, 
rise in cardi ac output and a fall in total peripheral resistance. The pressor response to Ketalar is 
reduced or blocked b y chlorpromazine (central depressant and peripheral α -adrenergic blockade), 
by β-adrenergic blocka de, and by  [CONTACT_154930].
Finding sfrom anim al studies suggest that the increase in blood pressure produced by 
[CONTACT_113883]/esketamine is due to selective activation of central cardiac stimulating mechanisms 
leading to an increase in cardiac output.
In a 3-month repeat -dose toxicity  study with intranasa lly administered esketamine in dogs, no 
relevant electrocardiogram (ECG )changes were noted up to the highest dose tested, 
ie,72mg/d ay.Heart rate was slightl y increased. The cardiovascular safety  of racemic ketamine 
and esketamine in humans and animals is summarized in the Investigator's Brochure.42
Toxicology
Repeat -Dose Toxicity Studies
In repeat -dose toxicity  studies with intranasally  administered esketamine in rats up to 9 mg/day  
for 6 months, and dogs up to 72 mg/day for 3 months ofduration , the clinical observations 
mainly  related to the central nervous sy stem (eg, changes in activity  and gait) . No adverse effects 
were noted up to the highest dose tested, ie, 9 mg/day  in rats and 72 mg/day  in dogs. These 
observations reflected the (exaggerated) pharmacology  of the test compound. Minor histologic 
findings were noted in the nasal cavity . These tissue changes were not considered adverse.
In 3-and 9 -month repeat -dose toxicity  studies with intranasall y administered esketamine in dogs, 
no relevant electrocardiogram (ECG) changes were noted up 72 mg/day . Heart rate was slightl y 
increased. 
Further details can be found in the Investigator's Brochure.42
Genetic Toxicity
A series of in vitro and in vivo genotoxicity  studies was conducted with ketamine and 
esketamine . The weight of evidence indicates that esketamine poses no genotoxic risk to 
humans .42
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3002 Amendment 2
Status: Approved , Date: 3 June 2016 57Neurotoxicity
Racemic ketamine has been reported to induce neurotoxicity  in animal fetuses, and in juvenile, 
adolescent, and adult animals, as evidenced by [CONTACT_154931]. The precise thresholds for dose and duration of exposure causing neurotoxicity  in 
animals remain to be established. The relevance to humans of ketamine’s neurotoxic action in 
animals is unknown.
In studies exploring neurotoxic effects of ketamine on juvenile and prenatal monkey s, 
neuroapoptosis was observed to be more widespread in fetal brains than in neonatal brains, after 
administration of ketamine anesthesia IV for [ADDRESS_508641] severel y affected. In neonatal brains, the 
cerebellum was not affected; the strongest neuroapoptotic response was noted in the basal 
ganglia and several thalamic areas.
In juvenile rodents, ketamine induced apoptotic neurodegeneration was observed that was more 
widespread than in adult rodents, with the developi[INVESTIGATOR_154843]. 
Neuronal cell death was induced in the dorsolateral thalamus at blood levels of ketamine of 
14µg/mL  (7 times the h uman anesthetic blood level of approximately  2 µg/mL ).
No significant neurotoxic effects occurred in juvenile Rhesus monkey s if the anesthesia was 
administered as IM induction followed by [CONTACT_154932] 3 hours. Ketamine 
infusion for 9 or 24 hours increased neuronal cell death in the frontal cortex, but no significant 
changes were noted in the hippocampus, thalamus, striatum, or amygdala. Cognitive 
impairments were observed beginning around 10 months of age, and persisted at 3.5 years of 
age.
The clinical studies will exclude neonates, infants, children, pregnant women, and breastfeeding 
women. Therefore, ketamine’s neurotoxicity  in juvenile animals does not represent a safet y risk 
to eligible adult subjects. Moreover, the large dosages and prolonged treatment durations 
associated with neurotoxicity  in juvenile animals do not suggest a concern.
Chronic treatment with ketamine at high dose levels affected the brain of adolescent monkey s, as 
evidenced b y histopathologic lesions and functional impai rment. 
The neurotoxicity  of ketamine in adult animals is also associated with high dose levels, in 
contrast to the relatively  low dose levels of esketamine associated with antidepressant efficacy  in 
humans. In single -dose and 14-day repeated -neurotoxicity  studies with intranasall y administered 
esketamine in rats, no histopathologic brain lesions were noted even upon high exposures, as 
achieved at 54 mg/day  in the 14-day study. In the 6-month rat and 9-month dog repeat -dose 
toxicology  studies with intranasall y administered esketamine, where the animals were of 
adolescent age at initiation of treatment, and in the pre-and post-natal developmental toxicit y 
study  in rats, no evidence of neurotoxicity  was found. Consequentl y, the risk of neurotoxicity  
associated with intranasal administration of esketamine to adult and adolescent patients is 
considered low .42
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3002 Amendment 2
Status: Approved , Date: [ADDRESS_508642] current.26The inhibitory action on membrane 
currents may  partl y explain the species and tissue differences in inotropic responses to ketamine.
Blood pressure responses to ketamine also vary with the laboratory  species and with 
experimental conditions. Blood pressure is increased in normotensive and renal hy pertensive rats 
with and without adrenalectom y and under pentobarbital anesthesia. The US prescribing 
information for the anesthetic Ketalar®(ketamine hydrochloride [ HCl]for injection) provides the 
following guidance. 
Intravenous Ketalar produces a fall in arterial blood pressure in the Rhesus monkey  and a rise in 
arterial blood pressure in the dog. In this respect the dog mimics the cardiovascular effect 
observed in man. The pressor response to Ketalar injected into intact, unanesthetized dogs is 
accompanied by a tachycardia, rise in cardiac output and a fallin total peripheral resistance. It 
causes a fall in perfusion pressure following a large dose. The tachycardia and increase in 
myocardial contractile force seen in intact animals does not appear in isolated hearts. These 
observations support the hypothesi s that the hy pertension produced by  [CONTACT_154933]. 
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3002 Amendment 2
Status: Approved , Date: [ADDRESS_508643] predictive species in terms of ketamine’s cardiovascular 
effects in humans, but the antidepressant effects of ketamine were studied only in rodent models. 
The myocardial contractility  effects and blood pressure responses to ketamine vary between 
species.42Consequently , a margin of safety  could not be reliably  derived from the available 
animal data.
Overall Conclusion
The currentl y available nonclinical safety  studies support chronic intranasal administration of 
esketamine in human subjects up to a dosage of 84 mg/day .
Further details can be found in the Investigator's Brochure.42
1.1.2. Clinica l Studies
[IP_ADDRESS]. Pharmacokinetics and Product Metabolism
Metabolism
Ketamine (and esketamine) undergoes extensive metabolism by [CONTACT_154934] P450 
(CYP). In humans, N-demethy lation to norketamine is the major route of metabolism, which can 
undergo further metabolism to form hydroxy norketamine. Ketamine and norketamine are 
extensively  hydrox ylated to a series of [ADDRESS_508644] at 
the NMDA receptor.25Norketamine has a half-life in plasma of approximately  5  hours.37The 
major human hepatic CYPs that catal yze ketamine N-demeth ylation in vitro are CYP2B6 and 
CYP3A4.38,68,95The CYP enzymes responsible for the formation of norketamine metabolites 
include CYP2A6 and CYP 2B6.68Published results of a clinical pharmacokinetics (PK)study 
indicate that esketamine does not invert to the R -enantiomer.[ADDRESS_508645] been previously  shown to be predominantly  excreted 
in the urine. An average of 91% and 3% of a tritium -labeled dose (1mg/kg) administered to 
6healthy  subjects was recovered in urine and feces, respectivel y.5Less than 3% of an 
administered dose was excreted in urine as parent drug.[ADDRESS_508646] received 0.2 mg/kg or 0.4 mg/kg esketamine as a 40-minute IVinfusion 
during Study  ESKTIV TRD2001.10Maximum concentrations of esketamine were observed at the 
end of the infusion. Mean values for maximum plasma concentration (Cmax) and area under the 
concentration -time curve (AUC )increased with an increase in the esketamine dose administered 
(80.9 and 135 ng/mL, respectively , and 150 and 218 ng*h/mL, respectively , for 0.2mg/kg and 
0.4 mg/kg esketamine ). The mean plasma clearance of esketamine was high (109 L/h and 
141L/h for the 0.2 mg/kg and 0.4 mg/kg doses, respectivel y),as it was similar to or exceeded 
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3002 Amendment 2
Status: Approved , Date: 3 June 2016 60hepatic blood flow in humans .10The large volume of distribution suggests that esketamine 
distributes widely  into tissues (236 L and 303 L, respectively ). The half-life of esketam ine in 
plasma was 2.14 and 2.65 hours, respectively , for the 2doses . 
Intranasal Esketamine
Plasma esketamine PK results from Studies ESKETINTRD1001, ESKTINTRD1002, 
ESKETINTRD1003, and the double -blind phase of Panel A of the ESKETI NTRD2003 that 
inform dose selection for the Phase 3 program are described below. The results demonstrate that 
plasma esketamine concentrations produced by [CONTACT_154935] (0.2 mg/kg and 0.4 mg/kg 
as 40 -minute infusions) may  be achieved by  [CONTACT_24625]. 
Study  ESKETINTRD1001 included [ADDRESS_508647] 
supervision of the investigator or designee. Subjects in Cohorts 1 and 3 received esketamine 
doses that ranged from 28 to 112 mg. The regimens were self-administered in the uprig ht 
position. No instructions were given with regards to sniffing after administration. The reported 
median time of Cmax(Tmax)of esketamine ranged from 0.[ADDRESS_508648] 
spray  was administered (ie, 0.[ADDRESS_508649] spray  was administered). The doses of 
28 to 112mg produced mean Cmaxvalues ranging from 63.3 to 151 ng/mL, whereas mean 
AUC ∞ values ranged from 164 to 565 ng*h/mL. Mean Cmaxand AUC values of esketamine 
increased in a less than dose-proportional manner across the dose regimens. Further more, there 
was substantial overlap in the range of individual Cmaxand AUC values among the 3 doses. The 
mean terminal half-life of esketamine ranged from 5.86 to 9.83 hours across all treatments.
Subjects in Cohort 2 rece ived 84 mg in a semi -reclined position and were instructed to sniff after 
each spray . Higher mean Cmaxand AUC ∞values were observed in this cohort (174 ng/mL  and 
437ng*h/mL, respectively ) compared with the same esketamine dose self-administered by 
[CONTACT_154936] 1 (107 ng/mL and 400ng*h/mL , respectivel y). The semi -reclined position of 
the head and the instruction to subjects to sniff gently following intranasal dosing are believed to 
be the cause for the increase in exposure observed in Cohort 2 compared with Cohort 1. As a 
result, the instructions for self-administration of intranasal esketamine were adapted to include 
the semi -reclined position of the head and sniffing following dosing for all future studies.
During the Phase 1 study ESKETINTRD1002 ,healthy  Japanese and Caucasian subjects received 
single intranasal doses of esketamine 28 mg, 56 mg, and 84 mg in a crossover manner.8On 
average, plasma esketamine Cmaxand AUC values were up to 48% higher in Japanese subjects 
compared with Caucasian subjects.
Study  ESKETINTRD1003 compared the PK, safety , and tolerability  of intranasall y administered 
esketamine in healthy  elderly  (65 years of age) and younger adult subjects (18 to 55 years of 
age, inclusive).9Subject s received a single intranasal treatment of esketamine 28 mg. Median 
time to reach the maximum plasma concentration (Tmax) of esketamine was approximately 
30minutes for both age groups. The geometric means of Cmaxand area under the plasma 
concentration -time curve from time 0 to infinite time, AUC ∞, for esketamine were 
approximately  21% and 17% higher, respectivel y, in the elderl y compar ed with younger adult 
subjects.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3002 Amendment 2
Status: Approved , Date: 3 June 2016 61Study  ESKETINTRD2003 is an ongoing 2-panel, doubly  randomized, double -blind, 
placebo- controlled, multicenter stud y.70Panel A was conducted in the [LOCATION_002] and Belgium 
and Panel B in Japan. Panel A assessed the efficacy  and safety  of 3 dose strengths of intranasal 
esketamine (28, 56, and 84 mg) administ ered twice a week in subjects with TRD. Panel B 
(ongoing) is designed to assess the efficacy  and safet y of 14-mg and 56 -mg dose strengths. 
Results of a preliminary  analysis of data from the double -blind phase of Panel A indicate mean 
(standard deviation) esketamine concentra tions at 40 minutes postdose were 36.4 ng/mL  (16.4), 
58.1 ng/mL  (24.5), and 72.5 ng/mL  (34.2), respectively , for the 3 doses (data on file). The mean 
esketamine concentrations in plasma samples collected on Days 1 and 11 were similar ,
suggesting that the PK are consistent after repeated administration.
[IP_ADDRESS]. Pharmacody namics and Efficacy
The efficacy  of subanesthetic doses (0.5 mg/kg IV administered over 40 minutes ) of IVketamine 
has been evaluated in approximately  192 subjects with MDD (cases andcontrols), and 2 studies 
in bipolar depressed subjects (meta -analyses).32This recent meta -analy sis of studies suggests that 
ketamine has a rapid onset (within 1 day ) of antidepressant efficacy ,including in those who have 
not benefitted from other antidepressant treatment s, used as monotherapy  or in combina tion with 
oral antidepressant treatment s.
Esketamine (0.2 and 0.4 mg/kg administered over 40 minutes) has similar, rapid, and robust 
antidepressant effect as that seen with IV ketamine. Adouble -blind, double -randomization, 
placebo- controlled study (ESKETIV TRD2001) enrolled [ADDRESS_508650] : 10 in the 
IV placebo group, 9 in the IV esketamine 0.20-mg/kg group, and 11 in the IV esketamine 
0.40-mg/kg group (based on Day 1  randomization).10The intent -to-treat (ITT) analysis of the 
primary  efficacy  variable (change in Montgomery -Asberg Depression Rating Scale [MADRS ]
total score from baseline Day 1  to Day 2)indicated that the improvement in both esketamine 
dose groups was statistically  significant (1-sided p-value=0.001 in both dose groups) compared 
with the placebo group. The mean (standard deviation) change from baseline Day 1 to Day 2 in 
MADRS total score was -4.9 (4.72) in the placebo group, -16.8 (10.12) in the esketamine 
0.20-mg/kg group, and -17.8 (9.45) in the esketamine 0.40-mg/kg group. 
The studies listed above assessed the efficacy  of ketamine or esk etamine after a single dose as 
the primary  endpoint. The average duration of response to a single dose of ketamine (0.5 mg/kg) 
wasapproximately  [ADDRESS_508651] dose 
could be maintained by [CONTACT_154937] 3times a week over 2 weeks. The duration of 
response lasted for approximately  19 day s.1
The KETIVTRD2002 study  assessed whether multiple doses of ketamine given twice a week 
would also maintain the antidepressant response ;the data from this study  suggest thatketamine 
(0.50 mg/kg IV over 40 minutes) administ ered twice a week was sufficient for maintain ing the 
initial effect over a 4 -week treatment period.11
As noted above, Study ESKETI NTRD2003 is a 2-panel, doubly  randomized, double -blind, 
placebo- controlled, multicenter stud y.70Panel A was conducted in the [LOCATION_002] and Belgium 
and Panel B in Japan. Panel A assessed the efficacy  and safety  of 3 dose strengths of intranasal 
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3002 Amendment 2
Status: Approved , Date: 3 June 2016 62esketamine (28, 56,and 84 mg) administered twice a week in subjects with TRD. Panel B 
(ongoing) is designed to assess the efficacy  and safet y of 14-mg and 56- mg dose strengths. In 
Panel A, subjects in period 1 (1-week duration) were randoml y assigned in a 3:1:1:1 ratio to 
placebo (33 subjects), esketamine 28 mg (11 subjects), esketamine 56 mg (11subjects) ,or 
esketamine 84 mg (12 subjects). An initial analysis of the data from the double -blind phase of 
Panel A indicates that of the 67 subjects randomized in Period 1, 63 entered Period 2(1-week 
duration), in which 28 placebo subjects who were eligible for re-randomization at the end of 
Period 1, were randoml y assigned in a1:1:1:1 ratio to placebo (N=6), esketamine 28 mg (N=8), 
esketamine 56 mg (N=9), or esketamine 84 mg (N=5) (data on file). Subjects eligible for re-
randomization had to have a Quick Inventory  of Depressive Symptomatology  –Self Report 
(QIDS-SR16) total score >11 at the end of Period 1. 
The improvement (with respect to change in MADRS total score from baseline Day 1 to Day 8) 
in all 3 esketamine dose groups reached statistical significance (p=0.021, p=0.001 ,and p<0.001 
for esketamine 28 mg, 56 mg,and 84 mg, respectively ) compared with placebo. The results of 
the 2periods were consistent. The mean differences from placebo on Day 8(after 1 week of 
treatment), estimated using data from the combined periods ,were: 
Esketamine 28 mg: -4.2 (SE 2.09)
Esketamine 56 mg: -6.3 (SE 2.07)
Esketamine 84 mg: -9.0 (SE 2 .13)
The effect sizes in P eriod 1 for esketamine compared with placebo were:
Esketamine 28 mg: 0.43 (CI  -0.259 -1.118)
Esketamine 56 mg: 0.92 (CI 0.201-1.621)
Esketamine 84 mg: 1.19 (CI  0.473-1.883)
The duration of effect with the 28-mg dose appears to be shorter ,with the MADRS total score 
higher on D ay [ADDRESS_508652] size (Cohen’s D) with the 56-mg and 
84-mg dose groups , supporting further development.
[IP_ADDRESS]. Safety  and Tolerability
Ketamine is a rapi[INVESTIGATOR_2478] y acting general anesthetic that is approved and widel y used intravenousl y or 
intramuscularl y for the induction and maintenance of anesthesia in children and adults at a dose 
of 1 to 3 mg/kg given as a bolus. Ketamine is marketed as a racemic mixture and inEurope also 
as the S-enantiomer, esketamine. Ketamine was first introduced as an anesthetic in 1963 and is 
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3002 Amendment 2
Status: Approved , Date: [ADDRESS_508653] an excellent medical safety  profile (Ketalar®Summary  of Product 
Characteristics [S mPC] 2011; Ketanest®S SmPC 2011 ).36,44
In the US prescribing information for ketamine HCl for injection and the SmPC for esketamine 
HCl for injection, the following adverse reactions were listed as very common, common, or 
frequen t occurrences: Emergence or recovery  reactions, elevated blood pressure and pulse rate, 
stimulation of respi[INVESTIGATOR_1516], nausea, and vomiting. See Table 1for details.
Tabl e 1: Adverse Reactions Listed as Very Common, Common, or Frequent Occurrences in the Product 
Inform ation of Anesthetic Ketam ine and Esketamine
System  
Organ Class"Frequent" Adverse Reactions
Per Anesthetic Ketam ine USPI45,a"Very Comm on" or "Common" Reactions
Per Anesthetic Esketamine SmPC89,b
Psychiatric 
disordersFrequency: Emergence reactions occurred in 
approximately 12% of patients.
Characteristics: Severity varied from pleasant 
dreamlike states, vivid imagery, hallucinations, 
and emergence delirium. Some states were 
accompanied by [CONTACT_33165] n, excitement, and 
irrational behavior, which some patients 
recalled as an unpleasant experience.Frequency: Recovery reactions w ere common. 
When esketamine was the sole anesthetic, up to 
30% of patients displayed dose- dependent 
recovery reactions.
Charac teristics: Reactions included vivid dreams 
(including nightmares), nausea and vomiting, 
increased salivation, blurred vision, dizziness, 
and motor restlessnessc
Cardiac 
disordersBlood pressure and pulse rate were frequently 
elevated after administratio n. How ever, 
hypotension and bradycardia have been 
observed. Arrhythmia has also occurred.Common occurrences were temporary 
tachycardia and increase in blood pressure and 
heart rate (approximately 20% of the initial value 
was typi[INVESTIGATOR_2855]).
Respi[INVESTIGATOR_696], 
thoracic, and 
mediastinal 
disordersAlthough stimulation of respi[INVESTIGATOR_3333] a 
frequently observed effect, severe depression 
of respi[INVESTIGATOR_154844].Common effects were increase in vascular 
resistance in pulmonary circulation and increase 
in mucus secretion. Increased oxygen 
consumption, laryngospasms, and temporary 
respi[INVESTIGATOR_154845]; the risk of 
respi[INVESTIGATOR_154846].
Gastro -
intestinal 
disordersNo gastrointestinal effects were listed as 
frequent, but the USPI [INVESTIGATOR_154847], 
nausea, and vomiting have been observed.Common effects included nausea and vomiting.
Abbreviations: SmPC, Summary of Product Characteristics; USPI, [LOCATION_002] Prescribing Information
a."Frequent" w as not defined numerically, except in the case of emergence reactions (12%). The terms "very 
common" and "common" did not appear in the adverse effects section of the USPI.
b."Very common" w asdefined in the SmPC as 1/10 and "common" w as defined as 1/100 to <1/10.
c.The incidence of these events can be greatly reduced by [CONTACT_43602] a benzodiazepi[INVESTIGATOR_050] .
Source: Investigator's Brochure for esketamine (JNJ -54135419).42
Adverse Events Associated with Short- term Use of Intranasal Esketamine in Patients with 
MDD
According to the SmPC for esketamine,46the following are reported as common adverse effects: 
transient tach ycardia, vivid dreams (including nightmares), nausea and vomiting, increased blood 
pressure, increased salivation, blurred vision, dizziness, motor unrest, increase in vascular 
resistance in pulmonary  circulation and increase in mucus secretion, increased oxygen 
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3002 Amendment 2
Status: Approved , Date: 3 June 2016 64consumption, laryngospasms, and temporary  respi[INVESTIGATOR_2477]. It is reported that the risk of 
respi[INVESTIGATOR_2477] t ypi[INVESTIGATOR_154848].44
Administration of esketamine is associate d with a number of adverse events, which are transient 
in nature and t ypi[INVESTIGATOR_43331] 2 h ours or less from the start of drug administration. In Panel A 
of the Phase 2 study  with intranasal esketamine (ESKETINTRD2003), the most common 
treatment -emergent adverse events (TEAE s) (>10% of subjects in the pooled esketamine 
treatment groups ) during the double -blind phase were : Dizziness, headache, dissociation, 
dysgeusia (metallic taste), nausea, dissociative disorder, and oral hypoesthesia.76Dissociative 
symptoms were the most typi[INVESTIGATOR_154849]. Transient 
perceptual changes (dissociation), dizziness, and nausea were typi[INVESTIGATOR_154850] y after 
drug administration, resolving by  2hours.
No deaths were reported in the double -blind or open -label phases of ESKETINTRD2003. One 
subject experienced a serious adverse event of esophagitis in Panel A (double -blind phase, 
placebo/placebo treatment group). A total of [ADDRESS_508654] in the placebo/esketamine [ADDRESS_508655] in the esketamine group 
(84mg/esketamine 84mg) experienced a TEAE of dissociative disord er (verbatim term: 
Dissociative syndrome) of moderate intensity  on Day 8 of Period 2 (day of the third esketamine 
84 mg dose in the study ). The subject discontinued from the study due to the event of 
dissociative disorder, which resolved on the same day. The investigator considered the event to 
be very  likel y related to the study agent.76
Dissociative symptoms measured on the Clinician Administered Dissociative States Scale 
(CADSS) were dose-dependent and were observed to reduce significantly  with multiple doses 
over 2 weeks. No psychotic symptoms were seen. Transient increases in mean blood pressure
(systolic and diastolic) were observed post dose following the intranasal esketamine
administration.
The mean (standard deviation; SD) peak systolic blood pressure after the first administration in 
each dose group was :
Placebo: 124.2 (11.51 )mmHg ; an increase of 5.4 (7.84) mmHg
Esketamine 28 mg: 131.8 (15.49) mmHg ; an increase of 10.4 (10.44) mmHg
Esketamine 56 mg: 130.4 (18.64) mmHg ; an increase of 11.2 (15.01) mmHg
Esketamine 84 mg: 146.1 (19.9) mmHg ; an increase of 17.1 (15.5 )mmHg
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3002 Amendment 2
Status: Approved , Date: 3 June 2016 65Mean (SD) p eak diastolic blood pressure after the first administration in each dose group was:
Placebo: 81.2 (8.36) mmHg ; an increase of 3.8 (7.99)mmHg
Esketamine 28 mg: 85.7 (9.16 )mmHg ; an incre ase of 6.5 (7.00 )mmHg
Esketamine 56 mg: 86.5 (11.34) mmHg ; an increase of 7.2 (9.67) mmHg
Esketamine 84 mg: 87.8 (10.62 )mmHg ; an increase of 8.1 (9.12 )mmHg
The blood pressure increase ty pi[INVESTIGATOR_1306] y resolve dwithin 2 hours. Unlike dissociative sy mptoms , the
blood pressure changes observed do not appear to attenuate over time with multiple doses . 
Transient increases in heart rate were also observed in parallel with blood pressure change . There 
was no clinicall y meaningful change in blood ox ygen level.
Adverse Events Associated with Chronic Use of Ketamine
There are no controlled studies of long-term use with esketamine/ketamine in patients with 
MDD. Much of the literature on chronic use of ketamine comes from data gathered from 
street /illegal use of the drug ,rather than sy stematically  conducted clinical studies. Data therefore 
should be interpreted with caution, as in many  cases, no baseline pre-drug data are available and 
drug exposure is poorly  documented. 
In a 1- year longitudinal study , 150 subjects were divided into 5 groups of 30subjects each: 
Frequent ketamine users (more than 4 times per week), infrequent ketamine users (at least once a 
month), abstinent users (abstinent for at least 1 month), polydrug controls, and non- users of illicit 
drugs.58Eight y percent of the participants were retested at the end of 1year. Cognitive deficits 
(including impairment in spatial working memory , pattern recognition memory  and category 
fluency ) were mainl y observed in frequent users and not with the infrequent users. Short -lasting ,
dose-dependent effects of psychosis were associated with ketamine users. There was no increase 
in symptoms over time,and symptoms were completely  reversible upon stoppi[INVESTIGATOR_154851]. As noted, these data should be interpreted with caution, as baseline data predating 
drug use were not available. Furthermore, in their recent review, Morgan and Curran report that 
there is little evidence of any link between chronic, heav y use of ketamine and diagnosis of a 
psychotic disorder.[ADDRESS_508656] findings are that frequent ketamine users (more than 5 times a week) exhibit impairments in 
both short -and long-term memory .56Although dosages have varied, dosages reported by [CONTACT_154938]. Memory  impairments may be reversible when 
individuals stop using the drug, as they  were not found in a group of [ADDRESS_508657] a y ear.57,58
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3002 Amendment 2
Status: Approved , Date: [ADDRESS_508658] common 
symptoms are frequency and urgency  of urination, dysuria, urge incontinence , and occasionall y 
painful hematuria (blood in urine). Computerized tomograph y scans of these subjec tsrevealed a 
marked thickening of the bladder wall, a small bladder capacit y,and perivesicular stranding 
consistent with severe inflammation. At cystoscopy ,all patients had severe ulcerative cystitis. 
Biopsies in 4of these cases found denuded urothelial mucosa with thin layers of reactive and 
regenerating epi[INVESTIGATOR_1663],and ulcerations with vascular granulation tissue and scattered 
inflammatory  cells. Cessation of ketamine use provided some relief of symptoms. Most of the 
described cases are in near-daily users of ketamine for recreational purposes. The prevalence is 
difficult to determine ,as it is seen in recreational users who often do no t seek help.
The majority  of cases resolve after stoppi[INVESTIGATOR_154852], one-third remaining static.
Abuse Liability, Dependence , and Withdrawal
There are a number of reports of ketamine dependence in the literature41,43,55,65but no large -scale 
studies, and so the incidence of ketamine dependence is largel y unknown.57An interview study  
of 90 ketamine users found that 57% of frequent users, 43% of infrequent users, and 60% of 
ex-users expressed concerns about ketamine addiction.59The majority  of frequent users in that 
study  reported using the drug without stoppi[INVESTIGATOR_154853], so compulsive patterns of 
behavior are also a concern. Oral ketamine has also been evaluated as a positive control in 
human abuse potential studies, with dosages of 65 mg and 110 mg reported as appropriate for 
use as positive controls for future abuse potential studies of compounds with a similar 
mechanism of action or with possible perception- altering effects.82There is conflicting evidence 
of the existence of a "withdrawal syndrome" after cessation of ketamine use.57Cravings seem to 
be a key problem in frequent users: 28 of the 30 daily  users in 1 study  reported having tried to 
stop taking the drug but failed; all reported ketamine cravings as the reason for failure.57The 
same study  found that 12 of the 30 daily  users reported withdrawal symptoms characterized by 
[CONTACT_112344] , shaking, sweating, and palpi[INVESTIGATOR_154854]. A few published case 
studies also show craving and somatic and psychological aspects of anxiety  as withdrawal 
symptoms.12,50However, a specific ketamine withdrawal s yndrome has not y et been described.57
Please refer to the Investigator's Brochure for a summary  of the adverse events reported in 
ketamine and esketamine studies.42
1.1.3. Marketing Experience
No intranasal formulation of esketamine is currently  marketed.
1.2. Active Comparator sin Double -blind Induction Phase
This study  will evaluate a flexible dose regimen ofintranasal esketamine (56 mg or 84 mg) plus 
a newly  initiated oral antidepressant compared with a newly  initiated oral antidepressant (active 
comparator) plus intranasal placebo.
In the double -blind induction phase, subjects will be assigned to receive 1 of 4 commerciall y 
available oral antidepressant medications from 2 different classes of antidepressant medications, 
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3002 Amendment 2
Status: Approved , Date: 3 June 2016 67selective serotonin reuptake inhibitors (SSRI s: Escitalopram orsertraline ),or serotonin and 
norepi[INVESTIGATOR_5608] (SNRI s:Duloxetine or venlafaxine extended release [ XR]).
The indications and safety information provided below for each oral antidepressant are from the 
US prescribing information.22,27,79,87For further information, please refer to the appropriate 
package insert applica ble to the local country  in which the study  is being conducted.
In the US, all of the oral antidepressant options include a black box warning in the prescribing 
information regarding suicidality  and antidepressant drugs. The black box warning informs the 
prescriber that antidepressant treatment s increased the risk compared with placebo of suicidal 
thinking and behavior (suicidality ) in children, adolescents, and young adults in short -term 
studies of MDD and other psychiatric disorders. It states that anyone considering using the 
antidepressant in this population must balance the risk with the clinical need. Refer to the US 
prescribing information for the entire content of the black box warning.22,27,79,87
1.2.1. Selective Serotonin Reuptake Inhibitors
[IP_ADDRESS]. Escitalopram
Escitalopram is indicated in adults for acute and maintenance treatment of MDD and acute 
treatment of generalized anxiety  disorder.[ADDRESS_508659] been seen at 20 mg/day  dose .
In adult MDD subjects treated with escitalopram, the most commonly  observed adverse rea ctions 
with escitalopram (incidence of approximately  5% or greater and approximately  twice the 
incidence in placebo subjects) were insomnia, ejaculation disorder (primarily  ejaculatory  delay), 
nausea, sweating increased, fatigue, and somnolence.
Contraindi cations to the use of escitalopram include serotonin s yndrome and monoamine oxidase 
inhibitor (MAOI) use (concomitant use with MAOIs intended to treat psychiatric disorders, 
linezolid, or IVmethy lene blue; use within 14 days of stoppi[INVESTIGATOR_154855] [in addition, an MAOI should not be used within 14days 
of stoppi[INVESTIGATOR_154856]]); concomitant use with pi[INVESTIGATOR_3924]; and known hypersensitivity  to 
escitalopram or citalopram or any  of the inactive ingredients.
As with most SSRI s, a gradual reduction in the dosage rather than abrupt cessation of 
escitalopram treatment is recommended whenever possible.
[IP_ADDRESS]. Sertraline
Sertraline hydrochloride is indicated in adults for the treatment of MDD, obsessions and 
compulsions in patients with obsessive compulsive disorder, panic disorder (with or without 
agoraphobia), post-traumatic stress disorder, premenstrual dysphoric disorder, and social anxiet y 
disorder.79
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3002 Amendment 2
Status: Approved , Date: [ADDRESS_508660]-traumatic 
stress disorder , or social anxiety  disorder, patients were dosed in a range of 50- 200 mg/day  in the 
clinical trials demonstrating the effectiveness of sertraline for the treatment of these indicati ons. 
Consequently , a dose of 50 mg, administered once daily, is recommended as the initial 
therapeutic dose. Patients not responding to a 50 mg dose may benefit from dose increases up to 
a maxi mum of 200 mg/day . Given the 24-hour elimination half-life of sertraline, dose changes 
should not occur atintervals of less than 1 week. The maximum dose of sertraline in the current 
study  is 200 mg/day .
Contraindications to the use of sertraline include serotonin syndrome and MAOI use 
(concomitant use with MAOIs intended to treat psychiatric disorders, linezolid, or IVmethy lene 
blue; use within 14 days of stoppi[INVESTIGATOR_154857]); concomitant use with pi[INVESTIGATOR_3924]; and known hy persensitivity  to sertraline or any  of the 
inactive ingredients. 
In adult subjects, the most common TEAEs associated with the use of sertraline (incidence of at 
least 5% for sertraline orat least twice that for placebo within at least one of the indications) 
were ejaculation failure, dry mouth, increased sweating, somnolence, tremor, dizziness, fatigue, 
pain, malaise, abdominal pain, anorexia, constipation, diarrhea/loose stools, dyspepsi a, nausea, 
agitation, insomnia, and decreased libido.
As with most SSRI s, a gradual reduction in the dosage rather than abrupt cessation treatment is 
recommended whenever possible.
1.2.2. Serotonin and Norepi[INVESTIGATOR_75618]
[IP_ADDRESS]. Duloxetine
Duloxetine is indicated in adults for MDD, generalized anxiety  disorder ,diabetic peripheral 
neuropathic pain, fibromyalgia, and chronic musculoskeletal pain.22
The starting dosage for MDD in the US prescribing information is 40 to 60 mg/day . The dosage 
for acute treatment is 40 to 60mg/day , with maintenance treatment at 60 mg/day .For some 
patients, it may  be desirable to start at [ADDRESS_508661] s should be initiated with 60mg/d ay. Subjects thathave in the past 
shown increased sensitivity  towards SSRI /SNRI s can, at the discretion of the treating physician,
be started on a 30 mgdose and up-titrated into the therapeutic range of 60mg by [CONTACT_154939] 2 of the double -blind induction phase.
The maximum dosage is 120 mg/day , although there is no evidence that dosages greater than 
60mg/day  confer any additional benefits. The maximum dose to be used in this study  is 
60mg/day .
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3002 Amendment 2
Status: Approved , Date: [ADDRESS_508662] commonly  observed adverse reactions 
in duloxetine -treated subjects (incidence of at least 5% and at least twice the incidence in 
placebo subjects) were nausea, dry  mouth, somnolence, fatigue, constipation, decreased appetite, 
and hyperhidrosis. As observed in diabetic peripheral neuropathy  studies, duloxetine treatment 
worsens gl ycemic control in some subjects with diabetes.
Contraindications to the use of duloxetine include use of an MAOI  concomitantly  or within 
2weeks of MAOI use ; and use in patients with uncontrolled narrow -angle glaucoma.
A gradual reduction in the dosage rather than abrupt cessation is recommended whenever 
possible.
[IP_ADDRESS]. Venlafaxine Extended-r elease
Venlafaxine XR is indicated in adults for MDD and social anxiety  disorde r.87
The starting dosage for MDD in the US prescribing information is 75 mg/day  (in some patients, 
37.5 mg/day  for 4 to 7 days), with a dosage incre ase by 75 mg/day at intervals of 4 days or 
longer, and a maximum dosage of 225 mg/day. 
Dosage reductions are recommended for hepatic impairment (including mild) and renal 
impairment.
Contraindications to the use of venlafaxine XR include serotonin syndrom e and MAOI use 
(concomitant use with MAOIs intended to treat psychiatric disorders, linezolid, or IVmethy lene 
blue; use within 14 days of stoppi[INVESTIGATOR_154857] ); concomitant use with pi[INVESTIGATOR_3924]; and known hy persensitivity  to venlafaxine XR or an y 
of the inactive ingredients.
In adult subjects with MDD, adverse events in short -term studies that occurred in at least 5% of 
the subjects receiving venlafaxine hydrochloride XRcapsules and at a rate at least twice that of 
the placebo group were abnormal ejaculation, gastrointestinal complaints (nausea, dry mouth, 
and anorexia), central nervous sy stem complaints (dizziness, somnolence, and abnormal dreams), 
and sweating.
Sustain ed hypertension is noted within the Warnings and Precautions section. Preexisting 
hypertension should be controlled before treatment with venlafaxine XR. It is recommended that 
patients receiving venlafaxine XRtablets have regular monitoring of blood pres sure. For patients 
who experience a sustained increase in blood pressure while receiving venlafaxine XR, either 
dosage reduction or discontinuation should be considered.
Across most indications, a dose-related increase in supi[INVESTIGATOR_154859]-treated patients. Across all clinical studies , 1.4% of subjects in 
the venlafaxine XR-treated groups experienced a 15-mmHg increase in supi[INVESTIGATOR_154860] ,with blood pressure 105 mmHg ,compared with 0.9% of subject s in the placebo 
groups. Similarly , 1% of subjects in the venlafaxine XR-treated groups experienced a 
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3002 Amendment 2
Status: Approved , Date: 3 June 2016 7020-mmHg increase in supi[INVESTIGATOR_9219] ,with blood pressure 180 mmHg ,
compared with 0.3% of subjects in the placebo groups. 
Agradual dosage reduction, individualized as necessary , is recommended to avoid 
discontinuation sy mptoms.
1.3. Overall Rationale for the Study
This study  is being conducted to evaluate the efficacy , safet y, and tolerability of flexibly  dosed
intranasal esketamine (56 mg or 84 mg) plus anewly initiated oral antidepressant in adult 
subjects with TRD . The study  will serve as a pi[INVESTIGATOR_154861] [ADDRESS_508663] from a prior antidepressant treatment (to which they have not responded) to flexibly  dosed 
intranasal esketamine (56 mg or 84 mg) plus a newly  initiated or al antidepressant compared with 
switching to a newly  initiated oral antidepressant (active comparator) plus intranasal placebo, in 
improving depressive symptoms, as assessed by [CONTACT_403387]  1 (pre -randomization ) to the end of the 4 -week double -blind induction phase.
Key Secondary Objective s
The key secondary  objective s are to assess the effect of intranasal esketamine plus a newl y
initiated oral antidepressant compared with a newly initiated oral antidepressant (active 
comparator) plus intranasal placebo on the following parameters in adult subjects with TRD :
Onsetof clinical response by  [CONTACT_2006]  2
Function ingand associated disability
Depressive s ymptoms (subject -reported)
Other Secondary Objectives
To assess the effect of intranasal esketamine plus a newly initiated oral antidepressant 
compared with a newl yinitiated oral antidepressant (active comparator) plus intranasal 
placebo on the following parameters in adult subjects with TRD :
Depression response rates
Depre ssion remission rates
Overall s everity  ofdepressive illness
Anxiety  symptoms
Health-related qualit y of life and health status
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3002 Amendment 2
Status: Approved , Date: 3 June 2016 71To investigate the safet y and tolerability  of intranasal esketamine plus a newly initiated oral 
antidepressant compared with a newl yinitiated oral antidepressant (active comparator) plus 
intranasal placebo in adult subjects with TRD, including the following parameters:
TEAEs , including AEs of special interest
Local nasal tolerability
Effects on heart rate, blood pressure, respi[INVESTIGATOR_92196], and blood oxy gen sat uration
Effects on alertness and sedation
Potential p sychosis -like effects
Dissociative sy mptoms 
Potential e ffects on cognitive function 
Potential e ffects on suicidal ideation/behavior 
Potential t reatment -emergent s ymptoms of cy stitis and/or lower urinary  tract symptoms 
Potential withdrawal and/or rebound symptoms following cessation of intranasal 
esketamine treatment
Potential e ffects on sense of smell 
To assess the PKof intranasal esketamine in adult subjects with TRD receiving intranasal 
esketamine plus a newly -initiated oral antidepressant.
Exploratory Objectives
To assess the pharmacokinetic /pharmacody namic (PK/PD) relationship of intranasal 
esketamine and MADRS total score in adult subjects with TRD
To assess the potential relationship of biomarkers with response/non- response to intranasal 
esketamine or oral antidepressants in adult subjects with TRD
To assess medical resource utilization
2.2. Hypothesis
The hypothesis for this study  is that,in adult subjects with TRD , switching from a failed 
antidepressant treatment to intranasal esketamine plus a newly  initiated oral antidepressant is 
superior to switching to a newly  initiated oral antidepressant treatment (active comparator) plus 
intranasal placebo in improving depress ive s ymptoms .
3. STUDY DESIGN A ND RA TIONA LE
3.1. Overview  of Study  Design
This is a randomized, double -blind, active -controlled, multicenter study  in male and female adult 
subjects with TRD to assess the efficacy , safety , and tolerability  of flexibly dosed intrana sal 
esketamine (56mg or 84mg) plus a newly  initiated oral antidepressant compared with a newly 
initiated oral antidepressant (active comparator) plus intranasal placebo. 
The study  has 3 phases which are briefl y described below.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3002 Amendment 2
Status: Approved , Date: 3 June 2016 72Screening/prospective observational phase (4-week duration + optional 3-week taper 
period )
This phase will prospectivel y assess treatment response to the subject’s current oral 
antidepressant treatment regimen . 
At the start of the screening/prospective observational phase, thesubject must have had 
documented non-response to at least 1 antidepressant treatment (based on MGH -ATRQ) in the 
current epi[INVESTIGATOR_17108], and subject istaking a different oral antidepressant treatment (on 
the MGH -ATRQ ) for at least the previous 2 weeks at or above the minimum therapeutic dose. 
This antidepressant treatment, as well as any other ongoing medications being taken for 
depression at screening (including adjunctive/augmentation therapi[INVESTIGATOR_014]), will continue from the 
start of Week 1 through the end of Week 4 of the screening/prospective observational phase.
Dose adjustment is permitted per clinical judgment, but the oral antidepressant treatment is to
remain at or above the minimum therapeutic dose (per the MGH -ATRQ) through the end of 
Week 4.
After 4 weeks, subjects who are non-responders to their current oral antidepressant treatment (as 
assessed by [CONTACT_6222], remote raters) may be eligible to proceed to the double -blind induction 
phase. Non -response at the end of the screening/prospective observational phase is defined as 
≤25% improvement in the MADRS total score from Week 1 to Week 4 and a MADRS total 
score of   ≥ 28 on Week 2 and Week 4.
Eligible subjects who are entering the double -blind induction phase will discontinue all of their 
curre nt antidepressant treatment (s), including adjunctive/augmentation therapi[INVESTIGATOR_014]. Of note, 
subjects taking benzodiazepi[INVESTIGATOR_1651] (at dosages equal to or less than the equivalent of 6mg/day of 
lorazepam) and/or permitted non-benzodiazepi[INVESTIGATOR_154822] (eg, zolpi[INVESTIGATOR_6730], zaleplon) 
during the screening/prospective observational phase can continue these medications. No dose 
increases beyond the equivalent of 6 mg/day of lorazepam , or new benzodiazepi[INVESTIGATOR_154862]/prospective observational phase. If clinically  indicated, a subject’s current 
antidepressant treatment (s) may be tapered and discontinued over an additional, optional period 
of up to 3 week s per the local prescribing information or clinical judgment.
As a new oral antidepressant will be initiated on Day 1  of the double -blind induction phase, 
eligible subjects who do not require a tapered discontinuation of their antidepressant treatment (s) 
can proceed immediatel y into the double -blind induction phase .
Double -blind induction phase (4-w eek duration)
Approximately  196 subjects will be randomly  assigned at a 1:1 ratio (n=98 subjects per treatment 
arm) to receive double -blind treatment with either intranasal esketamine or intranasal placebo . 
The intranasal treatment sessions (esketamine or placebo) will occur twice weekl y. In addition, 
all subjects will initiate a new open -label oral antidepressant on Day  1 that will be taken daily  for 
the duration of this phase. The assigned oral antidepressant will be 1 of 4 oral antidepressant 
medications (duloxetine, escitalopram, sertraline, or venlafaxine extended release [XR]), that the 
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3002 Amendment 2
Status: Approved , Date: [ADDRESS_508664] has not previously had a non-response to in the current depressive epi[INVESTIGATOR_1865], has not been 
previously  intolerant to (lifetime), and is available in the participat ing country .
Subjects taking benzodiazepi[INVESTIGATOR_1651] (at dosage s equal to or less than the equivalent of 6mg/day of 
lorazepam) and/or permitted non-benzod iazepi[INVESTIGATOR_154822] (eg, zolpi[INVESTIGATOR_6730], zaleplon) 
during the screening/prospective observational phase can continue these medications during the 
induction phase. No dose increases beyond the equivalent of 6 mg/day  of lorazepam or new 
benzodiazepi[INVESTIGATOR_154823], with the exception of the 
use of permitted benzodiazepi[INVESTIGATOR_154824].
At the end of the induction phase, subjects who are responders (defined as ≥50% reduction in the 
MADRS total score from baseline [Day  1 pre-randomization] to the end of the 4-week 
double -blind induction phase) may be eligible to participate in the subsequent study  
ESKETINTRD3003 if they meet all other study  entry criteria (ESKETINTRD3003 is a longer -
term efficacy  maintenance study  involving repeated treatment sessions of intranasal esketamine).
If a subject withdraws from the study before the end of the double -blind induction phase for 
reasons other than withdrawal of consent, an Early  Withdrawal visit should be conducted within 
1 week of the date of discontinuation, followed by [CONTACT_6591] -up phase.
Follow -up phase (24- week duration)
This phase will include all subjects who are not eligible or who choose to not participate in the 
maintenance of effect study  ESKETINTRD3003 and have received at least 1 dose of intranasal 
study  medication in the double -blind induction phase. There will be no intranasal treatment 
sessions administered during this phase.
At the start of the follow -up phase, further clinical/standard of care for the treatment of 
depression will be arranged by [CONTACT_154941]/or the subject’s treating physician and 
medication changes are permitted . The decision to continue the oral antidepressant in this phase 
will be at the discretion of the investigator, however, in order to better assess potential 
withdrawal symptoms from intranasal study  medication, the oral antidepressant medication 
should be continued for at least the first [ADDRESS_508665]’s major depressive epi[INVESTIGATOR_81633] a 6 -month period.
An open -label safet y extension study , 54135419TRD3008, may be available (pending country  
and site approval) for eligible subjects participating in the ESKETINTRD3002 study . Please 
refer to the [ADDRESS_508666]’s study  participation in the current study will be 11weeks (for subjects continuing into 
ESKETINTRD3003) or 35 weeks (for subjects completing the follow -up phase).
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3002 Amendment 2
Status: Approved , Date: 3 June 2016 74A diagram of the stud y design is provided in Figure 1.
Figure 1: Study Design for ESKETINTRD300 2
Abbreviations: AD, antidepressant; D/C, discontinued; MDD, major depressive disorder; OL,open -label;
PBO, placebo
Note: Subjects who withdraw  early  from the double -blind induction phase and receive at least [ADDRESS_508667] an Early Withdrawal visit performed and then 
proceed into the follow -up phase .
An Independent Data Monitoring Committee (IDMC) will be commissioned for this study . 
Please r efer to Section 11.9, Independent Data Monitoring Comm ittee, for details.
3.2. Study Design Rationale
3.2.1. Study Population
The study  population will include adult men and women , therefore, the age range of 18 (or older 
if the minimum legal age of consent in the country  in which the study  is taking place is >18) to 
64 years of age (inclusive) is considered appropriate.
The subjects will meet the Diagnostic and Statistical Manual of Mental Disorders (5th Edition; 
DSM -5) diagnostic criteria for single -epi[INVESTIGATOR_154831] (if single -epi[INVESTIGATOR_154831], the duration of the 
epi[INVESTIGATOR_154832]2years) or recurrent MDD, without psychotic features, based upon clinical 
assessment, and confirmed by [CONTACT_11605] -International Neurops ychiatric Interview (MINI). In 
addition , the subject must have an Inventory  of Depressive Sy mptomatology -Clinician rated, 30-
item (IDS -C30) total score of ≥34, which corresponds to moderate to severe depression. 
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3002 Amendment 2
Status: Approved , Date: [ADDRESS_508668] had non-response (defined as 
≤25% improvement) to 1but ≤5 (if current epi[INVESTIGATOR_154806] >[ADDRESS_508669] 2 years)oral antidepressant t reatments taken at adequate dosage and for adequate 
duration, as assessed on the [LOCATION_005] General Hospi[INVESTIGATOR_307] –Antidepressant Treatment 
Response Questionnaire (MGH -ATRQ) and documented by [CONTACT_154918] (eg, medical /
pharmacy /prescription records or a letter f rom the treating phy sician, etc. )forthe current epi[INVESTIGATOR_376634]. Subjects who have had some initial response but then lose the response 
(eg,tolerance effects/bra dyphylaxis) to an antidepressant treatment will not be considered to 
have failed that antidepressant treatment. The use of historical data to define non-response to 
treatment prior to patient enrollment in a treatment study  is considered practical and valid. The 
MGH -ATRQ is a validated tool assessing treatment response. 
In addition, atthe start of the screening/prospective observational phase, the subject istaking a
different oral antidepressant treatment (on the MGH -ATRQ ) for at least the previous 2 weeks at 
or above the minimum therapeutic dose.This antidepressant treatment, as well as any other 
ongoing medications being taken for depression at screening (including adjunctive/ augmentation 
therapi[INVESTIGATOR_014]), will continue from the start of Week 1 through the end of Week 4 of the 
screening/prospective observational phase. Dose adjustment ispermitted per clinical judgment, 
but the oral antidepressant treatment is toremain at or above the minimum therapeutic dose (per 
the MGH -ATRQ) through the end of Week 4 .
Non-response at the end of the screening/prospective observational phase is defined as ≤25% 
improvement in the MADRS total score from Week 1 to Week 4 and a MADRS total score of 
≥[ADDRESS_508670]’s current major depressive epi[INVESTIGATOR_1865], depression symptom severity  (Week 1MADRS
total score ≥28 required ), and antidepressant t reatment response in their current depressive 
epi[INVESTIGATOR_1865] (retrospectivel y assessed) must be deemed valid for participation in the clinical study  
based on a Site-Independent Qualification Assessment. The Site Independent Qualification 
Assessment is a tool to f acilitate subject selection for MDD clinical studies , with a goal to ensure 
enrollment of subjects who have symptoms that reflect the current state of illness and that these 
symptoms can be reliably  measured with appropriate measurement tools, as well as to minimize 
placebo response.
3.2.2. Study Phases
The 4 -week duration of the screening/prospective observational phase will provide adequate time 
to assess subject eligibility  according to the study  entry criteria, while also allowing for a 
prospective confirmation of non-response to the current antidepressant treatment(s) that is 
continued for the duration of this phase. This method of recruitment allows subjects to enter the 
study  on a variet y of different antidepressant medications that they had been taking, which 
mimics clinical practice and yet allows for prospective demonstration of treatment resistance to 
the current antidepressant treatment. Even though there is no depression rating score available at 
the start of the antidepressant treatment, thesubjects at screening will have to meet criteria for 
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3002 Amendment 2
Status: Approved , Date: [ADDRESS_508671] ive/augmentation 
therapi[INVESTIGATOR_014], prior to starting the next phase. Non -responders who are eligible to enter the double -
blind induction phase are permitted to have up to 3additional weeks to taper and discontinue 
their current antidepressant treatment prior to entry  into the double -blind induction phase per the 
local prescribing information or clinical judgment (eg, tolerability  concerns). The optional taper 
period of up to 3weeks is expected to provide an adequate amount of time for taper and 
discontinuation.
As described in Section 1.1.[ADDRESS_508672] of typi[INVESTIGATOR_154863]. 
Preliminary  findings from an analysis of antidepressant treatment s were presented recently , as 
well as a completed analy sis of 24 recent MDD studies that compar ed study durations of 4, 6,
and 8weeks. Exploratory  analyses were conducted for each of the study  duration susing 
mixed -effects model for repeated measures (MMRM) , but excluding data beyond the duration of 
interest. These preliminary  findings suggest that it is plausible to shorten the study duration 
down to 4 weeks.48,96Similarly , it has been demonstrated that improvement of 25% on the 
Hamilton Depression 17-item rating scale on Day [ADDRESS_508673] 
response after 5 weeks of treatme nt and a lack of improvement (ie, <25%) by [CONTACT_2006] [ADDRESS_508674] dose of 
intranasal study  medication will allow sufficient time to assess safet y and tolerability after 
cessation of intranasal study medication , including potential withdrawal symptoms. During this 
phase, further clinical/standard of care for the treatment of depression will be arranged by [CONTACT_154942]/or the subject’s treating physician and medication changes are permitted . 
In addition, thisphase will allow collection of additional informative data to assess the course of 
the subject’s major depressive epi[INVESTIGATOR_81633] a [ADDRESS_508675] attributes (eg, demographic and 
baseline characteristics) are evenly  balanced across treatment groups, and to enhance the validity 
of statistical comparisons across treatment groups. The randomization will be stratified by 
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3002 Amendment 2
Status: Approved , Date: 3 June 2016 77country  and class of antidepressant (SNRI or SSRI) with an allocation ratio of 1:1 to placebo or 
esketamine .The stratification is aimed at balancing treatment groups across country  and class of 
antidepressant .
3.2.4. Treatment Groups and Dose Selection
The 2 treatment groups in the double -blind induction phase are:
Intranasal esketamine (56mgor 84mg)
Intranasal placeb o
In all treatment groups, subjects will switch to a new, oral antidepressant, initiated on Day 1 of 
the double -blind induction phase, that will continue for the duration of the phase and longer, if 
applicable.
The treatment groups will allow for an evalua tion of the efficacy , safety , and tolerability  of 
flexibly  dosed intranasal esketamine plus a newl y initiated oral antidepressant as compared with
a newl y initiated oral antidepressant treatment (active comparator) plus intranasal placebo in 
adult subjects with TRD .
Intranasal Study Drug
The dose selection (56 mg and 84 mg) and administration interval ( 2treatment sessions per week 
for 4 weeks) for this study  were based on the sponsor’s previous clinical data, in particular the 
results from Studies ESKETIVTRD2001, KET IVTRD2002, ESKETINTRD1001, and Panel A 
of Study ESKETINTRD2003, described above in Section 1.1.[ADDRESS_508676] will be assigned to receive 1 of 4 oral antidepressant 
medications from 2 different classes of antidepressant treatments, an SSRI  (escitalopram or 
sertraline) or an SNRI (duloxetine or venlafaxine XR). 
The antidepressant medication will be assigned by [CONTACT_154944] -ATRQ and relevant prior antidepressant medication information.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3002 Amendment 2
Status: Approved , Date: [ADDRESS_508677] has not previously  had a non-response to in the current 
depressive epi[INVESTIGATOR_1865], has not been previously  intolerant to (lifetime), and is available in the 
participating country . Dosing of the oral antidepressant will begin on Day 1and will follow a 
protocol specific titration schedule (Attachment 3).The use of thetitration schedule is 
mandatory . Doses are not to exceed the maximum dose de fined in the titration schedule to ensure 
that the oral antidepressant is taken at an adequate dos age and duration for efficacy  assessment at 
the end of the double -blind induction phase , as well as for potential maintenance of effect (in the 
subsequent ESKETINTRD3003 study ).
If higher doses are not tolerated, a down -titration is permitted based on clinician’s judgment. 
However, the subject’s maximum tolerated dose should not be lower than the following 
minimum therapeutic doses at the end of the induction phase : Sertraline (50 mg/day ), 
venlafaxine XR (150 mg/day ), escitalopram (10 mg/day ), and duloxetine (60 mg/day ). While 
subjects requiring lower doses can continue in the study  and complete the double -blind induction 
phase, such subjects are not eligible to participate in the ESKETINTRD3003 study  and will 
proceed to the follow -up phase after completion of the double -blind induction phase .
3.2.5. Efficacy  Measures
MADRS
The 10-item clinician -administered MADRS was designed to be used in subjects with MDD to 
measure the overall severity  of depressive symptoms .53,54The MADRS scale has been selected
as the primary  efficacy  measure for this study  because it is validated, reliable, and acceptable to 
regulatory  health authorities as a primary  scale to deter mine efficacy  in major depression. 
The primary  efficacy  endpoint is the change in the MADRS total score from baseline (Day  1 
prior to randomization) to the end of the 4 -week double -blind induction phase.
In this study , subjects in any of the 2treatment groups who respond to the study  medication 
(ie,responders) are defined as subjects who meet the criterion for response defined as ≥50% 
reduction in the MADRS total score from baseline (Day  1 pre-randomization) to the end of the 
4-week double -blind inductio n phase.
In addition to being the primary  efficacy  measure, the MADRS will also be used to evaluate the 
key secondary  efficacy  endpoint of onset of clinical response (ie, antidepress ant effect) by[CONTACT_2006] 2
that is maintained for the duration of the double -blind induction phase . Onset of c linical response 
is defined as 50% improvement in MADRS total score by [CONTACT_2006] 2 (ie, the day after taking the 
first dose of double -blind intranasal medication) that continues through theend of the double -
blind phase with one excursion allowed.
MADRS will also be used to evaluate a secondary  objective assessing proportion of subjects 
with response and those in remission (defined as subjects with a MADRS total score 12) at the
end of the 4- week double -blind induction phase.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3002 Amendment 2
Status: Approved , Date: 3 June 2016 79Patient Health Questionnaire – 9 (PHQ -9)
The PHQ -[ADDRESS_508678] -reported outcome measure of depressive sy mptomatology .84
Please refer to Section [IP_ADDRESS].2 for additional information regarding PHQ -9.
SDS
The Sheehan Disab ility Scale (SDS) isa subject -reported outcome measure and is included as an
assessment of functional impairment and associated disability .49,81Please refer to 
Section [IP_ADDRESS].1 Error! Refere nce source not found. for additional information regarding SDS.
Clinical Global Impression –Severity (CGI-S)
The CGI-S is included to rate the severity  of the subject’s illness at thetime of assessment, 
relative to the clinician’s past experience with subjects who have the same diagnosis and 
improvement with treatment .35Please refer to Section [IP_ADDRESS].1 for additional information 
regarding CGI- S.
Generalized Anxiety Disorder 7 -item Scale (GAD-7 )
GAD-7 is included as a brief and validated measure of overall anxiety .83Please refer to 
Section [IP_ADDRESS].1 for additional information regarding GAD -7.
EuroQol -5 Dimension -5 Level ( EQ-5D-5L)
The EQ-5D- 5L is included as a standardized subject -completed instrument for use as a measure 
of health-related quality of life and health status.29,30Please refer to Section [IP_ADDRESS].2 for 
additional information regarding EQ -5D- 5L.
3.2.6. Safety  Evaluations
Physical examination, body  weight, vital signs (including blood pressure measurements) , 12-lead 
ECG, pulse oximetry , clinical laboratory  tests, nasal examinations, and evaluation of TEAEs and 
concomitant therapi[INVESTIGATOR_154864] y. 
TEAEs of special interest will be examined separately  groupe d in the following categories: D rug 
abuse, dependence and withdrawal (standardized Medical Dictionary  for Regulatory  Activities 
[MedDRA ] queries [SMQ] ), increased blood pressure, increased heart rate, transient 
dizziness/vertigo , impaired cognition , anxiety ,and cy stitis.
A subject -completed nasal symptom questionnaire will also be conducted as per the Time and 
Event Schedule to assess for an y treatment -emergent nasal tolerability  symptoms .
The Columbia Suicide Severity  Rating Scale (C-SSRS )will be performed to assess suicidal 
ideation and behavior, the CADSS will be administered to assess treatment -emergent 
dissociative symptoms, the Brief Psychiatric Rating Scale (BPRS+ ; four-item positive symptom 
subscale) will be administered to assess treatment- emerge nt psychotic symptoms, the Modified 
Observer’s Assessment of Alertness/Sedation (MOAA/ S)will be used to measure 
treatment -emergent sedation, the CGA DRwill be used to measure the subject’s readiness for 
discharge based on parameters includi ng sedation, blood pressure, and adverse events, and the 
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3002 Amendment 2
Status: Approved , Date: [ADDRESS_508679]; 20-item (PWC-20 )will be administered (as applicable) to 
assess potential withdrawal symptoms after cessation of esketamine treatment.
Given the potential for treatment emergent transient elevation in systolic and diastolic blood 
pressure, heart rate and blood pressure will be monitored throughout the study  and at multiple 
time points on dosing days. Specific guidance to be followed on intranasal dosing days is 
provided in Section 6.2.[ADDRESS_508680] -completed Bladder Pain/ 
Interstitial Cystitis Symptom Score (BPIC-SS) at specific time points.40A score >[ADDRESS_508681]-Revised (HVLT -R). The cognitive battery  will provide assessment of multiple cognitive 
domains, including attention, visual learning and memory , and executive function. The HVLT -R
isa measure of verbal learning and memory .
The University  of Pennsy lvania Smell I dentification Test ( UPSI T)and Smell Threshold Test will 
be performed to assess any  treatment -emergent effects on the sense of smell.
On all intranasal dosing days, subjects must remain at the site until study  procedures have been 
completed and the subject is ready for discharge , and should be accompanied by a responsible 
adult when released from the clinical site. Subjects must not drive a car or work with machines 
for [ADDRESS_508682] of prohibited medications is provided inAttachment 1asgeneral guidance for the 
investigator (but is not all inclusiv e).
3.2.7. Medical Resource Utilization 
Superior and sustained response and remission rates to the current antidepressant medication(s) 
areexpected to result in low utili zation of services, whereas non -response is expected to result in 
higher utilization of healthcare services (such as outpatient visits, emergency  room visits, or 
hospi[INVESTIGATOR_059]), as assessed using the Health care Resource Use Questionnaire (HRUQ)during 
the follow -up phase . The HRUQ includes information regarding utilization of healthcare 
services , including the timing of services, enabling changes in level and quantity  of services to 
be considered as a variable in economic models.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3002 Amendment 2
Status: Approved , Date: 3 June 2016 813.2.8. Other A ssessments
Patient Adherence Questionnaire
During the screening/prospective observational phase, the subje ct-reported Patient Adherence 
Questionnaire (PAQ )will be used to assess how often the subject has taken, and whether he or 
she has made any changes to, his or her antidepressant treatment regimen in the last 2week s. 
This assessment will provide confirmat ion of medication adherence when evaluating 
antidepressant treatment response. Subjects who report missing ≥4days of antidepressant 
medication treatment(s) during a 2- week recall period will be discontinued because of inadequate 
adherence.
3.2.9. Pharmacokinetic Assessments
PKsamples will be obtained during the study  for measurement of the plasma concentration sof 
esketamine, noresketamine, and/or additional metabolites, if warranted.
3.2.10. Biomarker, Pharmacogenomic (DNA ), and Expression (RNA )
Evaluation s
Assessment of biomarker s (protein and RNA) and their potential relationship to the different 
treatment groups and to maintenance /stabilization of response , non- response, and relapse will be 
explored. Blood samples will be collected to measure genetic and epi[INVESTIGATOR_27787] (including 
but not limited to BDNF allelic variants) and protein markers (including but not limited to 
growth factors, inflammation, endocrine, or metabolic). Samples of deox yribonucleic acid 
(DNA) and biomarker smay be used to help address emerging issues and to enable the 
development of safer, more effective, and ultimately individualized therapi[INVESTIGATOR_014].
Genetic variation can be an important contributory  factor to inter-individual differences in drug 
distribution and response and can also serve as a marker for disease susceptibility  and prognosis. 
Pharmacogenomic research may help to explain inter-individual variability in clinical outcomes 
and may help to identify population subgroups that respond differentl y to a drug or subgroups 
that are more suscept ible to relapse . In addition, pharmacogenomics research may allow for the 
identification of genetic factors that influence the PK, PD, efficacy , safet y, or tolerability  of the 
different treatment groups ,and for the identification of genetic factors associated with TRD or 
MDD. Specifically , genetic and epi[INVESTIGATOR_154865] s relevant to 
depression (eg,hypothalam icpi[INVESTIGATOR_154883] [HPA ]axis, inflammation, growth factors, 
monoamine transporters, ion channels, and circadi an rh ythm) will be evaluated.
Protein, metabolite, and ribonucleic acid (RNA )biomarkers may aid in the elucidation of the 
mechanism of action of the different treatment groups or help to explain inter-individual 
variability  in clinical outcomes or may help to identify  population subgroups that respond 
differentl y to a drug or may help to identify  subgroups that are more susceptible to relapse . The 
goal of the biomarker analy ses is to evaluate the PDof the different treatment groups , and aid in 
evaluating the drug- clinical response relationship.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3002 Amendment 2
Status: Approved , Date: 3 June 2016 82On the day of biomarker sample collection, it is preferred that subjects adhere to a low fat diet 
(as an alternative to fasting) to reduce the level of postprandial lipemia in blood samples, since 
moderatel y or grossl y lipemic specimens may  interfere with assay  results.
4. STUDY POPULA TION
The inclusion and exclusion criteria for enrolling subjects in this study  are described in the 
following [ADDRESS_508683] satisfy all of the following criteria to be enrolled in the study . 
1.At the time of signing the informed consen t form (I CF), s ubject must be a man or woman 18 
(or older if theminimum legal age of consent in the country in which the study  is taking 
place is >18) to 64 y ears of age, inclusive.
2. At the start of the screening /prospective observational p hase, subject must meet theDSM -5 
diagnostic criteria for single -epi[INVESTIGATOR_154831] (if single -epi[INVESTIGATOR_154831], the duration must be 
2years) or recurrent MDD, without psy chotic features, based upon clinical assessment and 
confirmed b y the MINI.
3.Criterion modified per amendment 1
3.1. Criterion modified per a mendment 2
3.2. At the start of the screening /prospective observational p hase, subject must have had 
non-response (≤25% improvement) to ≥1but ≤5 (if current epi[INVESTIGATOR_154806] >2years, upper limit 
is applicable to only the last 2 years)oral antidepressant treatments in the current epi[INVESTIGATOR_154807], assessed using the MGH -ATRQ and confirmed by [CONTACT_154899] (eg, 
medical /pharmacy /prescription records or a letter from a treating physician , etc.). In 
addition, the subject is taking a different oral antidepressant treatment (on the MGH -ATRQ ) 
for at least the previous 2 weeks at or above the minimum therapeutic dose .
For specific tricy clic antidepressants which are ongoing and being taken at a dose below 
the MGH -ATRQ minimum therapeutic dose, a blood level that is within the therapeutic 
(antidepressant) range, is acceptable to establish the adequacy  of the antidepressant 
treatment.
Subjects must be adherent to the continued oralantidepressant treatment medication (s)
through the screening/prospective observational phase, as documented on the PAQ. 
Missing ≥4days of antidepre ssant medication in the prior 2-week period will be 
considered as inadequate adherence.
Subjects who are n on-responders to the ir current oral antidepressant medication (s)from 
the screening/prospective observational phase (as assessed by [CONTACT_6222], remote 
raters) may be eligible for randomization if all other entry  criteria are met.Non-
response at the end of the screening/prospective observational phase isdefined as ≤25% 
improvement in the MADRS total score from Week 1 to Week 4 and a MADRS total 
score of ≥28on Week 2 and Week 4.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3002 Amendment 2
Status: Approved , Date: 3 June 2016 834. At the start of the screening /prospective observational p hase, subject must have an IDS-C30
total score of 34.
5. Criterion modified per amendment [ADDRESS_508684]’s current major depressive epi[INVESTIGATOR_1865] ,depression symptom severit y (Week 1
MADRS total score ≥28 required ), and antidepressant treatment response in the current 
depressive epi[INVESTIGATOR_1865], must be confirmed using aSite I ndep endent Qualification Assessment .
6.Subject must be medically  stable on the basis of phy sical examination, medical history , vital 
signs (including blood pressure) ,pulse oximetry, and 12-lead ECG performed in the
screening /prospective observational phase . If there are any abnormalities that are not 
specified in the inclusion and exclusion criteria, the determination of their clinical 
significance must be determined by [CONTACT_57127]'s source 
documents and initialed by  [CONTACT_093] .
7.Criterion modified per amendment [ADDRESS_508685] be medically  stable on the basis of clinical laboratory  tests performed in 
the screening /prospective observational phase . If the results of the serum chemistry  panel, 
hematology , or urinal ysis are outside the normal reference ranges, the subject may be 
included only if the investigator judges the abnormalities or deviations from normal to be 
not clinically  significant or to be appropriate and reasonabl e for the population under study . 
This determination must be recorded in the subject's source documents and initialed by [CONTACT_1275].
Subjects with a pre-existing history  of thyroid disease/disorder who are treated with 
thyroid hormones must be on a stable dosage for 3 months prior to the start of the 
screening /prospective observational phase.
For any subject (regardless of thyroid history ), if the thyroid-stimulating hormone 
(TSH )value is out of range, a free thyroxine (FT4) will be conducted. If the FT4 value 
is abnormal and considered to be clinically  significant (after discussion with the medical 
monitor) , the subject is not eligible.
8.Subject must be comfortable with self -administration of intranasal medication and be able to 
follow the intranasal administration instructions provided.
9.Criterion modified per amendment [ADDRESS_508686] be either :
a.Not of childbearing potential defined as: 
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3002 Amendment 2
Status: Approved , Date: 3 June 2016 84opostmenopausal
A postmenopausal state is defined as no menses for 12 months without an 
alternative medical cause. A high follicle stimulating hormone (FSH) level (>40 
IU/L or mIU/mL in the postmenopausal range may be used to confirm a 
postmenopausal state in women not using hormonal contraception or hormonal 
replacement therapy, however in the absence of 12months of amenorrhea, a single 
FSH measurement is insufficient.
opermanentl y sterile
Permanent sterilization methods include hysterectomy, bilateral salpi[INVESTIGATOR_1656], 
bilateral tubal occlusion/ligation procedures, and bilateral oophorectomy.
b.Of childbearing potential and
opracticing a highl y effective method of contraception (failure rate of <1% per year 
when used consistentl y and correctly)
Examples of highly  effective contraceptives include
-user-independent methods:
implantable progestogen -only hormone contraception associated with 
inhibition of ovulation; intrauterine device (IUD); intrauterine hormone -
releasing s ystem (IUS); vasectomized partner; sexual abstinence (sexual 
abstinence is considered a highly effective method only if defined as 
refraining from heterosexual intercourse during the entire period of risk 
associated with the study drug. The reliability of sexual abstinence needs to be 
evaluated in relation to the duration of the study and the preferred and usual 
lifesty le of the subject. )
-user-dependent methods:
combined (estrogen -and progestogen -containing ) hormonal contraception 
associated with inhibition of ovulation: oral, intravaginal, and transdermal; 
progestogen-onl y hormone contraception associated with inhib ition of 
ovulation: oral and injectable
Typi[INVESTIGATOR_170439]. Use should be consistent with local regulations regarding the use of 
contraceptive methods for subjects participating in clinical studies.
Hormonal contraception may be susceptible to interaction with the study drug, 
which may reduce t he efficacy of the contraceptive method.
oagrees to usea highl y effective method throughout the study  and for at least [ADDRESS_508687] dose of study  drug.
Note: If the childbearing potential changes after start of the study  (eg,woman who is not 
heterosexually  active becomes active) ,a woman must begin a highly  effective method of 
birth control, as described throughout th e inclusion criteria .
10.Criterion modified per amendment [ADDRESS_508688] a negative highl y sensitive serum (β-
human chorionic gonadotropin [β-hCG]) at the start of the screening /prospective 
observational phase and a negative urine pregnancy  test must be obtained before the first 
dose of study  drug on Day 1 of the double -blind induction phase prior to randomization.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3002 Amendment 2
Status: Approved , Date: 3 June 2016 8511.Criterion modified per amendment 1
11.1. Criterion modified per amendment 2
11.2.During the study (ie, from Day 1 of the double -blind induction phase, prior to 
randomization) and for a minimum of 1 spermatogenesis cycle (defined as approximately 
90days) after receiving the last dose of intranasal study  medication , a man who is sexually  
active wit h a woman of childbearing potential
must be practicing a highly  effective method of contraception with his female partner 
from those listed above (see examples of highly  effective methods of contraception 
provided for female subjects).
must use a condom if his partner is pregnant.
must agree not to donate sperm .
Note : If the childbearing potential changes after start of the study , a female partner of a male 
study  subject, must begin a highl y effective method of birth control, as described above.
12. Subject must be willing and able to adhere to the prohibitions and restrictions specified in 
this protocol.
13.Each subject must sign an ICF indicating that he or she understands the purpose of and 
procedures required for the study  and is willing to participate in th e study .
4.2. Exclusion Criteria
Any potential subject who meets any  of the following criteria will be excluded f rom participating 
in the study .
1.Criterion modified per amendment [ADDRESS_508689]’s depressive sy mptoms have previously  demonstrated non- respon seto:
Esketamine or ketamine in the current major depressive epi[INVESTIGATOR_154866] , 
or
All of the oral antidepressant treatment options available in the respective country for 
the double -blind induction phase (ie,duloxetine, escitalopram, sertraline, and 
venlafaxine XR) in the current major depressive epi[INVESTIGATOR_1865] (based on MGH- ATRQ) , or
An adequate course of treatment with electroconvulsive therap y (ECT) in the current 
major depressive epi[INVESTIGATOR_1865], defined as at least 7 tr eatments with unilateral/bilateral ECT. 
2.Criterion modified per amendment [ADDRESS_508690] has received vagalnerve stimulation (VNS) or has received deep brain 
stimulation (DBS) in the current epi[INVESTIGATOR_17108].
3.Criterion modified per amendment [ADDRESS_508691] has a current or prior DSM -5 diagnosis of a psychotic disorder or MDD with 
psychotic features , bipolar or related disorders (confirmed by [CONTACT_42145]), obsessive 
compulsive disorder (current only), intellectual disability (DSM -5 diagnostic code s 317, 
318.0, 318.1, 318.2, 315.8, and 319), autism spectrum disorder, borderline personality 
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3002 Amendment 2
Status: Approved , Date: [ADDRESS_508692] has homicidal ideation/intent, per the investigator’s clinical judgment, or has 
suicidal ideation with some intent to actwithin 6 months prior to the start of the 
screening/prospective observational phase , per the investigator’s clinical judgment or based 
on the C-SSRS, corresponding to a respons e of “Yes” on Item 4 (active suicidal ideation 
with some intent to act, without specific plan) or Item5 (active suicidal ideation with 
specific plan and intent) for suicidal ideation on the C-SSRS, or a history  of suicidal 
behavior within the past yearprior to the start of the screening/prospective observational 
phase. Subjects reporting suicidal ideation with intent to act or suicidal behavior prior to the 
start of the double -blind induction phase should be excluded .
5. Subject ha s a history  of moderate or severe substance or alcohol use disorder according to 
DSM -5 criteria, except nicotine or caffeine, within 6 months before the start of the 
screening /prospective observational phase. 
A history  (lifetime) of ketamine, phency clidine (PCP), lysergic acid diethy lamide 
(LSD), or 3, 4-methy lenedioxy -methamphetamine (MDMA) hallucinogen -related use 
disorder is exclusionary .
6.Subjects with a current or past history  of seizures (uncomplicated childhood febrile seizures 
with no sequelae are not exclusionary ).
7. Subject has an UPSIT total score ≤18, indicative of anosmia , during the 
screening/prospective observational phase .
8.Criterion modified per amendment [ADDRESS_508693] iovascular -related conditions:
Cerebrovascular disease with a history  of stroke or transient ischemic attack
Aneury smal vascular disease (including intracranial, thoracic ,or abdominal aorta, or 
peripheral arterial vessels )
Coronary  artery  disease with myocardial infarction, unstable angina, or 
revascularization procedure (eg, coronary  angioplasty  or by [CONTACT_10956] ) within 12
months before the start of the screening /prospective observational phase .Subjects who 
have had a revascularization performed ˃12months prior to screening and are clinicall y 
stable and s ymptom -free, per investigator’s clinical judgment, can be included.
Hemody namicall y significant valvular heart disease such as mitral regurgitation, aortic 
stenosis, or aortic regurgitation. 
[LOCATION_001] Heart Association (NYHA) Class III-IV heart failure of any etiology (refer 
to Attachment 2).
9.Criterion modified per amendment [ADDRESS_508694] has ahistory  of uncontrolled hypertension despi[INVESTIGATOR_154867], exercise, or 
antihy pertensive therapy  at the start of the screening/prospective observational phase or any 
past history  of hy pertensive crisis or ongoing evidence of uncontrolled hypertension defined 
as a supi[INVESTIGATOR_9219] (SBP)>140 mmHg or diastolic blood pressure (DBP )
>90 mmHg during screening/prospective observational phase which continues to be above 
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3002 Amendment 2
Status: Approved , Date: 3 June 2016 87this range with repeated testing during this phase. Note: On Day 1 of the double -blind
induction phase prior to randomization a supi[INVESTIGATOR_152358] >140 mmHg or DBP >90 mmHg is 
exclusionary .
A potential subject may have his/her current antihy pertensive medication (s)adjusted 
during the screening/prospective observational phase and be re-evaluated toassess their 
blood pressure control .The subject must be on a stable regimen for at least 2weeks 
before Day [ADDRESS_508695] history  of significant pulmonary  insufficiency /condition or with 
an arterial blood oxygen saturation (SpO 2) of <93% at the start of the screening/prospective 
observational phase or Day  [ADDRESS_508696] h as clinically  significant ECG abnormalities at the start of the 
screening/prospective observational phase or on Day 1 of the double -blind induction phase 
prior to randomization , defined as:
During screening, a QT interval corrected according to Fridericia's formula (QTcF):
450 msec; if the QTcF is prolonged on the initial ECG, the average QTcF of 
three ECGs, recorded [ADDRESS_508697] not be ≥450 msec.
On Day 1 (predose), a QT interval corrected according to Fridericia’s formula (QTcF): 
≥450 msec based on the site-evaluated ECG; if the QTcF is prolonged on the initial 
ECG, the average QTcF of three ECGs, recorded [ADDRESS_508698] not be 
≥450 msec.
Evidence of 2nd and 3rd degree AV block, complete left bundle branch block (LBBB) ,
or complete right bundle branch block (RBBB) .
Features of new ischemia .
Arrh ythmia (except premature atrial contractions [PACs] and premature ventricular 
contractions [PVCs])
12.Criterion modified per amendment [ADDRESS_508699] has a history  of additional risk factors for Torsades des Pointes (eg, heart 
failure, h ypokalemia, family  history  of Long QT Sy ndrome)
13.Criterion modified per amendment [ADDRESS_508700] has a history  of, or symptoms and signs suggestive of,liver cirrhosis (eg,
esophageal varices, ascites, and increased prothrombin time) OR alanine aminotr ansferase 
(ALT) or aspartate aminotransferase (AST) values 2x the upper limit of normal or total 
bilirubin >1.[ADDRESS_508701] in the screening/prospective observational phase.
Repeat of screening test for abnormal ALT and AST is permitted once during the 
screening period provided per investigator discretion and provide d there is an 
alternative explanation for the out of range value.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3002 Amendment 2
Status: Approved , Date: 3 June 2016 88For elevations in bilirubin if, in the opi[INVESTIGATOR_154868]’s medical officer, the elevation in bilirubin is consistent with Gilbert’s disease , 
the subject may  participate in the study .
14.Criterion modified per amendment [ADDRESS_508702] result(s) for drugs of abuse (including barbiturates, 
methadone, opi[INVESTIGATOR_858], cocaine, phency clidine, and amphetamine/methamphetamine) at the 
start of the screening /prospective observational phase or Day 1 of the double -blind induction 
phase prior to randomization.
 Subjects who have a positive test result at screening due to prescribed psychostimulants (eg, 
amphetamine, methylphenidate, etc.) taken for an indication other than MDD arepermitted 
to continue to take this med ication during the study in accordance with Attachment 1.
Otherwise, subjects who have a positive test result at screening due to prescribed/over -
the-counter opi[INVESTIGATOR_154869] /prospective observational phase if the medication is discontinued at least 1
week or 5half-lives, whichever is longer, before Day 1 of the double -blind induction 
phase (prior torandomization) in accordance with Attachment 1restrictions. The result 
of the Day 1 (prior to randomization) test for drugs of abuse must be negative for the 
subject to be randomized.
oRetesting is not permitted for positive test result(s) , except for reasons stated above .
Prior intermittent use of cannabinoids prior to the start of the screening /prospective 
observational phase is not exclusionary  as long as the subject does not meet the criteria 
for substance use disorder. A positive test for cannabinoids at the start of the 
screening/prospective observational phase is not exclusionary , however, a positive test 
result for canna binoids predose on Day [ADDRESS_508703] has uncontrolled diabetes mellitus ,as evidenced by [CONTACT_13505]1c >9% in the
screening /prospective observational phase or history  in the prior 3 months prior to the start 
of the screening/prospective observational phase of diabetic ketoacidosis, hypergl ycemic 
coma ,or severe h ypogl ycemia with loss of consciousness.
16. Subject has untreated glaucoma, current penetrating or perforating eyeinjury , brain injury , 
hypertensive encephalopathy , intrathecal therapy  with ventricular shunts, or any other 
condition associated with increased intracranial pressure or increased intraocular pressure or 
planned ey e surgery .
17.Criterion modifie d per amendment [ADDRESS_508704] h as any anatomical or medical condition that, per the investigator’s clinical 
judgment based on assessment, may impede delivery  or absorption of intranasal study  drug.
18. Criterion deleted per amendment 1
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3002 Amendment 2
Status: Approved , Date: [ADDRESS_508705] has a history of malignancy  within 5 years before the start of the 
screening /prospective observational phase (exceptions are squamous and basal cell 
carcinomas of the skin and carcinoma in situ of the cervix, or malignancy  that,in the 
opi[INVESTIGATOR_871] , with concurrence with the sponsor's medical monitor , is 
considered cured with minimal risk of recurrence).
20. Subject has known allergies, hypersensitivity , intolerance, or contraindications to 
esketamine/ketamine and/or its excipi[INVESTIGATOR_154870] -blind induction phase .
21. Subject has taken any prohibited therapi[INVESTIGATOR_154871] 1,as noted 
in Section 8(Prestudy  and Concomitant Therap y)and Attachment 1.
22. Subject is taking a total daily  dose of benzodiazepi[INVESTIGATOR_154872] 
6mg/day  of lorazepam at the start of the screening/prospective observational phase.
23. Criterion modified per amendment [ADDRESS_508706] h as a score of [ADDRESS_508707] be ruled out (eg, apnea -hypopnea index [AHI]must be <30). A subject
with obstructive sleep apnea can be included if he or she is using a positive airway  pressure 
device or other treatment/therapy  that is effectively treating (ie, AHI <30) his or her sleep 
apnea .
24.Criterion modified per amendment [ADDRESS_508708] has received an investigational drug (including investigational vaccines) or 
used an invasive investigational medical device within 60 days before the start of the 
screening/prospective observational phase, or hasparticipated in 2 or more MDD or other 
psychiatric condition clinical interventional studies (with different invest igational 
medication) in the previous 1 y earbefore the start of the screening/prospective observational 
phase , or is currentl y enrolled in an investigational interventional study .
25. Subject is a woman who is pregnant, breast -feeding, or planning to become pregnant while 
enrolled in this study  or within [ADDRESS_508709] has a diagnosis of acquired immunodeficiency  syndrome (AIDS). Human 
immunodeficiency  virus ( HIV)testing is not required for this study .
27. Subject has any condition or situation/circumstance for which, in the opi[INVESTIGATOR_1070], participation would not be in the best interest of the subject (eg, compromise 
the well -being) or that could prevent, limit, or confound the protocol- specified asses sments.
28.Subject has had major surgery , (eg, requiring general anesthesia) within 12 weeks before the 
start of the screening /prospective observational phase , or will not have fully  recovered from 
surgery , or has surgery  planned during the time the subject is expected to participate in the 
study . 
Note: Subjects with planned surgical procedures to be conducted under local anesthesia may 
participate .
29. Subject is an employ ee of the investigator or study  site, with direct involvement in the 
proposed study  or other studies under the direction of that investigator or study  site, as well 
as family  members of the employ ees or the investigator.
30.Subject has severe renal impairment (creatinine clearance < 30 ml/min).
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3002 Amendment 2
Status: Approved , Date: 3 June 2016 90NOTE: Investigators should ensure that all study  enrollment criteria have been met. If a subject's 
status changes (including laboratory  results or receipt of additional medical records ) before the 
first dose of study  drug is given such that he or shenolonger meet sall eligibility  criteri a, then 
the subject should be excluded from participation in the study . Section 17.4, Source 
Documentation, describes the required documentation to support meeting the enrollment criteria .
The sponsor will evaluate and approve/reject requests to rescreen an individual subject on a 
case-by-case basis.
4.3. Prohibitions and Restrictions
Potential subjects must be willing and able to adhere to the following prohibitions and 
restrictions during the course of the stud y to be eligible for participation:
Refer to Section 4.1(Inclusion Criteria) and Section 4.2(Exclusion Criteria) for information 
regarding contraception requirements.
Refer to Section 8(Prestudy  and Concomitant Therap y) and Attachment 1(Prohib ited 
Concomitant Medications for Intranasal Study  Medication [Esketamine or Placebo]) for 
further information on prohibited therapi[INVESTIGATOR_014].
Subjects who were taking benzodiazepi[INVESTIGATOR_403372] s equal to or less than the equivalent of 
6mg/day  of lorazepam and/or permitted non-benz odiazepi[INVESTIGATOR_154822] (eg, 
zolpi[INVESTIGATOR_6730], zaleplon) during the screening/prospective observational phase can continue these 
medications during the induction phase . No dose increases beyond the equivalent of 6 
mg/day  of lorazepam or new benzodiazepi[INVESTIGATOR_403373], with the exception of the use of permitted benzodiazepi[INVESTIGATOR_154824]. 
Benzodiazepi[INVESTIGATOR_92650]-benzodiazepi[INVESTIGATOR_154825] (eg, zolpi[INVESTIGATOR_6730], zaleplon, 
eszopi[INVESTIGATOR_11123], and ramelteon ) are prohibited within 12 hours prior to the start of each 
intranasal treatment session or cognition testing.
A positive urine drug screen for use of phency clidine (PCP), or cocaine from Day 1 of the 
induction phase through the final visit in the double -blind induction phase will lead to 
discontinuation.
Subjects must abstain from using alcohol within [ADDRESS_508710] appears intoxicated, dosing should not occur (delay ed per the 
permitted visit windo w; see the Time and Events Schedule).
On all intranasal study  drug dosing days, all subjects must remain at the clinical study  site 
until study  procedures have been completed and the subject is ready for discharge .Subjects 
should be accompanied by a responsible adult when released from the clinical study  site. 
Subjects must not drive a car or work with machines for 24 hours after study drug dosing.
ECT, DBS, transcranial magnetic stimulation (TMS), and VNS are prohibited from study  
entry  through the end of the double -blind induction phase.
Subjects receiving psychotherap y (including cognitive behavioral therapy ; CBT) can 
continue receiving ps ychotherap y; however, CBT must have been ongoing for the last 
3months prior to the screening/prospective observation al phase. With the exception of new 
CBT, which is prohibited, new psychotherapy  is allowed during this study . Any change in 
existing therap y or new therap y must be documented on the concomitant therapi[INVESTIGATOR_77235].
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3002 Amendment 2
Status: Approved , Date: 3 June 2016 915. TREA TMENT ALLOCA TION AND BLINDING
Treatment Al location and Randomization
Central randomization will be implemented in this study . Subjects will be randomly  assigned to 
1 of 2treatment groups in a 1:1ratio based on a computer -generated randomization schedule 
prepared before the study  by [CONTACT_393400]. The randomization will be 
balanced by [CONTACT_403388] (SNRIorSSRI) to be initiated in the double -blind induction phase . The 
interactive web response system (IWRS) will assign a unique treatment code, which will dictate 
the treatment assignment and matching study  drug kitsfor the subject . After the investigator 
selects the oral antidepressant treatment for the double -blind induction phase, thesite will enter 
this information into IWRS. The requestor must use his or her own user identification and 
personal identification number when contact[CONTACT_23790], and will then give the relevant 
subject details to uniquely identify  the subject.
Blinding
The investigator will not be provided with randomization codes. The codes will be maintained 
within the IWRS, which has the functionality  to allow the investigator to break the blind for an 
individual subject.
Data that may potentially  unblind the treatment assignment (eg, intranasal study  drug plasma 
concentrations , treatment allocation) will be handled with special care to ensure that the integrity  
of the blind is maintained and the potential for bias is minimized. This can include making 
special provisions, such as segregating the data in question from view by [CONTACT_473], 
clinical team, or others as appropriate until the time of database lock and unblinding.
Under normal circumstances, the blind should not be broken until all subjects have completed
the study  and the database is finalized. Otherwise, the blind should be broken only if specific 
emergency  treatment/course of action would be dictated by [CONTACT_35496]. In such cases, the investigator may in an emergency  determine the identity  of the 
treatment by  [CONTACT_154946] I WRS. It is recommended that the investigator contact [CONTACT_3160] ,if possible ,to discuss the particular situation, before breaking the blind. Telephone 
contact [CONTACT_97500] 24hours per day, 7days per week. In 
the event the blind is broken, the sponsor must be informed as soon as possible. The date and
time of the unblinding will be documented by [CONTACT_8784], and reason for the unblinding must be 
docu mented by [CONTACT_154947] (eCRF )and in the source document. The 
documentation received from the IWRS indicating the code break must be retained with the 
subject's source documents in a secure manner .
Subjects who have had their treatment assignment unblinded should continue to return for 
scheduled earl y withdrawal and follow up visits.
In general, randomization codes will be disclosed fully  only if the study is completed and the 
clinical database is closed. 
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3002 Amendment 2
Status: Approved , Date: [ADDRESS_508711] treatment assignment will be revealed only to sponsor’s 
study  staff. The investigators and the site personnel will be blind ed to the treatment assignment 
until all subjects have completed study  participation through the follow -up phase.
To maintain the blinding of intranasal study  medication , the esketamine and placebo intranasal 
devices will be indistinguishable. Please refer to Section 14(Study  Drug Information) for 
information on the phy sical characteristics of the study  drugs and devices. 
6. DOSA GE A ND A DMINISTR ATION
6.1. Screening/Prospective Observational Phase
As described in Section 9.1.2 , at the start of screening/prospective observational phase, the 
subject is to be taking adifferent oral antidepressant treatment (on the MGH -ATRQ ) for at least 
the previous 2 weeks at or above the minimum therapeutic dose.This antidepressant treatment, 
aswell as any other ongoing medica tions being taken for depression at screening (including 
adjunctive/augmentation therapi[INVESTIGATOR_014]), will continue from the start of Week 1 through the end of 
Week 4 of the screening/prospective observational phase to confirm non-response. Dose 
adjustment is permitted per clinical judgment, but the oral antidepressant treatment is to remain 
at or above the minimum therapeutic dose (per the MGH -ATRQ) through the end of Week 4. 
The site and investigators are blinded to the study crite ria for non -response. The sponsor will not 
supply  these antidepressant medication(s).
During this phase, antidepressant treatment adherence will be assessed using the PAQ.
After 4 weeks subjects who are non -responders to their current oral antidepressant treatment may 
be eligible to proceed to the double -blind induction phase. Non -response at the end of the 
screening/prospective observational phase is defined as ≤ 25% improvement in the MADRS total 
score from Week 1 to Week 4 and a MADRS total score of ≥ 28 on Week 2 and Week 4.
After the completion of 4weeks of prospective antidepressant treatment and assessment of the 
antidepressant treatment response, eligible subjects who are entering the double -blind induction 
phase will discontinue all of their medication(s), including adjunctive/augmentation therapi[INVESTIGATOR_014]. Of 
note, subjects taking benzodiazepi[INVESTIGATOR_1651] (at dosages equal to or less than the equivalent of 6 mg/day  
of lorazepam) and/or permitted non-benzodiazepi[INVESTIGATOR_154822] (eg, zolpi[INVESTIGATOR_6730], zaleplon) 
during the screening/prospective observational phase can continue these medications. No dose 
increases beyond the equivalent of 6 mg/day  of lorazepam or new benzodiazepi[INVESTIGATOR_403374]/prospective observational phase . Ifclinically  indicated, the 
antidepressant medication may be tapered and discontinued over a period of up to 3 week sper 
the local prescribing information or clinical judgment (eg, antidepressant treatments with short
half-lives, such as paroxetine and venlafaxine XR; or tolerability  concerns) .Eligible subjects 
who do not require a tapered discontinuation of their antidepressant treatment(s) can immediatel y 
proceed into the double -blind induction phase.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3002 Amendment 2
Status: Approved , Date: 3 June 2016 936.2. Double -Blind Induction P hase
During this phase, subjects will self-administer double -blind intranasal treatment with 
esketamine (56 mg or 84 mg) or placebo twice per week for 4 weeks as a flexible dose regimen
at the study  site. In addition, subjects will simultaneously initiate a new, open -label oral 
antidepressant (ie,duloxetine, escitalopram, sertraline, or venlafaxine XR) on Day 1 that will be 
continued for the duration of this phase .
Intranasal Study Drug
On all intranasal treatment session days, a site staff membe r with training in cardiopulmonary 
resuscitation (eg, Basic Life Support course or equivalent course) that is up to date per local 
regulations must be present with the subject during the intranasal treatment session and the 
postdose observation period. In addition, equipment for supportive ventilation and resuscitation 
needs to be present.
Table 2describes how each intranasal treatment session will be administered in the double -blind 
induction phase. Please refer to Section 6.2.1 for guidance on blood pressure monitoring on 
intranasal dosing day s.
Table 2: Intranasal Treatment Administration during the Double -blind Induction Phase
Intranasal TreatmentTime of Intranasal Device Administrationc
0a5 minutes [ADDRESS_508712] intranasal 
device. 
b.One device will be used at each time point. Each individual intranasal device contains 2 sprays. The intranasal 
devices containing esketamine deliver 14 mg per spray, for a total of 28 mg per individual device (ie, 2 sprays).
c.The 3 intranasal devices for each intranasal treatment session should be administered in the medication kit order 
provided by [CONTACT_154948] (subject and healthcare provider versions) for intranasal study 
drug administration will be provided as separate documents. Details regarding study  drug 
administration will be recorded in the source documents and the electronic case report form 
(eCRF ).
Prior to the first intranasal dose on Day 1, subjects will practice spraying (into the air, not 
intranasall y) a demonstration intranasal device that is fi lled with placebo solution.
All subjects will self-administer the intranasal study  drug (esketamine or placebo) at treatment 
sessions twice a week for [ADDRESS_508713] on consecutive day s.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3002 Amendment 2
Status: Approved , Date: 3 June 2016 94On Day 1, subjects randomized to intranasal esketamine will start with a dose of 56 mg. On 
Day 4, the dose may  be increased to 84 mg or remain at 56 mg, as determined by  [CONTACT_403389] . On Day 8, the dose may be increased to 84 mg (if Day 4 dose 
was 56 mg), remain the same, or be reduced to 56 mg (if Day 4 dose was 84 mg), as determined 
by [CONTACT_170487] . On Day 11, the dose may be increased to
84 mg (if Day 8 dose was 56 mg), remain the same, or be reduced to 56 mg (if Day 8 dose was 
84 mg), as determined by [CONTACT_170487] . On Day 15, a dose 
reduction from 84 mg to 56 mg is permitted, if required for tolerability; no dose increase is 
permitted on Day 15. After Day 15, the dose must remain stable (unchanged). If there is no 
intranasal treatment session on Day 15 (eg, visit is missed), a dose reduction from 84 mg to 
56mg is permitted on Day 18 if required for tolerability ; no dose increase is permitted.
Food will be restricted for at least [ADDRESS_508714] has nasal congestion on the dosing day, an intranasal decongestant can be used to 
reduce congestion orthe dosing day be delay ed (per the permitted visit window ; see the Time 
and Events Schedule ). If an intranasal decongestant is used to reduce congestion, it cannot be 
used within [ADDRESS_508715] a car or work with machines for 24 hours after the intranasal treatment session.
Oral Antidepressant Medication
Starting on Day 1, a n ew, open -label oral antidepressant treatment will be initiated in all subjects
and continued for the duration of this phase .The oral antidepressant will be 1 of 4 oral 
antidepressant medications (duloxetine, escitalopram, sertraline, or venlafaxine XR). The 
antidepressant medication will be assigned by [CONTACT_154949] -ATRQ and relevant information regarding prior antidepressant treatments, and will be one
that the subject has not previously  had a non-response to in the current depressive epi[INVESTIGATOR_1865], has 
not been previousl y intolerant to (lifetime), and is available in the participating country. 
Dosing of the oral antidepressant will begin on Day 1.Use of thetitration schedule provided in 
Attachment 3is mandatory . Doses are not to exceed the maximum dose defined in the titration 
schedule. If higher doses are not tolerated, a down -titration is permitted based on clinical 
judgme nt. However, the subject’s dose should not be lower than the following minimum 
therapeutic doses at the end of the induction phase : Sertraline (50mg/day), venlafaxine XR 
(150 mg/day ), escitalopram (10mg/day), and duloxetine (60mg/day ). While subjects requiring 
lower doses can continue in the study  and complete the double -blind induction phase, such 
subjects will not be eligible to participate in the maintenance of effect study  ESKETINTRD3003 
and will proceed to the follow -up phase after completion of the double -blind induction phase.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3002 Amendment 2
Status: Approved , Date: [ADDRESS_508716] y of the oral antidepressant 
medication to ensure there is no interruption of antidepressant therapy  during the transition to 
further clinical/standard of care.
Study-site personnel will instruct subjects on how to take and store the oral antidepressant
treatment s supplied during this study  for at-home use. A subject diary  to capture oral 
antidepressant stud y medication use will be provided.
On intranasal dosing days, it is recommended that the oral antidepressant medication notbe 
taken until at least 3 hours after an intranasal treatment session. 
6.2.1. Guidance on Blood Pressure Monitoring on Intranasal Treatment 
Session Days
Given the potential for treatment emergent transient elevation in systolic and diastolic blood 
pressure, the following guidance should be followed on intranasal dosing day s:
If subsequent to fulfilling the inclusion and exclusion criteria on Day  1(ie, applicable for all 
other intranasal treatment session days after Day 1), a subject’s pre-dose systolic blood 
pressure (SBP) is >140 mmHg and/or diastolic blood pressure (DBP) is >90mmHg, it is 
recommended to repeat the blood pressure measurement after subject rests in sitting or 
recumbent position. If after rest andrepeated measurements, pre-dose SBP is >140 mmHg 
and/or DBP is >90mmHg, then dosing should be postponed and the subject scheduled to 
return on the following day or within the given visit window. If the blood pressure elevation 
still persist s on the next visit, the subject will be scheduled for a consultation by  [CONTACT_154908] , 
other specialist, or primary  care phy sician, prior to further dosing.
If at any postdose time point on the dosing day, the SBP is ≥180 mmHg but <200 mmHg 
and/or the DBP is ≥110 mmHg but <[ADDRESS_508717] may continue with 
intranasal dosing if the pre-dose blood pressure at the next scheduled visit is within the 
acceptable range (see bullet point above).
If at any postdose time point on the dosing day the SBP is ≥200 mmHg and/or the DBP is 
≥[ADDRESS_508718] or primary  care physician for a follow -up 
assessment.
During the double -blind induction phase, at 1.5 hours postdose, if the SBP is ≥160 mmHg and/or 
the DBP ≥100 mmHg, assessments should continue every  30 minute s unti l:
the blood pressure is <160 mmHg SBP and <100 mm Hg DBP ,or 
in the investigator’s clinical judgment, the subject it is clinically  stable and can be 
discharged from the study site, or
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3002 Amendment 2
Status: Approved , Date: 3 June 2016 96the subject is referred for appropriate medical care, if clinical ly indicated , or
if the blood pressure remains ≥180 mmHg SBP and/or ≥[ADDRESS_508719] 1 dose of intranasal study  medication in the double -blind induction 
phase ,but do not enter the subsequent maintenance clinical study  ESKETINTRD3003, will 
proceed into the 24- week follow -up phase . 
No intranasal stud y medication will be administered during this phase.
At the start of the follow -up phase , further clinical/standard of care for the treatment of 
depression will be arranged by [CONTACT_154941]/or the subject’s treating physician and 
medication changes are permitted .
The decision to continue the oral antidepressant medication in this phase will be at the discretion 
of the investigator; however, in order to better assess potential withdrawal symptoms from 
intranasal study  medication the oral antidepressant medication should be continued for at least 
the first [ADDRESS_508720] diary  will be provided to capture oral antidepressa nt study 
medication use.
Antidepressant treatment adherence during the screening/prospective observational phase will be 
assessed using the PAQ. Missing ≥4days of antidepres sant medication in the prior 2-week 
period will be considered as inadequate adhere nce.
Antidepressant treatment compliance during the double -blind induction and follow -up phase s
will be assessed b y performing pi[INVESTIGATOR_10685] (ie, compliance check) and drug accountabilit y.
All doses ofintranasal study  drug will be self-administered by [CONTACT_154950] , and will be recorded .
8. PRESTUDY AND CONCOMI TANT THERAPY
Prestudy  non-antidepressant therapi[INVESTIGATOR_43710] 30 days before the start ofthe 
screening/prospective observational phase must be recorded at the start of this phase. 
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3002 Amendment 2
Status: Approved , Date: 3 June 2016 97All antidepressant treatment(s), including adjunctive treatment for MDD, taken during the 
current depressive epi[INVESTIGATOR_1865] (ie,including those taken more than 30 days prior to the start of the 
screening/prospective observational phase) will be recorded at the start of the 
screening/prospective observational phase. In addition, information will also be obtained 
regarding any history  of intolerance to any of the 4 antidepr essant choices (ie, duloxetine, 
escitalopram, sertraline, and venlafaxine XR). Antidepressant treatments which are not listed on 
the MGH -ATRQ but were used, or currently  being used, as antidepressant treatment in the 
current depressive epi[INVESTIGATOR_403375] ‘Concomitant Therapy ’ eCRF .
Any medication that is listed on the MGH -ATRQ and is being taken at the start of the 
screening/prospective observational phase for an indication other than depression (eg, insomnia) 
should be continued during the screening/prospective observational phase but must be 
discontinued before the start of the double- blind induction phase.
Concomitant therapi[INVESTIGATOR_154875] , beginning with signing of the 
informed consent and continuing up to the last visit. Information on c oncomitant therapi[INVESTIGATOR_170443].
Subjects should continue to take their permitted concomitant medications (eg, antihy pertensive 
medications) at their regular schedule; however, restrictions as outlined in Section 4.3and 
Attachment 1should be taken into account. Of note, if a subject has routinely  taken his/her oral 
antihy pertensive medications in the morning on dosing days, the morning dose should be taken 
prior to intranasal dosing.
Subjects receiving psychotherap y (including cognitive behavioral therapy ; CBT) can continue 
receiving psychotherapy ;however, CBT must have been ongoing for the last 3months prior to 
the start of the screening/prospective observational phase . With the exception of new CBT,
which is prohibited, new psychotherap y is allowed during the study . Any change in existing 
therap y or new therap y must be documented on the concomitant therapi[INVESTIGATOR_77235] .
All therapi[INVESTIGATOR_014] (prescription or over-the-counter medications, including vaccines, vitamins, herbal 
supplements; nonpharmacologic therapi[INVESTIGATOR_014], such as psychotherapy , electrical stimulation, 
acupuncture, special diets, and exercise regimens) dif ferent from the stud y drug must be recorded 
in the eCRF. Modification of an effec tive preexisting therap y should not be made for the explicit 
purpose of entering a subject into the study , unless permitted by [CONTACT_990] (eg, adjustment of 
blood pressure medications.
Rescue Medications
Rescue medications will not be supplied by [CONTACT_456] . In case of treatment-emergent adverse 
events that cannot be resolved by [CONTACT_13635][INVESTIGATOR_154876]/placebo, the following rescue medications may  be considered:
For agitation or anxiety : As required, midazolam (maximum dose 2.5 mg orally or IM) or 
short acting benzodiazepi[INVESTIGATOR_050]
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3002 Amendment 2
Status: Approved , Date: 3 June 2016 98For nausea: As required, ondansetron 8 mg sublinguall y, metoclopramide (10 mg orally or 
IV or IM) or dimenhy drinate (25 to 50 mg, IV or IM)
Unless clinically  indicated, it is recommended that transient increase sin blood pressure not 
be treated, as the blood pressure typi[INVESTIGATOR_154877] [ADDRESS_508721] of prohibited medications is provided in Attachment 1as general guidance for the 
investigator (but is not all inclusive).
The sponsor must be notified in advance (or as soon as possible thereafter) of any instances in 
which prohibited therapi[INVESTIGATOR_23730].
9. STUDY EVA LUATIONS
9.1. Study Procedures
9.1.1. Overview
The Time and Events Schedule summarizes the frequency  and timing of efficacy , PK, biomarker, 
pharmacogenomic, medical resource utilization, health economi c, and safet y measurements 
applicable to this study .
With the exception of postdose assessments, visit-specific subject -reported outcomes
assessments should be conducted or completed before any tests, procedures, or other 
consultations for that clinic visit to prevent influencing subject perceptions. A recommended 
order of stud y procedures will be provided to sites as a separate document.
Actual dates and times of assessments will be recorded in the source documentation and eCRF.
The approximate total blood volume to be collected from each subject will be 116.0 mL (Table 3). 
Repeat or unscheduled samples may be taken for safety reasons or for technical issues with the 
samples. Additional serum or urine pregnancy  tests may  be performed, as determined necessary  by 
[CONTACT_31837], to establish the absence of pregnancy  at any time 
during the subject's participation in the study .
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3002 Amendment 2
Status: Approved , Date: 3 June 2016 99Table 3: Volume of Blood to Be Collected From Each Subject
Type of Sam pleVolume per 
Sample (mL)No. of Samples 
per SubjectTotal Volum e of 
Blood (mL)a
Screening/Prospective Observational Phase
Serum chemistryb5 1 5
TSH 3.5 1 3.5
Hem atologyc2 1 2
Biomarker: proteind10 1 10
Biomarker: DNA 6 1 6
Biomarker: RNA 2.5 1 2.5
Tricyclic Antidepressant Blood leveld6 1 6
FT4e3.5 1 3.5
Double -blind Induction Phase
Serum chemistry 2.5 2 5
Hem atology 2 2 4
Pharm acokinetics 2 4 8
Biomarker: protein 10 3 30
Biomarker: DNA 6 1 6
Biomarker: RNA 2.5 3 7.5
Follow -up Phase
Serum chemistry 2.5 1 2.5
Hem atology 2 1 2
Biomarker: protein d10 1 10
Biomarker: RNA 2.5 1 2.5
Approxim ate volume of blood collected during the study 116.0 mL
Abbreviations: DNA, deoxyribonucleic acid; FT4, free thyroxine; RNA, ribonucleic acid; TSH, thyroid -stimulating 
horm one
a.Calculated as number of samples multiplied by [CONTACT_40987].
b.Serum chemistry includes serum -hCG pregnancy tests (for w omen of childbearing potential) and lipid pan el.
c.As needed, HbA1c will be measured from the sample collected for hematology.
d.For specific tricyclic antidepressants which are being taken at a dose below  the MGH -ATRQ minimum 
therapeutic dose, a blood level that is within therapeutic (antidepressant) range, is acceptable to establish the 
adequacy of the antidepressant treatment.
e.For any subject (regardless of thyroid history), if the TSH value is out of range, a free thyroxine (FT4) will be 
conducted.
Note: An indw elling IV cannula may be used f or blood sample collection.
Note: Repeat or unscheduled samples may be taken for safety reasons or technical issues with the samples.
9.1.2. Screening /Prospective Observational Phase
Prior to conducting any study  procedure, the investigator (or designated study  personnel) will 
review and explain the written ICF to each subject. After signing the ICF, subjects who are 18 
(or older if the minimum legal age of consent in the country  in which the study  is taking place is 
>18) to 64 years of age (inclusive) will be screened to determine eligibility  for study 
participation (please refer to the study  entry  criteria listed in Section 4). 
Subjects must meet DSM -5 diagnostic criteria for single -epi[INVESTIGATOR_154831] (if single -epi[INVESTIGATOR_154831], 
the duration must be  2 years) or recurrent MDD, without psy chotic features, based upon clinical 
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3002 Amendment 2
Status: Approved , Date: 3 June 2016 100assessment and confirmed by [CONTACT_403390]. In addition, at the start of the screening/prospective 
observational phase, the subject must have an IDS -C30total score  34.
At the start of this phase, subjects must have had non-response (≤ 25% improvement) to 1but 
≤5(if current epi[INVESTIGATOR_154806] >[ADDRESS_508722] 2 years) oral
antidepressant treatments taken at adequate dosage and for adequate duration, as assessed using 
the MGH -ATRQ and documented by [CONTACT_154918] ( eg, medical /pharmacy /prescription records or a 
letter from treating physician , etc.) for the current epi[INVESTIGATOR_17108]. In addition, at the start 
of the screening/prospective observational phase, the subject is taking adifferent oral
antidepressant treatment (on the MGH -ATRQ ) for at least the previous 2 weeks at or above the 
minimum therapeutic dose. This antidepressant treatment, as well as any other ongoing 
medications being taken for depression (including adjunctive/augmentation therapi[INVESTIGATOR_014]), will 
continue from the start of Week 1 through the end of Week 4of the screening/prospective 
observational phase to confirm non-response prospectively . Dose adjustment is permitted per 
clinical judgment, but the oral antidepressant treatment is to remain at or above the minimum 
therapeutic dose (per theMGH -ATRQ) through the end of Week 4.Antidepressant treatment 
adherence will be assessed using the PAQ. Missing ≥4days of antidepre ssant medication in the 
prior 2-week period will be considered as inadequate adherence.
The subject’s current major depressi ve epi[INVESTIGATOR_1865] , depression symptom severity  (Week 1 MADRS
total score ≥28 required ),and antidepressant treatment re sponse inthe current depressive epi[INVESTIGATOR_154878] I ndependent Qualification Assessment.
An independent, blinded rater will perform remote MADRS assessments to assess depressive 
symptoms during this phase. 
After 4 weeks, subjects who are non-responders to the current oral antidepressant treatment may 
be eligible to proceed to the double -blind induction phase. Non -response at the end of the 
screening/prospective observational phase is defined as ≤ 25% improvement in the MADRS total 
score from Week 1 to Week 4 and a MADRS total score of ≥ 28 on Week 2 and Week 4 . Eligible 
subjects (determined by [CONTACT_403391]) who are entering the double -blind induction phase
will discontinue all of their current medication(s) being used for depression treatment, including 
adjunctive/augmentative therapi[INVESTIGATOR_014], and any other prohibited psychotropic medications, including 
adjunctive atypi[INVESTIGATOR_34922]. Subjects taking benzodiazepi[INVESTIGATOR_1651] (at dosages equal to or less 
than the equivalent of 6mg/day  of lorazepam) and/or permitted nonbenzodiazepi[INVESTIGATOR_170414] (eg, zolpi[INVESTIGATOR_6730], zaleplon) during the screening/prospective observational phase can 
continue these medications during the induction phase. No dose increases beyond the equivalent 
of 6mg/day  of lorazepam or new benzodiazepi[INVESTIGATOR_403373], with the exception of the use of permitted benzodiazepi[INVESTIGATOR_154824]. 
Benzodiazepi[INVESTIGATOR_92650]-benzodiazepi[INVESTIGATOR_154880] (eg, zolpi[INVESTIGATOR_6730], zaleplon, 
eszopi[INVESTIGATOR_11123], and ramelteon) are prohibited within 12hours prior to the start of each intranasal 
treatment session or cognition testing. 
All other subjec ts who do not proceed to the double -blind induction phase will end study 
participation at this time .Nofurther stud y visits or follow -up isrequired.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3002 Amendment 2
Status: Approved , Date: 3 June 2016 101Optional Antidepressant Taper Period
Since all nonresponder subjects will be starting a new oral antidepr essant during the double -blind 
induction phase, no washout or drug-free period is required after discontinuing the current 
antidepressant treatment. However, an additional, optional period of up to 3 weeks is permitted 
to taper and discontinue the current oral antidepressant medication per the local prescribing 
information or clinical judgment.
The taper period should not start until after the completion of 4 weeks of prospective 
antidepressant treatment and assessment of the antidepressant treatment respon se.
9.1.3. Double -Blind Induction Phase
During this phase, subjects will self-administer double -blind intranasal treatment with 
esketamine (56 mg or 84 mg) or placebo twice per week for 4 weeks as a flexible dose regimen. 
In addition, subjects will simultaneously initiate a new, open -label oral antidepressant (please 
refer to Section 6, Dosage and Administration).
Approximately  [ADDRESS_508723] will be randomly  assigned to 1 of the following  
2double -blind treatment groups at a 1:1 ratio (approximately  98 subjects per group):
Intranasal placebo
Intranasal esketamine (56 mg or 84 mg)
On the same day (ie, Day 1), subjects will be switched to a new, open -label oral antidepressant 
treatment. The oral antidepressant will be 1 of 4 oral antidepressant medications (duloxetine, 
escitalopram, sertraline, or venlafaxine XR). The antidepressant medication assigned by [CONTACT_1275] (based on review of the MGH -ATRQ and relevant prior antidepressant treatment 
information) will be onethat the subject has not previously  had a non-response to in the current 
depressive epi[INVESTIGATOR_1865], has not been previously  intolerant to (lifetime), and is available in the 
participating country . Dosing of the oral antidepressant will begin on Day 1.Use of thetitration 
schedule provided in Attachment 3is mandatory . Doses are not to exceed the maximum dose 
defined in the titration schedule.
For information obtained via telephone contact, written documentation of the communication 
must be available for review in the source documents. During telephone contact [CONTACT_154951] b y site personnel , adverse event and concomitant therapy  information will be obtained. In 
addition, specified clinician -administere d assessments will be performed by [CONTACT_11399] y 
qualified staff.
At the end of the double -blind induction phase, subjects who are responder s (defined as ≥50% 
reduction in the MADRS total score from baseline [Day  1 pre-randomization] to the end of the 
4-week double -blind induction phase ) may be eligible to enter the subsequent maintenance 
clinical study  (Study  ESKETINTRD3003). To maintain study  blinding, all responder subjects, 
including responders to the active comparator (ie, oral antidepressant plus intranasal placebo),
may be eligible to enter Study  ESKETINTRD3003. Participation in ESKETINTRD3003 will 
begin immediatel y after the completion of the double -blind induction phase . Subjects will 
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3002 Amendment 2
Status: Approved , Date: 3 June 2016 102receive oral antidepressant medication and will be instructed to continue taking their oral 
antidepressant medication through their next study visit (ie, first study visit of the stabilization 
phase in Study  ESKETINTRD3003).
Those subjects who do not enter Study  ESKETINTRD3003 will proce ed into the follow -up 
phase.
Earl y Withdrawal
If a subject withdraws before the end of the double -blind induction phase for reasons other than 
withdrawal of consent, the Earl y Withdrawal visit should be conducted within 1 week of the date 
of discontinuation, followed by [CONTACT_154952] .If the Early Withdrawal visit occurs on the 
same day as a scheduled visit, the early withdrawal visit can be performed on the same day and 
duplicate assessments are not required.
Further clinical/standard of care for the treatment of depression will be arranged by [CONTACT_154953]/or the subject’s treating physician. The study  investigator and/or treating 
physician will determine whether or not the current oral antidepressant medication will continue.
If applicable, subjects who withdraw earlywill receive additional oral antidepressant medication 
and it will be recommended that theycontinue taking the oral antidepressant medication for at 
least the first [ADDRESS_508724]’s current major depressive epi[INVESTIGATOR_81633] a 6 -month period.
Further clinical/standard of care for the treatment of depression will be arranged by [CONTACT_154953]/or the subject’s treating physicianand medication changes are permitted .No 
intranasal study  medication will beadministered during this phase. In order to better assess 
potential withdrawal symptoms from the intranasal medication the oral antidepressant 
medication should be continued for at least the first 2 weeks of the follow up phase unless 
determined as not clinically  appropriate. T he decision to continue the antidepressant will be at 
the discretion of the investigator.
An open -label safet y extension study , 54135419TRD3008, may be available (pending country  
and site approval) for eligible subjects participating in the ESKETINTRD3002 study . Please 
refer to the 54135419TRD3008 protocol for full details when available.
If information is obtained via telephone contact, written documenta tion of the communication 
must be available for review in the source documents. 
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3002 Amendment 2
Status: Approved , Date: [ADDRESS_508725]'s last study -related procedure.
9.2. Efficacy
9.2.1. Evaluations
It is recommended that the various subject -reported outcome assessment s be completed prior to 
other procedures.
[IP_ADDRESS]. Primary  Efficacy  Evaluation
The primary  efficacy  evaluation will be the MADRS total score. The MADRS will be performed 
by [CONTACT_154921] , using the Structured Interview Guide for the 
Montgomery  Asberg Depression Rating Scale (SIGMA: Williams 2008) .
The MADRS is a clinician -rated scale designed to measure depression severit y and detects 
changes due to antidepressant treatment .53The scale consists of 10 items, each of which is scored 
from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms), for a 
total possible score of 60. Higher scores represent a more severe condition. The MADRS 
evaluates apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, 
lassitude, inability  to feel (interest level ), pessimistic thoughts, and suicidal thoughts. The test 
exhibits high inter -rater reliability .
The typi[INVESTIGATOR_154881] 7 daysand will be used for the primary  efficacy 
evaluation.
[IP_ADDRESS]. Key Secondary  Efficacy  Evaluation (Clinician -completed )
The MADRS will also be administered using a modified recall period of 24 hours for the key 
secondary  efficacy  evaluation related to onset of clinical response by [CONTACT_2006] 2 that is maintained 
for the duration of the double -blind induction phase with one excursion allowed. 
The MADRS with a 24- hour recall period will be used on Day  2. The feasibility  of this shortened 
recall period has been confirmed with patients, and physicians, and there are data supporting the 
psychometric properties of this shortened recall period (data on file). The MADRS with a 7-day 
recall will be used for all subsequent MADRS assessments used for the key secondary  efficacy 
evaluation (maintenance of clinical response achieved on Day 2  for duration of double -blind 
induction phase).
[IP_ADDRESS]. Key Secondary  Effica cy Evaluation (Patient -reported Outcome )
[IP_ADDRESS].1. SDS
The SDS will be used to assess the secondary  objective of functional impact and associated 
disability . The SDS is a subject -reported outcome measure and is a 5-item questionnaire which 
has been widel y used and accepted for assessment of functional impairment and associated 
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3002 Amendment 2
Status: Approved , Date: [ADDRESS_508726] three items assess disruption of (1) work/school, (2) social life, and 
(3)famil y life/home responsibilities using a 0-[ADDRESS_508727] from school or work and one item on day s when underproductive. 
The recall period for this study  is 7 day s.
[IP_ADDRESS].2. PHQ -[ADDRESS_508728] -report ed outcome measure that will be used to assess depressive 
symptoms.84The scale scores each of the 9 sy mptom domains of the DSM -5 MDD criteria and it 
has been used both as a screening tool and a measure of response to treatment for depression. 
Each item is rated on a 4-point scale (0=not at all, 1=several days, 2=more than half the days, 
and 3=nearl y every  day). The subject’s item responses are summed to provide a total score 
(range of 0 to 27) with higher scores indicating greater severit y of depressive symptom s. The 
recall period is 2 weeks. 
[IP_ADDRESS]. Other Secondary  Efficacy  Evaluations (Clinician -completed)
[IP_ADDRESS].1. CGI-S
The CGI-S provides an overall clinician -determined summary  measure of the severit y of the 
subject’s illness that takes into account all available information , including knowledge of the 
subject’s history , psychosocial circumstances, symptoms, behavior, and the impact of the 
symptoms on the subject’s abilit y to function.35The CGI-S evaluates the severit y of 
psychopathology  on a scale of [ADDRESS_508729] is assessed 
on severity  of mental illness at the time of rating according to: 0=not assessed; 1=normal (not at 
allill); 2=borderline mentally  ill; 3=mildly  ill; 4=moderatel y ill; 5=markedly  ill; 6=severel y ill; 
7=among the most extremely  ill patients. The CGI-S permits a global evaluation of the subject’s 
condition at a given time.
[IP_ADDRESS]. Other Secondary  Efficacy  Evaluation s (Patient -reported Outcomes)
[IP_ADDRESS].1. GAD-[ADDRESS_508730] -reported GAD -7 will be used to measure the secondary  objective of 
symptoms of anxiety . The GAD-7 is a brief and validated measure of overall anxiety . Each item 
is rated on a 4-point scale (0=not at all; 1=several days; 2=more than half the days; 3=nearl y 
every  day).83Item responses are summed to yield a total score (range of 0 to 21), with higher 
scores indicat ingmore anxiety . The recall period is 2 weeks.
[IP_ADDRESS].2. EQ-5D-5L
The EQ-5D- 5L is a standardized instrument for use as a measure of health outcome, primarily 
designed for self -completion by  [CONTACT_170496]. It consists of the EQ -5D- 5Ldescriptive sy stem and 
the EQ visual analogue scale (EQ- VAS). The EQ-5D- 5L descriptive system compris es the 
following 5 dimensions: Mobility , self-care, usual activities, pain/discomfort and 
anxiety /depression. Each of the 5 dimensions is divided into 5 levels of perceiv ed problems 
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3002 Amendment 2
Status: Approved , Date: 3 June 2016 105(Level 1 indicating no problem, Level 2 indicating slight problems, Level 3 indicating moderate 
problems, Level 4 indicating severe problems, and L evel 5 indicating extreme problems).
The subject selects an answer for each of the [ADDRESS_508731] 
matches his or her health “today .” The descriptive system can be represented as a health state. 
The EQ-VAS self-rating records the respondent’s own assessment of his or heroverall health 
status at the time of completion, on a scale of 0 to 100 . 
The time taken to complete the questionnaire varies with age, health status, and setting but is 
likely  to be around 1 minute.
9.2.2. Endpoints
[IP_ADDRESS]. Primary  Endpoint
The primary  efficacy  endpoint is the change in the MADRS total score as measur ed by [CONTACT_154955] (Day  1  prior to randomization) to the end of the 4-week double -blind 
induction phase.
[IP_ADDRESS]. Secondary  Endpoints
The first key secondary  endpoint is the proportion of subjects showing onset of clinical response 
by [CONTACT_2006] 2 that is maintained through the end of the 4-week double -blind induction phase . Onset 
of clinical response is defined as ≥50% reduction in the MADRS total score by [CONTACT_154956] -blind medication (Day 2)that continued through the end of the 
4-week double -blind induction phase with one excursion allowed. Subjects who discontinue the 
study  prior to the end of the double -blind induction phase will not be considered to have 
maintained clinical response.
The second key secondary  endpoint is the change in SDS total score as measured by [CONTACT_7178] (Day  1 prior to randomization) to the end of the 4-week double -blind induction 
phase.
The third key secondary  endpoint is the change from baseline (Day  1 prior to randomization) to 
the end of the 4-week double -blind induction phase in subject -reported depressive symptoms, 
using the PHQ -9 total score.
Other secondary  efficacy endpoint s include:
Proportion of responders (50% reduction from baseline in MADRS total score) atthe end 
of the 4- week double -blind induction phase
Proportion of subjects in remission (MADRS 12) at the end of the 4-week double -blind 
induction phase
Change from baseline (Day  1 prior to randomization) to the end of the 4-week double -blind 
induction phase in: 
Severity  ofdepressive illness, using the CGI -S
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3002 Amendment 2
Status: Approved , Date: 3 June 2016 106Anxiety  symptoms, as measured by  [CONTACT_154957] -7
Health-related qualit y of life and health status, as assessed b y the EQ -5D- 5L
9.3. Pharmacokinetics
Whole blood samples will be used to evaluate the PK of esk etamine. Serum collected for PK
may additionally  be used to evaluate safet y or efficacy  aspects that address concerns arising 
during or after the study  period. Genetic analyses will not be performed on these serum samples. 
Subject confidentiality  will be maintained.
9.3.1. Evaluations
Venous blood samples of approximately 2 mL will be collected for measurement of plasma 
concentrations ofesketamine, noresketamine, and other metabolites (if warranted) at the time 
points specified in the Time and Events Schedu le. The exact dates and times of PK blood 
sampling must be recorded.
9.3.2. Analytical Procedures
Plasma samples will be analyzed to determine concentrations ofesketamine (and noresketamine , 
if warranted) using a validated, specific, achiral, and sensitive liquid chromatograph y-tandem 
mass spectrometry  (LC-MS/MS ) method by [CONTACT_43754]. If required, 
some plasma samples may be analy zed to document the presence of other analy tes 
(eg,circulating metabolites or denatonium) using a qualifie d research method. In addition, 
plasma PK samples may  be stored for future anal ysis of the metabolite profile.
The bioanaly tical report, including a description of the assay  and a summary  of the assay  
performance data, will be included in the final clinical study  report as an addendum.
9.3.3. Pharmacokinetic Parameters
The plasma concentration -time data of esketamine (and noresketamine , if warranted) will be 
analyzed using population PKmodeling. Typi[INVESTIGATOR_154882] 
(eg,esketam ine clearance distribution volume) will be estimated together with the 
inter-individual variability . Effects of subject demographics, laboratory  parameter values, and 
other covariates on the PKof esketamine will be explored. The results of the population PK
analyses may  be reported separately .
9.4. Pharmacokinetic/Pharmacody namic Evaluations
The relationship between MADRS total score (and possibly  selected adverse events as additional 
PDparameters) and PKmetrics of esketamine may be evaluated. If there is any visual trend in 
graphical analysis, suitable models will be applied to describe the exposure -effect relationships. 
The results of the exposure -response evaluations will be presented in a separate rep ort.
9.5. Biomarker, Pharmacogenomic (DNA ), and Expression (RNA )Evaluations
During the study , blood will be collected for the assessment of biomarkers at the time points 
indicated in the Time and Events schedule. The biomarker blood samples should be collected 
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3002 Amendment 2
Status: Approved , Date: 3 June 2016 107prior to dosing . It is preferred that subjects adhere to a low fat diet on the day of sample 
collection.
In blood, biomarkers (protein, metabolite, and ribonucleic acid [ RNA ]) related to (but not limited 
to) the immune system activity , hypothalamus pi[INVESTIGATOR_154883] (HPA) axis activation, 
neurotrophic factors ,and metabolic factors will be investigated. Biomarkers may be added or 
deleted based on scientific information or technical innovations under the condition that the total 
volume of blood c ollected will not be increased.
Biomarkers may be added or deleted based on scientific information or technical innovations 
under the condition that the total volume of blood collected will not be increased.
The biomarker data obtained from this study  may also be included in an ongoing cross- study 
analysis to investigate the relationship between depression severity and phenot ypes and 
biomarkers.
Blood samples for DNA analyses will be collected at the time points indicated in the Time and 
Events Schedule for the assessment of genetic and epi[INVESTIGATOR_154884] s 
relevant to depression (eg, HPA axis, inflammation, growth factors, monoamine transporters, ion 
channels, and circadian rhy thm).
Genoty pi[INVESTIGATOR_154885] y on the screening sample; pharmacogenomic and epi[INVESTIGATOR_154886] y/all collected samples.
DNA samples will be used for research related to esketamine , oral antidepressants, TRD, or 
MDD . They  may  also be used to develop tests/assay s related to esketamine , oral antidepressants, 
TRD, or MDD . Pharmacogenomic research may consist of the analy sis of 1or more candidate 
genes or of the analysis of genetic markers throughout the genome (as appropriate) in relation to 
esketamine , oral antidepressants, TRD, or MDD clinical endpoints.
Further information regarding handling, shipment, and labeling of biological samples will be 
provided in a separate laboratory  manual.
9.6. Medical Resource Utilization
Medical resource utilization data, associated with healthcare encounters, will be collected during 
the follow -up phase of the study . Protocol -mandated procedures, tests, and encounters are 
excluded. The data collected may be used to conduct exploratory  economic analyses and will 
include:
Number, duration, and t ypeof healthcare encounters (inpatient and outpatient)
Duration of hospi[INVESTIGATOR_059] (total day s length of stay , including duration by [CONTACT_54006])
9.7. Safety  Evaluations
Details regarding the Independent Data Monitoring Committee are provided in Se ction 11.9.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3002 Amendment 2
Status: Approved , Date: [ADDRESS_508732] be recorded on the Adverse 
Event section of the eCRF.
Any clinically  significant abnormalities persisting at the end of the study/earl y withdrawal will 
be followed b y the investigator until resolution or until a clinically  stable endpoint is reached.
The study  will include the following evaluations of safet y and tolerability  according to the time 
points provided in the Time and Events Schedule.
There may  be instances where a subject has started a sche duled clinic visit in which an intranasal 
treatment session is planned, but due topredose vital sign measurements (eg, blood pressure 
value) , a decision has been made to postpone/delay  the intranasal treatment session within the 
visit window permitted per protocol. In such cases, all time points (including predose) of the 
following assessments must be repeated on the actual intranasal treatment session day: vital sign 
(ie, blood pressure, pulse, respi[INVESTIGATOR_2842], andtemperature) , 12- lead ECG, C- SSRS (since last 
visit), MOAA/S, pulse oximetry , BPRS+, and CADSS .
Adverse Events
Adverse events will be reported by [CONTACT_423] (or, when appropriate, by a caregiver, surrogate, 
or the subject's legall yacceptable representative) for the duration of the study . Adverse events 
will be followed by  [CONTACT_23803] 12, Adverse Event Reporting.
TEAEs of special interest will be examined separately  (please refer to Sections 3.2.6 and 11.8).
Clinical Laboratory Tests
Blood samples for serum chemistry  and hematology  and a urine sample for urinal ysis will be 
collected. The investigator must review the laboratory  report, document this review, and record 
any clinically  relevant changes occurring during the study  in the adverse event section of the 
eCRF. The laboratory  reports must be filed with the source documents.
The use of local laboratories is allowed in cases where initiation of treatment or safety  follow -up 
is time-critical and the central laboratory  results are not expected to be available before the need 
to begin dosing or if actions need to be taken for safet y reasons.
The following tests will be performed b y the central laboratory, unless noted otherwise:
Hematology Panel
-hemoglobin -platelet count
-hematocrit
-red blood cell (RBC) count
-white blood cell (WBC) count with differential
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3002 Amendment 2
Status: Approved , Date: 3 June 2016 109Serum Chemistry Panel
-sodium -alkaline phosphatase
-potassium -creatine phosphokinase (CPK)
-chloride -calcium
-bicarbonate -phosphate
-blood urea nitrogen (BUN) -albumin
-creatinine -total protein
-glucose -total bilirubin
-aspartate aminotransferase (AST)
-alanine aminotransferase (ALT)
-gamma -glutam yltransferase (GGT)
Urinalysis
Dipstick Sediment (if dipstick result is abnormal)
-specific gravit y -redblood cells
-pH -white blood cells
-glucose -epi[INVESTIGATOR_1663]
-protein -crystals
-blood -casts
-ketones -bacteria
-bilirubin
-urobilinogen
-nitrite
-leukocy te esterase
If dipstick result is abnormal, flow cytometry  or microscop y will be used to measure 
sediment. In case of discordance between the dipstick results and the flow cytometric 
results, the sediment will be examined microscopi[INVESTIGATOR_897] .
The following tests will be done at time points specified in the Time and Events Schedule or as 
required based on subject status (noted below) :
Lipid panel: Total cholesterol, low density  lipoprotein (LDL)-cholesterol, high density  
lipoprotein ( HDL )-cholesterol , and trigl ycerides
Serum and u rine pregnancy  testing (for women of childbearing potential only)
Urine Drug Screen: Barbiturates, methadone, opi[INVESTIGATOR_858], cocaine, cannabinoids (cannabinoids 
are onl y tested at Day 1 predose ), phency clidine, and amphetamine/methamphetamine
Alcohol breath test 
Thyroid- stimulating hormone (TSH)
Free thy roxine (FT4), only  if required for abnormal TSH (refer to Inclusion criteria)
Calculation of creatinine clearance
Glycated hemoglobin ( HbA1c ) test
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3002 Amendment 2
Status: Approved , Date: 3 June 2016 110A serum follicle stimulating hormone (FSH) level test, only if required for documentation
that a female subject is not of childbearing potential (refer to Inclusion Criteria No. 9)
Single, 12-Lead ECG
During the collection of ECGs, subjects should be in a quiet setting without distractions 
(eg,television, cell phones). Subjects should rest in a supi[INVESTIGATOR_21683] 5minutes 
before ECG collection and should refrain from talking or moving arms or legs.
All ECG tracings will be sent to a central ECG laboratory . The ECGs will be read at the 
scheduled time points and summarized by  a central ECG laboratory . The central ECG laboratory 
will send the sponsor an electronic copy of the data for inclusion in the clinical database. In 
addition, the investigator or sub-investi gator is required to review all ECGs at the study  visit to 
assess for any potential safet y concerns or evidence of exclusionary  conditions.
A subject must be discontinued from at an y time point after baseline (Day 1, predose) if:
QTcF change from baseline is ≥60msecAND QTcF >480 ms ec, or
QTCF > 500msec.
Vital Signs (temperature, pulse/heart rate, respi[INVESTIGATOR_697], blood pressure)
Blood pressure and pulse/ heart rate measurements will be assessed supi[INVESTIGATOR_139731] a completely 
automated device or using manual techniques.
Blood pressure and pulse/heart rate measurements should be preceded by [CONTACT_2669] [ADDRESS_508733] in a quiet setting without distractions (eg, television, cell phones).
For further details regarding blood pressure, please see Guidance on Blood Pressure Monitoring 
on Intranasal Dosing Day s (Section 6.2.1 ).
Tympanic temperature is recommended.
An automated device will be used for measurement of respi[INVESTIGATOR_13521] y rate.
Pulse Oximetry
Pulse oximetry  will be used to measure arterial oxygen saturation. On each dosing day, the 
device will be attached to the finger, toe, or ear before the first nasal spray  and then, after the 
first spray  it will be monitored and documented. Any arterial oxygen saturation (SpO 2) <93% 
should be confirmed b y an additional measurement on another part of the body.
On intranasal treatment session days, pulse oximetry  will be recorded every  15 minutes from 
predose to t=1.5 hours postdose . If oxygen saturation levels are <93% at any time during the 1.5 
hour postdose interval, pulse oximetry  will be recorded every  5  m inutes until levels return to 
≥93% or until the subject is referred for appropriate medical care, if clinically  indicated.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3002 Amendment 2
Status: Approved , Date: 3 June 2016 111Physical Examination , Height, Body Weight , and Neck Circumference
Physical examinations, body  weight , and height will be performed /measured as per the Time 
and Events Schedule.
In addition, body  mass index (BMI) will be calculated and neck circumference measured as part 
of the information required for the STOP -Bang questionnaire.
Nasal Examinations 
Nasal examinations (including the upper respi[INVESTIGATOR_53121]/throat) will be conducted by  a qualified 
healthcare practitioner. The objective of the examination at screening isto rule out any subjects 
with anatomical or medical conditions that may  impede drug delivery  or absorption. 
Subsequent examinations will consist of a visual inspection of the nostrils, nasal mucosa, and 
throat for nasal erythema, rhinorrhea, rhinitis, capi[INVESTIGATOR_1396] /blood vessel disruption ,and epi[INVESTIGATOR_3940] ,
and will be graded as follows: A bsent , mild, moderate, or severe. 
Nasal Symptom Questionnaire
Subjects will complete a nasal symptom questionnaire. The nasal symptom questionnaire was 
developed by [CONTACT_154958]. The questionnaire asks about nasal s ymptoms, which are rated by  [CONTACT_154959], mild, 
moderate, or severe, based on how he or she feels at the time of the assessment.
C-SSRS
The C -SSRS will be performed to assess potential suicidal ideation and behavior. 
The C-SSRS is a low-burden measure of the spectrum of suicidal ideation and behavior that was 
developed in the National Institute of Mental Health Treatment of Adolescent Suicide 
Attempters Study  to assess severit y and track suicidal events through any treatment.69It is a 
clinical interview providing a summary  of both suicidal ideation and behavior that can be 
administered during any  evaluation or risk assessment to identify  the level and ty pe of suicidality  
present. The C -SSRS can also be used during treatment to monitor for clinical wor sening.
Two versions of the C-SSRS will be used in this study , the Baseline/Screening version, and the 
Since Last Visit version. The Baseline/Screening version of the C-SSRS will be used in the 
screening/prospective observational phase. In this version, suicidal ideation will be assessed at 
2time points (“lifetime” and “in the past 6 months” )and suicidal behavior will be assessed at 
2time points (“lifetime” and “in the past year”).All subsequent C-SSRS assessments in this 
study  will use the Since Last V isit version, which will assess suicidal ideation and behavior since 
the subject’s last visit.
CADSS
The CADSS is an instrument for the measurement of present- state dissociative symptoms ,4and 
will be administered to assess treatment -emergent dissociative sy mptoms.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3002 Amendment 2
Status: Approved , Date: 3 June 2016 112The CADSS consists of 23 subjective items, divided into 3 components: Depersonalization 
(Items 3 to 7, 20, and 23), derealization (Items 1, 2, 8 to 13, 16 to 19, and 21) and amnesia 
(Items 14, 15, and22). Participant’s responses are coded on a 5-point scale (0=notat all through 
to 4=extremely ). CADSS has excellent inter -rater reliability  and internal consistency . 
BPRS+
Four items ofthe BPRS will be administered to assess potential treatment -emergent psychotic 
symptoms. 
The BPRS is an 18-item rating scale that is used to assess a range of psychotic and affective 
symptoms ,rated from both observation of the subject and the subject's own report.64It reportedl y 
provides a rapid and efficient evaluation of treatment response in clinic drug studies and in 
clinical settings.73
Only  the 4-item positive symptom subscale BPRS+ ( ie, suspi[INVESTIGATOR_23703], hallucinations, unusual 
thought content, and conceptual disorganization) will be used in this study . It is highl y sensitive 
to change, and excellent inter-rater reliability  can be achieved with training and a standard 
interview procedure. 
MOAA/S
The MOAA/S will be used to measure treatment -emergent sedation ,with correlation to levels of 
sedation defined b y the American Societ y of Anesthesiologists (ASA) continuum.
The MOAA/S scores range from 0=no response to painful stimulus (corresponds to ASA 
continuum for general anesthesia )to 5=readil y responds to name [CONTACT_154992] (awake; 
corresponds to ASA continuum for minimal sedation).
On each intranasal dosing day, the MOAA/S will be performed every  15 minutes from predose
to t=+1.5 hours postdose.
If the score is ≤3 at any time during the 1.5 hour postdose interval, the MOAA/S will be 
performed every  5 minutes until a score of 4 is reached (at which point a frequency  of every 
15 minutes can be resumed until t=+1.[ADDRESS_508734] dose). 
If a subject does not have a score of at least 5 at t=+1.5 hours postdose, they  should continue 
to be monitored. For subjects with a score of 4, the assessment should be repeated every 
15minutes. And for subjects with a score of ≤3, the assessment should be repeated every 
5minutes until the score returns to [ADDRESS_508735]’s current clinical status and is the clinician’s 
assessment of the readiness to be discharged from the study  site.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3002 Amendment 2
Status: Approved , Date: 3 June 2016 113The clinician will answer “Yes” or “No” to the question “Is the subject considered ready to be 
discharged based on their overall clinical status ( eg, sedation, blood pressure , and other adverse 
events )?”
On each intranasal dosing day, the CGADR will be performed at 1 hour and 1.5 hours postdose; 
if the response is not “Yes” at 1.5 hours postdose, the assessment will be repeated every 
15minutes until a “Yes” response is achieved or until the subject is referred for appropriate 
medical care ,if clinically indicated .A subject should not be discharged prior to the 1.[ADDRESS_508736] -reported outcome measure that was developed to identify  an 
appropriate bladder pain syndrome/interstitial cystitis population for clinical studies evaluating
new treatments for bladder pain s yndrome .[ADDRESS_508737] 7 days, and addresses key 
symptoms identified by [CONTACT_154960]/or pressure 
of the bladder andurinary  frequency .Subjects respond to items using a 5-point scale (0=never , 
1=rarely, 2=sometimes, 3=most of the time, 4=alway sfor frequency -based questions ,and 0=not 
at all , 1=a little, 2=somewhat, 3=moderately, and 4=a great deal for items related to bother 
associated with symptoms ). Question [ADDRESS_508738] . The range of scores for the scale is 0 to 38 .
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3002 Amendment 2
Status: Approved , Date: 3 June 2016 114A total score of 19 or more has demonstrated good sensitivity /specificity  and is consider ed a 
relevant cut -off to distinguish those with significant bladder s ymptoms or cy stitis .[ADDRESS_508739] be discontinued from the study  and followed up with 
appropriate medical care. As such, in addition to urinaly sis, a urine culture should also be obtain 
if BPI C-SS score is >18 on applicable stud y day.
Cognition Testing: Computerized Cognitive Battery and HVLT -R
The computerized cognitive battery  provides assessment of multiple cognitive domains,
including attention, visual learning and memory , and executive function. The tests use 
culture -neutral stimuli, enabling use in multilingual/multicultural settings. The computerized 
battery  includes :
Simple and choice reaction time tests; scored for speed of respon se (mean of the 
log10-transformed reaction times for correct response s)
Visual epi[INVESTIGATOR_10682] ; visual recall test scored using arcsine transformation of the 
proportion of correct responses
Working memory  (n back); scored for speed of correct respon se (mean of the 
log10-transformed reaction times for correct responses)
Executive function; maze/sequencing test ,scored for total number of errors
All measures have been validated against traditional neuropsy chological tests and are sensitive to 
the effects of various drugs on cognitive performance ,including alcohol and benzodiazepi[INVESTIGATOR_1651].
Completing the cognitive battery requires approximately  [ADDRESS_508740].
Administration includes 3 learning trials, a delay ed recall (20-minute) trial, and a 24-word 
recognition list (including 12 target and 12foil words ).3The test administrator reads instructions 
and word lists aloud, and records wordsrecalled /recognized by [CONTACT_423]. Scores include
learning, delay ed recall , and recognition. The HVLT -R is a well-validated and widely used 
measure of verbal epi[INVESTIGATOR_10682]. 
The tests will be administered in the following order: HVLT -R, computeriz ed cognitive test 
battery , and HVLT -R D elayed.
All subjects will complete a practice session for the computerized cognitive battery  during the 
screening/prospective observational phase. There is no practice session for the HVLT -R.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3002 Amendment 2
Status: Approved , Date: [ADDRESS_508741]
To assess any potential treatment -emergent effects on the sense of smell, olfactory  function will 
be qualitatively  and quantitatively  assessed using validated standardized olfactory  tests prior to 
and at specified time points during the study . The 2tests to be administered are: 
The UPSI T assesses a subject ’s ability  to identify  odors. This standardized test, the most 
widely  used olfactory test in the world, is derived from basic psychological test 
measurement theory  and focuses on the comparative ability  of subjects to identify  odorants 
at the suprathreshold level. The UPSI T consists of 4envelope -sized booklets, each 
containing 10“scratch and sniff” odorants embedded in 10-to 50-µm polymer 
microcapsules positioned on brown strips at the bottom ofthe pages of the booklets. The 
internal consistency  and test-retest reliability  coefficients of this instrument are >0.90.17,18,[ADDRESS_508742] shown this and related tests to be sensitive to subtle changes in smell 
function associated with multiple etiologies, including those due to viruses, head trauma, 
and a number of neurodegenerative diseases.
The Smell Threshold Test will assess the smell threshold using a forced -choice single 
staircase threshold procedure. This test quantifies a detection threshold for the rose-like 
smelling odorant pheny l ethyl alcohol (PEA). This odorant is used because it has little 
propensity  to stimulate the trigeminal nerve within the nose. This test is sensitive to 
olfactory  deficits from a wide range of disorders. 
These tests will be administered bilaterally  (ie, both nostrils at the same time). Testing will occur 
during the screening /prospecti ve observational phase to establish a subject’s baseline sensitivity . 
The degree of change from this baseline will be determined subsequently  over time. The percent 
change from baseline will serve as the dependent measure for each subject for each test. 
If the subject has significant nasal congestion on the day of ascheduled UPSI T and/or Smell 
Threshold Test, the site should consider postponing the smell test assessment(s) to the next 
scheduled clinic visit.
9.8. Other Evaluations
MINI
Subjects will undergo MINI (a brief , structured diagnostic interview )to confirm the diagnosis of 
MDD and to determine if there are other psychiatric conditions present. It has an administration 
time of approximately  15 minutes .
MGH -ATRQ
The MGH -ATRQ is used to determine treatmen t resistance in MDD .15
The MGH -ATRQ evaluates the adequacy  of duration and dosage of all antidepressant 
medications used for the current major depressive epi[INVESTIGATOR_1865] . In addition, the MGH -ATRQ asse sses 
the degree of improvement on a scale from 0% (not improved at all) to 100% (completely 
improved). The MGH -ATRQ will be completed by [CONTACT_154961].
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3002 Amendment 2
Status: Approved , Date: 3 June 2016 116STOP -Bang Questionna ire
The STOP -Bang Questionnaire is a concise, easy-to-use, validated, and sensitive screening tool 
for obstructive sleep apnea (OSA). This questionnaire has 8 items which address key risk factors 
for obstructive sleep apnea: snoring, tiredness, observed br eathing interruption during sleep, high 
blood pressure, body mass index, age, neck size, and gender. The STOP -Bang questions do not 
specify  a  recall period. Subjects will answer yes or no to questions about snoring, tiredness, 
observed breathing interrupti on, and high blood pressure (these are the “STOP” items in the 
STOP -BANG acron ym); this takes approximately  1 minute.6
Study  site staff will answer yes or no to questions about body  mass index (more than 35 kg/m²?), 
age (older than 50 years?), neck circumference (larger than 17 inches [43 cm] in men, or larger 
than 16 inches [41 cm] in women?), and gender (male?).
The total STOP -BANG score is calculated by [CONTACT_154962], 
yielding a score range of 0 to 8. A score of 5 on the STOP -Bang indicates a moderate to severe 
risk for Obstructive Sleep Apnea (apnea h ypopnea index of >30) .6
Site Indep endent Qualification Assessment
Independent psychiatrists/psy chologists will perform the Site Independent Qualification 
Assessment in the screening/prospective observational pha se for all subjects to confirm diagnosis 
of depression and eligibility  for the stud y.[ADDRESS_508743] been established in various study  samples.86
Mass achusetts General Hospi[INVESTIGATOR_154887] ( MGH -Female RLHQ): Module I and Menstrual Cycle Tracking
The MGH -Female RLHQ Module I (childbearing potential, menopausal status, and menstrual 
cycle) is abrief questionnaire aimed at standardizing the minimal collection of relevant 
information about reproductive hormones and status. Itwill be completed by a clinician. This 
information may facilitate exploratory  analyses of the impact of endogenous and exogenous 
reproductive hormones on the course of treatment of MDD and potentially  inform care of women 
with MDD in the future.33
Menstrual cycle tracking (start date of last menstrual period) will be documented at the study  
visits specified i n the Time and Events Schedule only for women with a menstrual cy cle.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3002 Amendment 2
Status: Approved , Date: 3 June 2016 117PAQ
Subjects’ adherence to their oral antidepressant treatment regimen during the 
screening/prospective observational phase will be assessed using the PAQ. It is a brief, 2-item 
subject -report outcome measure that was developed at the University  of [LOCATION_007] Southwestern 
Medical Center to assess how often the subject has taken, and whether heor she has made any 
changes tohis/her antidepressant treatment regimen in the last 2 weeks . The total score is based 
on the response selected to Question 1, and is interpreted as0to 1 =adherent and 2or 
more=nonadherent.
9.9. Sample Collection and Handling
The actual dates and times of sample collection must be recorded in the eCRF or laboratory 
requisition form. If blood samples are collected via an indwelling cannula, an appropriate 
amount (1 mL) of serosanguineous fluid slightly  greater than the dead space volume of the lock 
will be removed from the cannula and discarded before each blood sample is taken. After blood 
sample collection, the cannula will be flushed with 0.9% sodium chloride, [LOCATION_002] 
Pharmacopeia (USP) (or equivalent) and charged with a volume equal to the dead space volume 
of the lock.
Refer to the Time and Events Schedule for the timing and frequency  of all sample collections.
Instructions for the collection, handling, storage, and shipment of samples are found in the 
laboratory  manual that will be provided. Collection, handling, storage, and shipment of samples 
must be under the specified, and where applicable, controlled temperature conditions as indicated 
in the laboratory  manual.
10. SUBJECT COMPLETION/W ITHDRA WAL
10.1. Completion
A subject will be considered to have completed the double -blind induction phase of the study  if 
he or she has completed the MADRS assessment at the end of the 4 -week double -blind induction
phase (ie,Day 28 MADRS) .
Subjects who prematurely discontinue study  treatment for any reason before completion of the 
double -blind induction phase will not be considered to have completed the double -blind 
induction phase of the study .
Subjects who enter the follow -up phase will be consider ed to have completed thisphase of the 
study if he or she has completed the MADRS asse ssment atWeek [ADDRESS_508744] will be withdrawn from the stud y for any of the following reasons:
Lost to follow -up
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3002 Amendment 2
Status: Approved , Date: 3 June 2016 118Withdrawal of consent (Note: See “Withdraw of Consent” section below; this should only 
be selected as a reason for withdrawal if the subject does not agree to any further study  
assessments or procedures. If the subject is agreeable to participating in the Early 
Withdrawal visit and the follow -up phase, another reason for withdrawal should be 
selected.)
Violation of protocol procedures (determined on a case- by-case basis)
Blind is broken (double -blind induction phase)
Lack of efficacy
The investigator or sponsor believes (eg, that for safety or tolerability  reasons such as an 
adverse event) it is in the best interest of the subject to discontinue the study .See also 
guidance on blood p ressure monitoring on intranasal dosing day s (Section 6.2.1 ).
At any  time point after baseline (Day  1, predose), the subject has a:
 QTcF change from baseline ≥ 60msec AND QTcF >480 msec, or
 QTcF >500 msec.
Subject becomes pregnant
Study  is terminated by  [CONTACT_154963]
Death
If the subject withdraws from the study  before the end of the double -blind induction phase, an 
Early Withdrawal visit is to be performed .
If a subject is lost to follow -up, every reasonable effort must be made by  [CONTACT_43757]/withdrawal. This should 
include at least [ADDRESS_508745] numbers (eg, home, work, and mobile phone numbers), as well as other contact 
[CONTACT_3031] (eg, email addresses) from subjects before randomization. In addition, the study  site 
should emphasize the importance of follow -up information to the subject before randomization . 
The measures taken to follow up must be documented.
When a subject withdraws before completing the study , the reason for withdrawal is to be 
documented in the eCRF and in the source document. Subjects who withdraw will not be 
replaced.
Withdrawal of Consent
Every  effort will be made in the study  to ensure withdrawal of consent is not selected as a reason 
for discontinuation when in fact the subject withdrew for an identifiable reason (e.g due to an 
adverse event or withdrew due to lack of efficacy).
Subjects who wish to withdraw from the study  should be asked if they are agreeable to continue 
to an early withdrawal visit (if withdrawing from the double -blind induction phase) and the 
follow up ph ase, or to be contact[CONTACT_132610] -up information. Subjects who are not 
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3002 Amendment 2
Status: Approved , Date: [ADDRESS_508746] will be withdrawn from thestudy  as “withdrawal of consent .”
Subjects who no longer wish to take study  drug but agree to provide follow -up information will 
be withdrawn from the double -blind induction phase with the reason noted as “Other” and will 
specify  the reason wh y.
For a subject who does “withdrawal of consent”, it is recommended that the subject withdraw 
consent in writing; if the subject refuses or is physically  unavailable, the study  site should 
document and sign the reason for the subject’s failure to withdraw consent in writing and 
maintain it with the subjects source records.
The investigator will be responsible for making all required notifications to the Institutional 
Review Board (I RB) or Independent Ethics Committee (IEC).
10.3. Withdrawal from the Use of Sample s in Future Research
The subject may withdraw consent for use of sample s for research (refer toSection 16.2.5 , 
Long -Term Retention of Samples for Additional Future Research). In such a case, samples will 
be destro yed after they are no longer needed for the clinical study . Details of the sample 
retention for research are presented in the main ICF.
11. STATISTICA L METHODS
Statistical analy sis will be done by [CONTACT_43758]. A general 
descriptio n of the statistical methods to be used to anal yze the efficacy  and safet y data is outlined 
below. Specific details will be provided in the Statistical Analy sis Plan.
At the end of the double -blind induction phase the database will be locked for the analy sis and 
reporting of this phase. The subject treatment assignment will be revealed only to sponsor’s 
study  staff. The investigators and the site personnel will be blinded to the treatment assignment 
until all subjects have completed study  participation thr ough the follow- up phase.
11.1. Subject Information
The primary  efficacy  and safet y analysis sets are defined below.
Full Analysis Set: All randomized subjects who receive at least 1dose of intranasal study 
medication and 1 dose of oral antidepressant in the double -blind induction phase .
Safety Analysis Set: All randomized subjects who receive at least 1dose of intranasal study  
medication or [ADDRESS_508747] deviation of 12, a 1-sided significance level of 0.025 ,and a drop-
out rate of 25% .A total of about 98 subjects will need to be randomized to each treatment group 
to achieve 90% power .The treatment difference and standard deviation used in this calculation 
were based on results of Panel A of the ESKETINTRD2003 study  andon clinical judgment.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3002 Amendment 2
Status: Approved , Date: [ADDRESS_508748] 1 dose of intranasal study  drugand 1 dose of oral antidepressant 
medication in the do uble-blind induction phase.
With the exception of European Union (EU) dossier, theprimary  efficacy  variable, change from 
baseline in MADRS total score at Week 4 in the double -blind induction phase , will be analyzed 
using MMRM. The model will include basel ine MADRS total score as a covariate, and 
treatment, country , class of antidepressant (SNRIor SSRI), day, and day-by-treatment 
interaction as fixed effects, and a random subject effect. Comparison of theesketamine plus oral 
antidepressant arm versus oral antidepressant plus intranasal placebo will be performed u sing the 
appropriate contrast.
For the EU dossier, the primary  efficacy  analysis will be based on an analysis of covariance 
(ANCOVA) model using last observation carried forward (LOCF) data.The model will include 
factors for treatment, country , and class of oral antidepressant (SNRIorSSRI) and baseline 
MADRS total score as a covariate. Comparison of theesketamine plus oral antidepressant arm 
versus intranasal placebo plus oral antidep ressant will be performed using the appropriate 
contrast .
For the analy sis of the first key secondary  efficacy endpoints, the proportion of subjects showing 
onset of clinical response by [CONTACT_2006] [ADDRESS_508749] 
adjusting for country  and class of antidepressant (SNRIor SSRI).Clinical response is defined as 
50% improvement in MADRS total score by [CONTACT_2006] 2 (ie, the day after taking the first dose of 
double -blind intranasal medication) that continues through the end of the double -blind phase
with one excursion allowed. Subjects who discontinue the study  prior to end of the double -blind 
induction phase will not be considered to have maintained clinical response.
The second and third key secondary  efficacy  endpoints, change from baseline in SDS total score 
at Week 4 and change from baseline in PHQ -9 total score at Week 4(subject to regulatory  
acceptance of PHQ -9) in the double -blind induction phase , will be analy zed using the same 
models described above for the MADRS total score .Responses to questions H1 to H3 from the 
SDS will be summarized separately.
A serial gatekeepi[INVESTIGATOR_007] (fixed sequence) approach20,21will be applied to adjust for multiplicity  and 
to strongl y control type I error across the prim ary and the 3 key secondary  efficacy  endpoints 
(onset of clinical response, change in SDS total score ,and change in PHQ -9 total score,). Further 
details of this approach will be provided in the SAP.
Response and remission rates will be summarized at each visit.
Change from baseline in GAD-7 total scores and ranks of change from baseline in CGI-S scores 
at the end of the double -blind induction phase will be analy zed based on LOCF data using an 
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3002 Amendment 2
Status: Approved , Date: 3 June 2016 121ANCOVA model, with country  and class of antidepressant (SNRI or SSRI) as factors, and the 
respective baseline score (unranked score in the case of CGI- S) as the covariate. 
Dimension scores of EQ-5D- 5L data, health status index, and the overall health status score will 
be summarized over time.
Additionally , scores of all efficacy  endpoints will be summariz ed for all visits in the 
double -blind induction phase . Summaries will be provided to show consistency  of effect among 
relevant subgroups (eg, antidepressant class S NRI and S SRI).
11.4. Pharmacokinetic Analyses
Plasma esketam ine (and noresketamine , if warranted) concentrations will be listed for all 
subjects. The plasma concentration -time data of esketamine (and noresketamine , if warranted)
will be analyzed using population PKmodeling. Data may be combined with those of other 
selected studies to support a relevant structural model. Typi[INVESTIGATOR_154889]-individual variability . Effects of subject 
demographics, laboratory parameter values, and other covariates on the PKof esketamine will be 
explored. The results of the population PKanalyses may  be reported separately .
11.5. Pharmacokinetic/Pharmacody namic A nalyses
The relationship between MADRS total score (and possibly  selected adverse events as additional 
PDparameters) and PKmetrics of esketamine may be evaluated. If there is any visual trend in 
graphical analysis, suitable models will be applied to describe the exposure -effect relationships. 
The results of the PK/PDanalysesmay be reported separately .
11.6. Biomarker and Pharmacogenomic Analyses
Baseline biomarker values and changes from baseline biomarker values to the time points 
specified in the Time and Events Schedule will be summarized. Exploratory  analyses may 
include comparison of biomarker measures between the treatment groups and correlation with 
baseline and change from baseline biomarker values in the efficacy and other measures. 
Additional exploratory  analyses may also include relationship of baseline and change from 
baseline in biomarker measures to clinical response, maintenance/stabilization of response, 
relapse, and non -response.
Pharmacogenomic analyses may include candidate gene analy ses or genome -wide association 
analyses in relation to treatment response, maintenance/stabilization of response, relapse, 
non-response , and MDD/TRD. Expression analy ses may include testing of known messenger 
RNA/mi croRNA (mRNA/miRNA) transcripts or transcriptome -wide analy sis in relationship to 
antidepressant treatment response a nd MDD/TRD.
Details of the analy sis plan and summary  of results from both biomarker and pharmacogenomics 
analyses will be reported separately .
11.7. Medical Resource Utilization Analyses 
Medical resource utilization data will be descriptively  summarized.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3002 Amendment 2
Status: Approved , Date: 3 June 2016 [ZIP_CODE].8. Safety Analyses
Safety  data will be analy zed for the double -blind induction phase using the safety  analysis set. 
The safet y data from the follow -up phase will be summarized separatel y.
Adverse Events
The verbatim terms used in the eCRF by [CONTACT_154967] . All reported adverse events with onset during the double -blind induction 
phase (ie, TEAEs, and adverse events that have worsened since baseline) will be included in the 
analysis. For each adverse event, the percentage of subjects who experience at least [ADDRESS_508750] will be examined separatel y (please refer to Section 3.2.6 ).AEs of 
special interest will be further listed in the SAP.
Subjects who die, who discontinue treatment due to an adverse event, or who experience a severe 
or a serious adverse event will be summarized separatel y.
Clinical Laboratory Tests
Laboratory  data will be summarized by [CONTACT_23821]. Reference ranges and markedl y 
abnormal results (specified in the Statistical Analy sis Plan) will be used in the summary  of 
laboratory  data.Descriptive statistics will be calculated for each laboratory  analyte at baseline 
and at each scheduled time point in each phase of the study .Changes from baseline results will 
be presented. Frequency tabulations of the abnormalities will be provided . Listing sof subjects 
with laboratory  results outside the reference ranges andmarkedl y abnormal results will also be 
provided.
ECG
The effects on cardiovascular varia bles will be evaluated by [CONTACT_23822]. These tables will include observed values and change from baseline 
values.
Electrocardiogram data will be summarized by [CONTACT_105292]. Descriptive statistics will be 
calcu lated at baseline and for observed values and changes from baseline at each scheduled time 
point. Frequency  tabulations of the abnormalities will be made.
The ECG variables that will be analy zed are heart rate, PR interval, QRS interval, QT interval, 
and QTc interval using the following correction methods: QT corrected accor ding to Bazett's 
formula (QTcB) and QTcF .2,39,77
Descriptive statistics of QTc intervals and changes from double -blind baseline will be 
summarized at each scheduled time point. The percentage of subjects with QTc interval 
>450 msec , >480 msec , or >500 msec will be summarized, as will the percentage of subjects 
with QTc interval increase s from baseline <30 msec, 30 -60 msec, or >60 msec .
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3002 Amendment 2
Status: Approved , Date: 3 June 2016 123All important abnormalities in ECG waveform that are changes from the baseline readings will 
be reported (eg, changes in T -wave morphology  or the occurrence of U -waves).
Vital Signs
Descriptive statistics of temperature, pulse/heart rate, respi[INVESTIGATOR_2842], pulse oximetry , and blood 
pressure (s ystolic and diastolic) (supi[INVESTIGATOR_050]) values and changes from baseline will be summarized at 
each scheduled time point. The percentage of subjects with values beyond clinica lly important 
limits will be summarized.
Nasal Exam ination
Changes in findings from the baseline nasal examination (including the upper respi[INVESTIGATOR_53075]/throat) will be listed by [CONTACT_1570]. Examinations will provide ratings (absent ,mild, 
moderate, or severe) that are based on a visual inspection of the nostrils, nasal mucosa, and 
throat for nasal erythema, rhinorrhea, rhinitis, capi[INVESTIGATOR_1396] /blood vessel disruption and epi[INVESTIGATOR_3940]. A 
shift table for changes from double -blind baseline in rating sfor each examination will be 
presented b y treatment group.
Nasal Symptom Questionnaire
Scoring from the nasal symptom questionnaire will be summarized descriptivel y for each 
scheduled time point by [CONTACT_1570].
C-SSRS 
Suicide -related thoughts and behaviors based on the C-SSRS will be summarized by [CONTACT_154969]. Separate endpoints for suicidal ideation and suicidal behavior 
will be defined and summarized descriptively  by [CONTACT_1570]. Missing scores will not be
imputed. 
CADSS, BPRS+, and MOAA/S
Descriptive statistics of each score and changes from predose will be summarized at each 
scheduled time point.
Clinical Global Assessment of Discharge Readiness , PWC-20, BP IC-SS, UPSIT, and Smell 
Threshold Test
Descriptive statistics of each score and changes and/or percent changes from baseline will be 
summarized at each scheduled time point.
Cognition Testing
Descriptive statistics of the cognitive domain scores and changes from baseline will be 
summarized at e ach scheduled time point.
11.9. Independent Data Monitoring Committee
An IDMC will be established to monitor data on an ongoing basis to ensure the continuing safet y 
of the subjects enrolled in this study . The committee will meet every  6months to review safet y 
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3002 Amendment 2
Status: Approved , Date: [ADDRESS_508751] Operating Procedures in 
conformity  with regulatory  requirements worldwide to ensure appropriate reporting of safet y 
information; all clinical studies conducted by [CONTACT_43765].
12.1. Definitions
12.1.1. Adverse Event Definitions and Classifications
Adverse Event
An adverse event is any untoward medical occurrence in a clinical study  subject administered a 
medicinal (investigational or non-investigational) product. An adverse event does not necessaril y 
have a causal relationship with the treatment. An adverse event can therefore be any  unfavorable 
and unintended sign (including an abnormal finding), sy mptom, or disease temporally  associated 
with the use of a medicinal (investigational or non-investigational) product, whether or not 
related to that medicinal (investigational or non-investigational) product (definition per 
International Conference on Harmonisation [I CH]) .
This includes any  occurrence that is new in onset or aggravated in severit y or frequency  from the 
baseline condition, or abnormal results of diagnostic procedures, including laboratory  test 
abnormalitie s.
Note: The sponsor collects adverse events starting with the signing of the ICF (refer to 
Section 12.3.[ADDRESS_508752] adverse event recording).
Serious Adverse Event
A serious adverse event based on ICH and EU Guidelines on Pharmacovigilance for Medicinal 
Products for Human Use is any  untoward medical occurrence that at an y dose:
Results in death
Is life-threat ening (for example, the subject was at risk of death at the time of the event. 
“Life threatening” d oes not refer to an event that hy pothetically  might have caused death if it 
were more severe.)
Requires inpatient hospi[INVESTIGATOR_8686]
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3002 Amendment 2
Status: Approved , Date: 3 June 2016 125Results in persistent or significant disability /incapacity
Is a congenital anomal y/birth defect
Is a suspected transmission of an y infectious agent via a medicinal product
Is medicall y important*
*Medical and scientific judgment should be exercised in deciding whether expedited reporting is 
also appropriate in other situations, such as important medical events that may not be 
immediately  life threatening or result in death or hospi[INVESTIGATOR_23738]. 
These should usually  be considered serious.
If a serious and unexpected adverse event occurs for which there is evidence suggesting a causal 
relationship between the study  drug and the event (eg, death from anaph ylaxis), the event must 
be reported as a serious and unexpected suspected adverse reaction even if it is a component of 
the study  endpoint (eg, all -cause mortalit y).
Unlisted (Unexpected) Adverse Event/Reference Safety Information
An adverse event is considered unlisted if the nature or severity  is not consistent with the 
applicable product reference safet y information. Foresketamine, the expectedness of an adverse 
event will be determined by [CONTACT_403392] y Information 
Section of the Investigator's Brochure .
For duloxetine, escitalopram, sertraline, and venlafaxine XR, the expectedness of an adverse 
event will be determined by [CONTACT_154971] .22,23,27,28,79,80,87,88
Adverse Event Associated With the Use of the Drug
An adverse event is considered associated with the use of thedrug if the attribution is possible, 
probable, or very  likel y by [CONTACT_23826] 12.1.2 .
12.1.2. Attribution Definitions
Not Related
An a dverse event that is not related to the use of the drug.
Doubtful
An adverse event for which an alternative explanation is more likely, eg,concomitant drug(s), 
concomitant disease(s), or the relationship in time suggests that a causal relationship is unli kely.
Possible
An adverse event that might be due to the use of the drug. An alternative explanation, 
eg,concomitant drug(s), concomitant disease(s), is inconclusive. The relationship in time is 
reasonable; therefore, the causal relationship cannot be exc luded.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3002 Amendment 2
Status: Approved , Date: 3 June 2016 126Probable
An adverse event that might be due to the use of the drug. The relationship in time is suggestive 
(eg, confirmed by [CONTACT_23827]). An alternative explanation is less likely , eg,concomitant 
drug(s), concomitant disease(s).
Very Likely
An adverse event that is listed as a possible adverse reaction and cannot be reasonabl y explained 
by [CONTACT_4867], eg,concomitant drug(s), concomitant disease(s). The relationship 
in time is very  suggestive (eg, it is confirmed b y dechallenge and rechallenge).
12.1.3. Severity Criteria
An assessment of severity  grade will be made using the following general categorical 
descriptors:
Mild: Awareness of symptoms that are easily tolerated, causing minimal discomfort and not 
interfering with every day activities.
Moderate: Sufficient discomfort is present to cause interference with normal activity .
Severe: Extreme distress, causing significant impairment of functioning or incapacitation. 
Prevents normal every day activities.
The investigator should use clinical judgment in assessing the severit y of events not directly  
experienced b y the subject (eg, laboratory  abnormalities).
12.2. Special Reporting Si tuations
Safety  events of interest on a sponsor study  drugthat may require expedited reporting and/or 
safet y evaluation include, but are not limited to:
Overdose of a sponsor study  drug
Suspected abuse/misuse of a sponsor study  drug
Inadvertent or accidental exposure to a sponsor study  drug
Medication error involving a sponsor product (with or without subject/patient exposure to 
the sponsor study  drug , eg, name [CONTACT_2976])
Special reporting situations should be recorded in the eCRF. Any special reporting situation that 
meets the criteria of a serious adverse event should be recorded on the serious adverse event page 
of the eCRF.
12.3. Procedures
12.3.1. All Adverse Events
All adverse events and special reporting situations, whether serious or non-serious, will be 
reported from the time a signed and dated ICFis obtained until completion of the subject's last 
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3002 Amendment 2
Status: Approved , Date: 3 June 2016 127study -related procedure (which may include contact [CONTACT_20687] -up of safety ), with the exception 
of pregnancy  which will be reported up to [ADDRESS_508753] dose of study  medication 
(females) or [ADDRESS_508754] dose of study  medication (partners of male participants) . 
Serious adverse events, including those spontaneously  reported to the investigator ,must be 
reported using the Serious Adverse Event Form. The sponsor will evaluate any safet y 
information that is spontaneously reported by [CONTACT_154972].
All events that meet the definition of a serious adverse event will be reported as serious adverse 
events, regardless of whether they are protocol -specific assessments. Anticipated events will be 
recorded and reported as described in Attachment 4.
All adve rse events, regardless of seriousness, severity , or presumed relationship to study  drug, 
must be recorded using medical terminology  in the source document and the eCRF. Whenever 
possible, diagnoses should be given when signs and symptoms are due to a common etiology 
(eg,cough, runny nose, sneezing, sore throat, and head congestion should be reported as "upper 
respi[INVESTIGATOR_23739]"). Investigators must record in the eCRF their opi[INVESTIGATOR_23740] . All measures required for adverse event 
management must be recorded in the source document and reported according to sponsor 
instructions.
The sponsor assumes responsibility  for appropriate reporting of adverse events to the regulatory  
authorities. The sponsor will also report to the investigator (and the head of the investigational 
institute where required) all suspected unexpected serious adverse reactions (S[LOCATION_003]Rs). The 
investigator (or sponsor where required) must report S[LOCATION_003]Rs to the appropriate Independent
Ethics Committee/Institutional Review Board (IEC/I RB) that approved the protocol unless 
otherwise required and documented b y the IEC/IRB.
For all studies with an outpatient phase, including open -label studies, the subject must be 
provided with a "wallet (study )card" and instructed to carry  this card with them for the duration 
of the study  indicating the following:
Study number
Statement, in the local language(s), that the subject is participating in a clinical study
Investigator's name [INVESTIGATOR_1238] 24- hour contac t telephone number
Local sponsor's name [INVESTIGATOR_1238] [ADDRESS_508755] telephone number (for medical staff only )
Site number
Subject number
Any other information that is required to do an emergency  breaking of the blind
12.3.2. Serious A dverse Events
All serious adverse even ts occurring during the studymust be reported to the appropriate sponsor 
contact [CONTACT_9702] b ystudy -site personnel within 24 hours of their knowledge of the event.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3002 Amendment 2
Status: Approved , Date: [ADDRESS_508756] be completed and signed by a physician from the study  site, 
and transmitted to the sponsor within 24 hours. The initial and follow -up reports of a serious 
adverse event should be made b y facsimile (fax).
All serious adver se events that have not resolved by [CONTACT_2054] , or that have not 
resolved upon discontinuation of the subject's participation in the study , must be followed until 
any of the following occurs:
The event resolves
The event stabilizes
The event returns to baseline, if a baseline value/status is available
The event can be attributed to agents other than the study  drug or to factors unrelated to 
study  conduct
It becomes unlikely  that any additional information can be obtained (subject or health care 
practitioner refusal to provide additional information, lost to follow -up after demonstration 
of due diligence with follow-up efforts)
Suspected transmission of an infectious agent by a medicinal product will be reported as a 
serious adverse event. Any event requiring hospi[INVESTIGATOR_059] (or prolongation of hospi[INVESTIGATOR_059]) 
that occurs during the course of a subject's participation in a study  must be reported as a serious 
adverse event, except hospi[INVESTIGATOR_23741]:
Hospi[INVESTIGATOR_23742] (eg, social reasons 
such as pending placement in long -term care facility )
Surgery  or procedure planned before entry  into the study  (must be documented in the 
eCRF ). Note: Hospi[INVESTIGATOR_23743], and where 
the underl ying condition for which the hospi[INVESTIGATOR_23744] ,will 
not be considered serious adverse events. Any  adverse event that results in a prolongation of 
the originall y planned hospi[INVESTIGATOR_23745] a new serious adverse event.
For convenience the investigator may choose to hospi[INVESTIGATOR_154891].
The cause of death of a subject in a study , whether or not the event is expected or associated w ith 
the study  drug , is considered a serious adverse event.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3002 Amendment 2
Status: Approved , Date: [ADDRESS_508757] be reported to the sponsor by [CONTACT_1758] -site personnel
within 24 hours of their knowledge of the event using the appropriate pregnancy  notification 
form. Abnormal pregnancy  outcomes (eg, spontaneous abortion, fetal death, stillbirth, congenital 
anomal ies, ectopic pregnancy ) are considered serious adverse events and must be reported using 
the Serious Adverse Event Form. Any subject who becomes pregnant during the study  must be 
promptly  withdrawn from the study  and discontinue further stud y treatment.
Because the effect of the study  drug on sperm is unknown, pregnancies in partners of male 
subjects included in the study  will be reported by [CONTACT_1758] -site personnel within 24 hours of 
their knowledge of the event using the appropriate pregnancy  notification form.
Follow -up information regarding the outcome of the pregnancy  and any  postnatal sequelae in the 
infant will be required .
12.4. Contact[CONTACT_23830] (and corresponding telephone numbers) of the individuals who should be contact[CONTACT_23831] y issues or questions regarding the study  are listed on the Contact [CONTACT_23832](s), which will be provided as a separate document.
13. PRODU CT QUA LITY COMPLA INTHANDLING
A product quality  complaint (PQC) is defined as any suspi[INVESTIGATOR_1884] a product defect related to 
manufacturing, labeling, or packaging, ie, any dissatisfaction relative to the identity , quality , 
durability , or reliability  of a product, including its labeling or package integrit y. A PQC may 
have an impact on the safet y and efficacy  of the product. Timely , accurate, and complete 
reporting and analysis of PQC information from studies are crucial for the protection of subjects, 
investi gators, and the sponsor, and are mandated by [CONTACT_23824]. The sponsor 
has established procedures in conformit y with regulatory  requirements worldwide to ensure 
appropriate reporting of PQC information; all studies conducted by [CONTACT_111168].
13.1. Procedures
All initial PQCs must be reported to the sponsor by  [CONTACT_1758] -site personnel within [ADDRESS_508758] report the 
PQC to the sponsor according to the serious adverse event reporting timelines (refer to 
Section 12.3.2 , Serious Adverse Events). A sample of the suspected product should be 
maintained for further investigation if requested by [CONTACT_456].
13.2. Contact[CONTACT_23834] (and corresp onding telephone numbers) of the individuals who should be contact[CONTACT_41035](s), which will be 
provided as a separate document.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3002 Amendment 2
Status: Approved , Date: 3 June 2016 [ZIP_CODE]. STUDY DRUG INFORMA TION
14.1. Physical Description of Study Drug(s)
Intranasal Study Drug
Esketamine will be supplied as a clear, colorless intranasal solution of esketamine hydrochloride 
(16.14% weight/volume [w/v]; equivalent to 14% w/v of esketamine base) in a nasal spray  
pump . The solution will consist of 161.4 mg/mL  esketamine hydrochloride (equivalent to 
140mg of esketamine base) formulated in 0.12 mg/mL ethylenediaminetetraacetic acid (EDTA) 
and 1.5 mg/mL citric acid at a pH of 4.5 in water for injection. It is provided in a nasal spray 
pump, which delivers 16.14 mg esketamine hydrochloride (14 mg esketamine base) per 100-L
spray . Each individual nasal spray  pump (device) contains a total of 28 mg (ie, 2 spray s). 
The placebo solution will be supplied as a clear, colorless intranasal solution of water for 
injection ,with a bittering agent (denatonium benzoate [Bitrex®] at a final concentration of 
0.001mg/mL) added to simulate the taste of the intranasal solution with active drug. The placebo 
solution will be provided in matching nasal spray  pump devices. Benzalkoniu m chloride is added 
as a preservative at a concentration of 0.3 mg/mL. Each individual nasal spray  pump (device) 
contains [ADDRESS_508759] igator's Brochure for a list of excipi[INVESTIGATOR_840].42
Oral Antidepressant Medications
Duloxetine
Duloxetine 30 mg will be obtained from commercial stock an d provided under the responsibility  of 
the sponsor. Please refer to the package insert/SmPC for the physical description and a list of 
excipi[INVESTIGATOR_840].22,23
Escitalopram
Escitalopram 10mg will be obtained from commercial stock and provided under the 
responsibility  of the sponsor. Please refer to the package insert/SmPC for the physical description 
and a list of excipi[INVESTIGATOR_840] .27,28
Sertraline
Sertraline 50 mg and 25 mg (as applicable) will be obtained from commercial stock and provided 
under the responsibility  of the sponsor. Please refer to the package insert/SmPC for the physical 
description and a list of excipi[INVESTIGATOR_840] .79,80
Venlafaxine XR
Venlafaxine 75 mg and 37.5 mg (as applicable) will be obtained from commercial stock and 
provided under the responsibility  of the sponsor. Please refer to the package insert/SmPC for the 
physical description and a list of excipi[INVESTIGATOR_840] .87,88
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3002 Amendment 2
Status: Approved , Date: 3 June 2016 [ZIP_CODE].2. Packaging
Intranasal Study Drug
Study  drug (ie, intranasal esketamine and placebo solution) will be supplied by [CONTACT_104222] a 
bi-dose nasal spray  device. The devices will contain 200 µL. Each device delivers 16.14 mg 
esketamine hydrochloride (14mg esketamine base) or 0.1µg of denatonium benzoate per 100µL
spray .
Each nasal spray  device will be individuall y packaged in a blister tray and subsequentl y put into a 
carton box. Each carton box constitutes a non-child -resistant subject kit, labeled with a unique 
medication kit number.
Device for Practicing Intranasal Study Drug Administration
The demonstra tion intranasal device will also be supplied by [CONTACT_369033]. Subjects will practice spray ing into the air and will not spray  intranasally .
Oral Antidepressant Medication
Oral antidepressant tablets or capsules will remain in their commercial packaging.
If blisters are supplied, each blister will be packaged into a child -resistant dose pack to constitute 
a subjec t kit, labeled with a unique medication kit number. These will be labeled according to 
applicable regulatory  requi rements.
14.3. Labeling
Study  drug labels will contain information to meet the applicable regulatory  requirements.
14.4. Preparation, Handling, and Storage
Study  drug will be stored at the study  site in a secure area with restricted access until dispensed to 
the subjects. 
All study  drug must be stored at controlled temperatures as indicated on the product -specific 
labeling.
Please refer to the pharmacy  manual/study  site investigational product manual and instructions for 
use documents for additional guidance on study  drug preparation ,handling , and storage .
14.5. Drug A ccountability
The investigator is responsible for ensuring that all study  drug received at the site is inventoried 
and accounted for throughout the study .
The dispensing of study drug to the subject, and the return of study  drug from the subject (if 
applicable), must be documented on the drug accountabilit y form. Subjects must be instructed to 
return all origin al containers, whether empt y or containing study  drug.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3002 Amendment 2
Status: Approved , Date: [ADDRESS_508760] be documented on the drug accountabilit y form. 
All study  drug will be stored and disposed of according to the sponsor's instructions. Study-site 
personne lmust not combine contents of the study  drug containers.
Study  drug must be handled in strict accordance with the protocol and the container label, and must 
be stored at the study  site in a limited -access area or in a locked cabinet under appropriate 
environmental conditions. Unused study  drug,and study  drug returned by [CONTACT_423], must be 
available for verification by [CONTACT_456]'s study  site monitor during on-site monitoring visits. The 
return to the sponsor of unused study  drug, or used returned study drug for destruction, will be 
documented on theinvestigational product destruction form . When the study  site is an authorized 
destruction unit and study drug supplies are destroyed on -site, this must also be documented on the
investigational product dest ruction form.
Potentiall y hazardous materials such as used ampules, needles, syringes and vials containing 
hazardous liquids, should be disposed of immediatel y in a safe manner and therefore will not be 
retained for drug accountabilit y purposes. 
Study  drug should be dispensed under the supervision of the investigator or a qualified member of 
the study -site personnel, or by a hospi[INVESTIGATOR_307]/clinic pharmacist. Study  drug will be supplied only to 
subjects participating in the study . Returned study drug must not be dispensed again, even to the 
same subject. 
Whenever a subject brings his or her study  drug to the study  site for pi[INVESTIGATOR_692] (ie,compliance 
check) , this is not seen as a return of supplies. 
Study  drug may not be relabeled or reassigned for use by [CONTACT_23837]. The investigator agrees 
neither to dispense the study  drug from, nor store it at, any site other than the study  sites agreed 
upon with the sponsor.
15. STUDY -SPECIFIC MATERIA LS
The investigator will be provided with the following supplies:
Practice in tranasal devices 
Investigator's Brochure for esketamine
Local prescribing information for oral antidepressant options in double -blind induction 
phase
Investigational Product (IP) Binder, including the IP Procedures Manual
Laboratory  manual and materials
Clinician -administered and subject -reported outcome assessments:
Paper versions, as applicable
Electronic devices and associated materials
IWRS Manual
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3002 Amendment 2
Status: Approved , Date: 3 June 2016 133ECG equipment and associated materials (e g, manual )
Instructions for Use documents (subject and healthcar e provider versions) for intranasal 
study  medication
Rater qualifications/requirements for select clinician -administered assessments
Computerized cognitive battery  and HVLT -R, and all associated equipment and materials
Device to measure respi[INVESTIGATOR_2842]
Procedural documents for Site -Independent Qualification Assessment
Procedural documents for independent, remote rater interviews
Guidance on recommended order of study  procedures
MGH -ATRQ Guidance document
SmPCs of the active comparators: Duloxetine, escital opram, sertraline, and venlafaxine XR
Subject diary
16. ETHICA L ASPECTS
16.1. Study -specific Design Considerations
Clinical Study in Treatment-resistant Major Depression
Major depressive disorder is a common, severe, chronic ,and often life-threatening illness. It is 
now the leading cause of disability  worldwide. There is a clear need to develop novel and 
improved therapeutics for treatment -resistant depression.
Studies with esketamine have shown robust antidepressant effects in several clinical studies and 
it has been well tolerated in these clinical studies.
Selection of Subjects
The primary  aim of the study  is to evaluate the efficacy  of intranasal esketamine plus an oral 
antidepressant for the treatment of TRD. Thus, the study cannot be completed in health y 
subjects. 
Potential subjects will be fully informed of the risks and requirements of the study  and, during 
the study , subjects will be given any new information that may affect their decision to continue 
participation.
For eligibility , subjects must have had non-response to at least 1 prior antidepres sant treatment 
and be currentl y taking an antidepressant treatment at the start of the screening/prospective 
observation al phase that will be continued as prospective treatment in the screening/prospective 
observational phase . Only  subjects with non-response to their current antidepressant treatment 
after 4 weeks of prospectivel y observe dtreatment (for a total duration of antidepressant 
treatment of at least 6 weeks by[CONTACT_154974]/prospective observational phase ),will 
be eligible to proceed to the double -blind induction phase, when all subject swill receive a new 
oral antidepressant in addition to intranasal esketamine or placebo. Subjects will receive 4 w eeks 
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3002 Amendment 2
Status: Approved , Date: 3 June 2016 134of treatment in the double -blind phase and at the end of this phase, those who are responders and 
willing to do so may participate in the maintenance study  (ESKETINTRD3003). Subjects who 
are not responders or who otherwise choose not to enter the ESKE TINTRD3003 study  will enter
the 24- week follow -up phase .
All subjects will be provided with an additional 4-week suppl y of the oral antidepressant 
medication and appropriate follow -up care will be arranged.
They  will be told that their consent to participa te in the study  is voluntary  and may  be withdrawn 
at any time with no reason given and without penalty  or loss of benefits to which they would 
otherwise be entitled. Only  subjects who are fully  able to understand the risks, benefits, and 
potential adverse events of the study , and provide their consent voluntaril y will be enrolled.
Justification for Using Placebo
Intranasal placebo is being used as a double -blind for intranasal esketamine to maintain study  
blinding . All subjects will also receive anewly initiated oral antidepressant during the induction 
phase. Subjects will not be on placebo alone. Assessment of the potential efficacy  of a new 
compound for the treatment of treatment -resistant major depression requires adequate and 
well-controlled clinical studies. This superiority  study  will compare intranasal esketamine plus a 
newly -initiated oral antidepressant to switching to an oral antidepr essant as an active comparator.
Recent analyses have shown response to placebo varies considerabl y,from 10% to 55%. 
Therefore, there is a concern that randomized, controlled studies that rely on comparison with 
standard antidepressant treatment s alone will generate unreliable results with limited assay  
sensitivity . However, some have considered it unethical to do pl acebo- controlled studies in major 
depression due to the potential risk of irreversible harm.72In a  m eta-analy sis of drug studies 
conducted in MDD , it was reported that adult subjects did not have higher rates of suicide 
behaviors or attempts in the placebo group compared with those receiving an active 
antidepressant.47These studies show edannual suicide rates of 0.8% on the investigational drug, 
0.7% on the active comparator, and 0.4% on placebo. Thus, t he risk of irreversible harm was not 
higher in the placebo arm compared with the active con trol arms. 
Some subjects may  decide to not participate in a placebo -controlled study  due to the potential for 
increased distress and d ysfunction from prolonged depression. 
Therefore, the use of anactive -controlled study  allows for assessment of efficacy  of a new 
compound to allow for scientifically  meaningful results. 
Moreover, the duration of the double -blind induction phase is relativel y short (4-week duration). 
Subjects will visit the study  site at least twice a week during the double -blind induction phase
and their symptoms will be carefully  monitored during each study  visit. Safety  evaluations will 
include evaluation of suicidal ideation/behavior at each clinic visit. At any  point in the study ,the 
subject may withdraw consent or be removed from the study  by [CONTACT_154975].
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3002 Amendment 2
Status: Approved , Date: [ADDRESS_508761]. The duration of the study  is short, minimizing the time on intranasal placebo (which 
is being administered with a newly -initiated oral antidepressant) . Potential disadvantages and 
adverse events of participating in the study  and alternative treatment options will be discussed. 
For subjects who do not meet predefined response criteria during the study , clinical care will be 
arranged between the study  investigator and their phy sician.
Compensation for any procedure will be fair per local standards and approved by [CONTACT_154977] y undue incentive to participate in the study .
Subjects will be carefully monitored during the study  and subjects who are unable to tolerate 
study  drug during the double -blind induction phase will be discontinued from the study . If the 
investigator judges it to be necessary  to immediately  stop study  drug, he or she has the option to 
do so.Specific guidance is provided regarding blood pressure monitoring on intranasal dosing 
days (Section 6.2.1 ).
Only  subjects who had non-response to their current oral antidepressant treatment, where a 
clinician would consider changing it in the future due to lack of response, will be enrolled.
Only  qualified and trained investigators will participate in the study .
The total blood volume to be collected is considered to be within the normal range allowed for 
thissubject population over this time frame. The approxim ate blood volume to be collected is 
116.0 mL,which will be less than a Red Cross blood donation.
16.2. Regulatory  Ethics Compliance
16.2.1. Investigator Responsibilities
The investigator is responsible for ensuring that the study  is performed in accordance with the 
protocol, current ICH guidelines on Good Clinical Practice (GCP), and applicable regulatory  and 
country -specific requirements.
Good Clinical Practice (GCP) is an international ethical and scientific qualit y standard for 
designing, conducting, recording, and reporting studies that involve the participation of human 
subjects. Compliance with this standard provides public assurance that the rights, safety , and 
well-being of study  subjects are protected, consistent with the principles that originated in the 
Declar ation of Helsinki, and that the study  data are credible.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3002 Amendment 2
Status: Approved , Date: [ADDRESS_508762]
(IEC/IRB)
Before the start of the study , the investigator (or sponsor where required) will provide the IEC/IRB 
with current and complete copi[INVESTIGATOR_23747] (as required by  [CONTACT_427]) :
Final protocol and, if applicable, amendments
Sponsor -approved ICF(and any  other written materials to be provided to the subjects)
Investigator's Brochure (or equivalent information) and amendments/addenda
Sponsor -approved subject recruiting materials
Sponsor -approved training and informational materials
Information on compensation for study -related injuries or payment to subjects for 
participation in the study , if applicable
Investiga tor's curriculum vitae or equivalent information (unless not required, as 
documented b y the IEC/IRB)
Information regarding funding, name [CONTACT_8152], institutional affiliations, other potential 
conflicts of interest, and incentives for subjects
Any othe r documents that the I EC/IRB requests to fulfill its obligation
This study  will be undertaken only after the IEC/IRB has given full approval of the final protocol, 
amendments (if any, excluding the ones that are purel y administrative, with no consequences for 
subjects, data or study  conduct), the ICF, applicable recruiting materials, and subject compensation 
programs, and the sponsor has received a copy  of this approval. This approval letter must be dated 
and must clearl y identify  the IEC/ IRB and the documents being approved.
During the study  the investigator (or sponsor where required) will send the following documents 
and updates to the IEC/IRB for their review and approval, where appropriate:
Protocol amendments (excluding the ones that are purel y adminis trative, with no 
consequences for subjects, data or study  conduct)
Revision(s) to ICFand any  other written materials to be provided to subjects
If applicable, new or revised subject recruiting materials approved b y the sponsor
Revisions to compensation for study -related injuries or payment to subjects for participation 
in the study , if applicable
New edition(s) of the Investigator's Brochure and amendments/addenda
Summaries of the status of the study  at intervals stipulated in guidelines of the IEC/IRB (at
least annuall y)
Reports of adverse events that are serious, unlisted/unexpected, and associated with the 
study  drug
New information that may adversel y affect the safet y of the subjects or the conduct of the 
study
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3002 Amendment 2
Status: Approved , Date: 3 June 2016 137Deviations from or changes to the protocol to eliminate immediate hazards to the subjects
Report of deaths of subjects under the investigator's care
Notification if a new investigator is responsible for the study  at the site
Development Safet y Update Report and Line Listings, where applicable
Any other requirements of the IEC/I RB
For all protocol amendments (excluding the ones that are purel y administrative, with no 
consequences for subjects, data or study conduct), the amendment and applicable ICFrevisions 
must be submitted promptly  to the IEC/IR B for review and approval before implementation of the 
change(s). 
At least once a year, the IEC/I RB will be asked to review and reapprove this study , where required . 
The reapproval should be documented in writing (excluding the ones that are purel y 
admini strative, with no consequences for subjects, data, or study  conduct).
At the end of the study , the investigator (or sponsor where required) will notify  the IEC/IRB about 
the study  completion.
16.2.3. Informed Consent
Each subjec tmust give written consent according to local requirements after the nature of the study 
has been fully explained. The ICF(s) must be signed before performance of any study-related 
activit y. The ICF(s) that is/areused must be approved by [CONTACT_111177]/IRB and be in a language that the subject can read and understand. The informed consent  
should be in accordance with principles that originated in the Declaration of Helsinki, current ICH 
and GCP guidelines, applicable regulatory  requirements, and sponsor policy .
Before enrollment in the study , the investigator or an authorized member of the study -site 
personnel must explain to potential subjects the aims, methods, reasonably  anticipated benefits, 
and potential hazards of the study ,and any discomfort participation in the study  may entail. 
Subjects will be informed that their participation is voluntary  and that they may withdraw consent 
to participate at any time. They  will be informed that choosing to not participate will not affect the 
care the subject will receive for the treatment of his or her disease. Subjects will be told that 
alternative treatments are available if they refuse to take part and that such refusal will not 
prejudice future treatment. Finall y, they will be told that the investigator will maintain a subject 
identification register for the purposes of long-term follow up if needed and that their records may 
be accessed by [CONTACT_154978] y of thesubject, to the extent permitted by [CONTACT_6983](s) or regulations. By 
[CONTACT_23842], and agrees to allow his or her study 
physician to re-contact [CONTACT_43774], if needed.
The subject will be given sufficient time to read the ICF and the opportunit y to ask questions. After 
this explanation and before entry  into the study , consent should be appropriatel y recorded by 
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3002 Amendment 2
Status: Approved , Date: [ADDRESS_508763]'s personally  dated signature. After having obtained the consent, a copy of the 
ICFmust be given to the subject.
Where local regulations require, a separate ICF may be used for the required DNA component of 
the study .
16.2.4. Privacy of Personal Data
The collec tion and processing of personal data from subjects enrolled in this study  will be limited 
to those data that are necessary  to fulfill the objectives of the study .
These data must be collected and processed with adequate precautions to ensure confidentialit y and 
compliance with applicable data privacy  protection laws and regulations. Appropriate technical 
and organizational measures to protect the personal data against unauthorized disclosures or 
access, accidental or unlawful destruction, or accidental loss or alteration must be put in place.  
Sponsor personnel whose responsibilities require access to personal data agree to keep the identit y 
of subjects confidential.
The informed consent obtained from the subject includes explicit consent for the processing of 
personal data and for the investigator /institution to allow direct access to his or her original medical 
records (source data/documents) for study -related monitoring, audit, IEC/I RB review, and 
regulatory  inspection. This consent also addresses the trans fer of the data to other entities and to 
other countries.
The subject has the right to request through the investigator access to his or her personal data and 
the right to request rectification of any data that are not correct or complete. Reasonable steps will 
be taken to respond to such a request, taking into consideration the nature of the request, the 
conditions of the study , and the applicable laws and regulations.
Exploratory  PK, PD, biomarker, DNA ,and RNA research is not conducted under standards 
appropriate for the return of data to subjects. In addition, the sponsor cannot make decisions as to 
the significance of any findings resulting from exploratory  research. Therefore, exploratory 
research data will not be returned to subjects or investigators, unless required by [CONTACT_154979]. Privacy  and confidentialit y of data generated in the future on stored samples will be 
protected by  [CONTACT_43778].
16.2.5. Long -Term Retention of Samples for Additional Future Research
Samples collected in this study  may  be stored for up to 15 years (or according to local regulations) 
for additional research. Samples will only be used to understand esketamine, oral antidepressants, 
to understand depression , to understand differe ntial drug responders, and to develop tests/assay s 
related to esketamine , oral antidepressants, and depression. The research may begin at any time 
during the study  or the post -study  storage period. 
Stored samples will be coded throughout the sample storag e and analysis process and will not be 
labeled with personal identifiers. Subjects may withdraw their consent for their samples to be 
stored for research ( refer to Section 10.3, Withdrawal f rom the Use of Samples in Future Research ).
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3002 Amendment 2
Status: Approved , Date: [ADDRESS_508764] not be implemented without prior IEC/IRB approval, or 
when the relevant competent authorit y has raised any grounds for non-acceptance, except when 
necessary  to eliminate immediate hazards to the subjects, in which case the amendment must be 
promptl y submitted to the IEC/IRB and relevant competent authority . Documentation of 
amendment approval by [CONTACT_23846]/IRB must be provided to the sponsor. When the 
change(s) involves only logistic or administrative aspects of the study , the IRB (and IEC where 
required) onl y needs to be notified.
During the course of the study , in situations where a departure from the protocol is unavoidable, 
the investigator or other phy sician in attendance will contact [CONTACT_66884] 
(see Contact [CONTACT_23774](s) provided separa tely). Except in emergency  situations, this contact 
[CONTACT_154980]. In all cases, contact [CONTACT_154981]. The data recorded in the eCRF and source documents will reflect any departure 
from the protocol, and the source documents will describe this departure and the circumstances 
requiring it.
17.2. Regulatory  Documentation
17.2.1. Regulatory  Approval/Notification
This protocol and any amendment(s) must be submitted to the appropriate regulatory  authorities in 
each respective country , if applicable. A study  may not be initiated until all local regulatory  
requirements are met.
17.2.2. Required Prestudy  Documentation
The followin g documents must be provided to the sponsor before shipment of study  drug to the 
study site:
Protocol and amendment(s), if an y, signed and dated by [CONTACT_458]
A copy of the dated and signed (or sealed, where appropriate per local regulations) , written 
IEC/IRB approval of the protocol, amendments, ICF, any recruiting materials, and if 
applicable, subject compensation programs. This approval must clearly  identify  the specific 
protocol by [CONTACT_43781] (or sealed, where appropriate per local 
regulations) by [CONTACT_23851].
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3002 Amendment 2
Status: Approved , Date: 3 June 2016 140Name [CONTACT_23875]/IRB, including a current list of the IEC/IRB members and 
their function, with a statement that it is organized and operates according to GCP and the 
applicable laws and regulations. If accompanied by a  letter of explanation, or equivalent, 
from the IEC/I RB, a general statement may be substituted for this list. I f an investigator or a 
member of the study -sitepersonnel is a member of the IEC/IRB, documentation must be 
obtained to state that this person did not participate in the deliberations or in the 
vote/opi[INVESTIGATOR_23748].
Regulatory  authority  approval or notification, if applicable
Signed and dated statement of investigator (eg, Form FDA 1572), if applicable
Documentation of investigator qualifications (eg, curriculum vitae)
Completed investigator financial disclosure form from the principal investigator, where 
required
Signed and dated clinical trial ag reement, which includes the financial agreement
Any other documentation required by  [CONTACT_43782]:
Completed investigator financial disclosure forms from all sub-investigators
Documentation of sub -investigator qualifications (eg, curriculum vitae)
Name [CONTACT_23876] , and a dated copy  of 
current laboratory  normal ranges for these tests, if applicable
Local laboratory  documentation demonstrating competence and test reliability 
(eg,accreditation/license), if applicable
17.3. Subject Identification, Enrollment, and Screening Logs
The investigator agrees to complete a subject identification and enrollment log to permit easy 
identification of each subject during and after the study . This document will be reviewed by [CONTACT_66886] -site contact [CONTACT_23853].
The subject identification and enrollment log will be treated as confidential and will be filed by  [CONTACT_154982]. To ensure subject confidentialit y, no copy will be made. All reports 
and communications relating to the study  will identify  subjects by  [CONTACT_154983]. In cases where the subject is not randomized intothe study , the date seen and date of birth 
will be used.
The investigator must also complete a subject screening log, which reports on all subjects who 
were seen to determine eligibilit y for inclusion in the study .
17.4. Source Documentation
At a minimum, sourc e documentation s consistent in the type and level of detail with that 
commonl y recorded at the study  site as a basis for standard medical care must be available for the 
following :subject identification, eligibilit y, and study  identification; study  discuss ion and date of 
signed informed consent; dates of visits; results of safety and efficacy  parameters as required by 
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3002 Amendment 2
Status: Approved , Date: 3 June 2016 141the protocol; record of all adverse events and follow -up of adverse events; concomitant 
medication; drug receipt/dispensing/return records; study drug administration information; and 
date of study  completion and reason for early  discontinuation of study  drug or withdrawal from the 
study , if applicable. 
The author of an entry  in the source documents should be identifiable.
Specific details required as source data for the study  and source data collection methods will be 
reviewed with the investigator before the study  and will be described in the monitoring guidelines 
(or other equivalent document).
The following data will be recorded directl y into the eCRF and will be considered source data:
Race
Blood pressure and pulse/heart rate
Height and weight 
Details of ph ysical examination
The minimum source documentation requirements for Section 4.1(Inclusion Criteria )and 
Section 4.2(Exclusion Criteria ) that specify  a need for documented medical history  are as follows:
Referral letter from treating ph ysician or
Complete history  of medical notes at the site
Discharge summ aries
Antidepressant treatment in the current epi[INVESTIGATOR_154892] a 
minimum by [CONTACT_41047] (eg, physical examination , 
laboratory  assessment) and documented in the source documents.
17.5. Case Report Form Completion
Case report forms are provided for each subject in electronic format. All CRF entries, corrections, 
and alterations must be made by [CONTACT_70464] -site personnel. The 
investigator must verify  that all data entries in the CRF are accurate and correct.
Electronic Data Capture (eDC) will be used for this study . The study  data will be transcribed by 
[CONTACT_3449] -sitepersonnel from the source documents onto an eCRF, and transmitted in a secure manner 
to the sponsor within the timeframe agreed upon between the sponsor and the study  site. The 
electronic file will be considered to be the eCRF.
Worksheets may be used for the capture of some data to facilitate completion of the eCRF. Any 
such worksheets will become part of the subject's source document s. All data relating to the study  
must be recorded in eCRFs prepared by [CONTACT_456]. Data must be entered into eCRFs in English. 
Study site personnel must complete the eCRF as soon as possible after a subject visit, and the 
forms should be available for review at the next scheduled monitoring visit.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3002 Amendment 2
Status: Approved , Date: [ADDRESS_508765] the eCRF (if applicable ) and complete the query .
If corrections to a n eCRF are needed after the initial entry  into the eCRF, this can be done in either 
of the following ways:
Investigator andstudy site personnel can make corrections in the eDC tool at their own 
initiative or as a response to an auto query  (generated by  [CONTACT_66832]) .
Sponsor or sponsor delegate can generate a query  for resolution by [CONTACT_23858] -site personnel.
17.6. Data Quality  Assurance/Quality  Control
Steps to be taken to ensure the accuracy  and reliability  of data include the selection of qualified 
investigators and appropriate study  sites, review of protocol procedures with the investigator and 
study -sitepersonnel before the study , periodic monitoring visits by  [CONTACT_456], and uploading data 
trans fers from external service providers into the sponsor's data base. Written instructions will be 
provided for collection, handling, storage, and shipment of samples. 
Guidelines for eCRF completion will be provided and reviewed with study -sitepersonnel before 
the start of the study .
The sponsor will review eCRFs for accuracy  and completeness during on -site monitoring visits and 
after transmission to the sponsor; any discrepancies will be resolved with the investigator or 
designee, as appropriate. After upload of the data into the study  database they will be verified for 
accuracy  and consistency  with the data sources.
17.7. Record Retention
In compliance with the ICH/GCP guidelines, the investigator/institution will maintain all eCRFs 
and all source documents that support the data collected from each subject, as well as all study 
documents as specified in ICH/GCP Section 8, Essential Documents for the Conduct of a Clinical 
Trial, and all study  documents as specified by [CONTACT_23859](s). The 
investigator/institution will take measures to prevent accidental or premature destruction of these 
documents.
Essential documents must be retained until at least 2years after the last approval of a marketing 
application in an ICH region and until there are no pending or contemplated marketing applications 
in an ICH region or until at least 2years have elapsed since the formal discontinuation of clinical 
development of the investigational product. These documents will be retained for a longer period if 
required by [CONTACT_66891]. It is the 
responsibilit y of the sponsor to inform the investigator/institution as to when these documents no 
longer need to be retained.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3002 Amendment 2
Status: Approved , Date: [ADDRESS_508766] be notified in writing of the name [CONTACT_66903]. Under no circumstance shall the investigator relocate or dispose of any  study  documents 
before having obtained written approval from the sponsor.
If it becomes necessary for the sponsor or the appropriate regulatory  authorit y to review any 
documentation relating to this study , the investigator /institution must permit access to such reports.
17.8. Monitoring
The sponsor will perform on-site monitoring visits as frequentl y as necessary . The monitor will 
record dates of the visits in a study  site visit log that will be kept at the study  site. The first 
post-initiation visit will be made as soon as possible after enrollment has begun. At these visits, the 
monitor will compare the data entered into the eCRFs with the hospi[INVESTIGATOR_40961] (source 
documents) ; a sample will be reviewed . The nature and location of all source documents will be 
identified to ensure that all sources of original data required to complete the eCRF are known to 
the sponsor and study -site personnel and are accessible for verification by [CONTACT_43786] -site 
contact. If electronic records are maintained at the study site, the method of verification must be 
discussed with the study -site personnel. 
Direct access to source documentation (medical records) must be allowed for the purpose of 
verify ing that the data recorded in the eCRF are consistent with the original source data. Findings 
from this review of eCRFs and source documents will be discussed with the study -site personnel . 
The sponsor expects that, during monitoring visits, the relevant study -site personnel will be 
available, the source documentation will be accessible, and a suitable environment will be provided 
for review of study -related documents. The monitor will meet with the investigator on a regular 
basis during the study  to provide feedback on the study  conduct.
In addition to on-site monitoring visits, the site monitor may contact [CONTACT_154985]. It is expected thatstudy-site personnel will be available to provide an 
updat e on the progress of the study  at the site .
17.9. Study Completion/Termination
17.9.1. Study Completion
The study  is considered completed with the last study  assessment for the last subject participating 
in the study . The final data from the study site will be sent to the sponsor (or designee) after 
completion of the final subject assessment at that study  site, in the time frame specified in the 
Clinical Trial Agreement.
17.9.2. Study Termination
The sponsor reserves the right to close the study site or terminate the study  at any time for any 
reason at the sole discretion of the sponsor. Study sites will be closed upon study  completion. A
study site is considered closed when all required documents and study supplies have been collected 
and a study -site closure visit has been perf ormed.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3002 Amendment 2
Status: Approved , Date: 3 June 2016 144The investigator may initiate study -site closure at any time, provided there is reasonable cause and 
sufficient notice is given in advance of the intended termination.
Reasons for the early closure of astudy site by [CONTACT_66892]:
Failure of the investigator to comply  with the protocol, the requirements of the IEC/I RB or 
local health authorities, the sponsor's procedures, or GCP guidelines
Inadequate recruitment of subjects by  [CONTACT_093]
Discont inuation of further study  drug development
Study  is terminated by  [CONTACT_403393]
17.10. On-site A udits
Representatives of the sponsor's clinical qualit y assurance department may visit the study  site at 
any time during or after completion of the study  to conduct an audit of the study  in compliance 
with regulatory  guidelines and company  policy . These audits will require access to all study 
records, including source documents, for inspection and comparison with the eCRFs. Subject 
privacy  must, however, be respected. The investigator and study -site personnel are responsible for 
being present and available for consultation during routinel y scheduled study -site audit visits 
conducted by  [CONTACT_3210] i ts designees. 
Similar auditing procedures may  also be conducted by  [CONTACT_23865] , either as part 
of a national GCP compliance program or to review the results of this study  in support of a 
regulatory  submission. The investigator should immediatel y notify  the sponsor if he or shehas
been contact[CONTACT_426]  a regulatory  agency  concerning an upcoming inspection.
17.11. Use of Information and Publication
All information, including but not limited to information regarding esketamine or the sponsor's 
operati ons (eg,patent application, formulas, manufacturing processes, basic scientific data, prior 
clinical data, formulation information) supplied by [CONTACT_154987] y published, and any  data, including pharmacogenomic or explor atory  biomarker research 
data, generated as a result of this study , are considered confidential and remain the sole property  of 
the sponsor. The investigator agrees to maintain this information in confidence and use this 
information only to accomplish thisstudy , and will not use it for other purposes without the 
sponsor's prior written consent.
The investigator understands that the information developed in the study  will be used by [CONTACT_154988], andthus may  be disclosed as 
required to other clinical investigators or regulatory  agencies. To permit the information derived 
from the clinical studies to be used, the investigator is obligated to provide the sponsor with all 
data obtained in the study.
Theresults of the study  will be reported in a Clinical Study  Report generated by [CONTACT_403394] 
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3002 Amendment 2
Status: Approved , Date: 3 June 2016 145uploaded data transferred from external service providers into the sponsor's database . Recruitment 
performance or specific expertise related to the nature and the key assessment parameters of the 
study  will be used to determine a coordinating investigator. Results of pharmacogenomic or 
exploratory  biomarker analyses perfo rmed after the Clinical Study  Report has been issued will be 
reported in a separate report and will not require a revision of the Clinical Study  Report. Study 
subject identifiers will not be used in publication of results. Any work created in connection with 
performance of the study  and contained in the data that can benefit from copyright protection 
(except any publication by [CONTACT_40999]) shall be the propert y of the 
sponsor as author and owner of copy right in such work.
Consiste nt with Good Publication Practices and International Committee of Medical Journal 
Editors guidelines, the sponsor shall have the right to publish such primary  (multicenter) data and 
information without approval from the investigator. The investigator has the right to publish study 
site-specific data after the primary  data are published. If an investigator wishes to publish 
information from the study , a copy  of the manuscript must be provided to the sponsor for review at 
least [ADDRESS_508767] been 
submitted for publication, within 12months of the availabilit y of the final data (tables, listings, 
graphs), or the sponsor confirms there will be no multicenter study  publication. Authorship of 
publications resulting from this study  will be based on the guidelines on authorship, such as those 
described in the Uniform Requirements for Manu scripts Submitted to Biomedical Journals, which 
state that the named authors must have made a significant contribution to the design of the study  or 
analysis and interpretation of the data, provided critical review of the paper, and given final 
approval of the final version.
Registration of Clinical Studies and Disclosure of Results
The sponsor will register and/or disclose the existence of and the results of clinical studies as 
required by  [CONTACT_2371].
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3002 Amendment 2
Status: Approved , Date: 3 June 2016 146REFERENCES
1. aan het Rot M, Collins KA, Murrough JW, et al. Safety and efficacy of repeated -dose intravenous ketamine for 
treatment -resistant depression. Biol Psychiatry. 2010;67(2):139 -145.
2. Bazett HC. An analysis of the time -relationship of electrocardiograms. Heart. 1920;7:[ADDRESS_508768] -Revised: normative data 
and analysis of inter -form and test -retest reliability. Clin. Neuropsychologist. 1998;12:43 -55.
4. Bremner JD, Krystal JH, Putnam FW, Southwick SM, Marmar C, Charney DS, Mazure CM. Measur ement of 
dissociative states with the Clinician -Administered Dissociative States Scale (CADSS). J Trauma Stress. 
1998;11(1):125 -136.
5. Chang T, Savory A, Albin M, Goulet R, Glasko AJ. Metabolic disposition of tritium -labelled ketamine 
(Ketalar®, CI-581) in n ormal human subjects. Clin Res. 1970;18:597.
6. Chung F, Yegneswaran B, Liao P, et al. STOP questionnaire: a tool to screen patients for obstructive sleep 
apnea. Anesthesiology. 2008;108:812 -821.
7. Clinical Study Report ESKETINTRD1001. An open -label Phase 1 stu dy to evaluate the pharmacokinetics of 
intranasal esketamine administered w ith and without a nasal guide on the intranasal device. Document No. 
EDMS -ERI-73676925 (21 Aug 2014).
8. Clinical Study Report ESKETINTRD1002. An open -label, single -dose study to asses s the pharmacokinetics, 
safety, and tolerability of intranasally administered esketamine in healthy Japanese and Caucasian subjects. 
Document No. EDMS -ERI-74234860 (21 Aug 2014).
9. Clinical Study Report ESKETINTRD1003. An open -label, single -dose study to ass ess the pharmacokinetics, 
safety, and tolerability of intranasally administered esketamine in healthy elderly and adult subjects. Document 
No. EDMS -ERI-81854053 ( 30 Dec 2014 ).
10. Clinical Study Report ESKETIVTRD2001. A double -blind, double -randomization, plac ebo-controlled study of 
the efficacy of intravenous esketamine in adult subjects w ith treatment -resistant depression. Document No. 
EDMS -ERI-63623355 (01 May 2014 ).
11. Clinical Study Report KETIVTRD2002. A double -blind, randomized, placebo -controlled, parallel group, dose 
frequency study of ketamine in subjects with treatment -resistant depression. Document No. EDMS ERI -63976766 
(5 Sep 2014).
12. Critchlow DG. A case of ketamine dependence with discontinuation sympto ms. Addiction. 
2006;101(8):1212 -1213.
13. Curran HV, Morgan C. Cognitive, dissociative and psychotogenic effects of ketamine in recreational users on 
the night of drug use and 3 days later. Addiction. 2000;95(4):575 -590.
14. Cusin C, Hilton GQ, Nierenberg AA, Fava M. Long -term maintenance with intramuscular ketam ine for 
treatment -resistant bipolar II depression. Am J Psychiatry. 2012 Aug;169(8):[ADDRESS_508769] antidepressant trials: a cl inician's guide to the antidepressant 
treatment response questionnaire. J Clin Psychiatry. 2011;72(8):1152 -1154.
16. DeWilde KE, Levitch CF, Murrough JW, Mathew SJ, Iosifescu DV. The promise of ketamine for treatment -
resistant depression: current evidence and future directions. Ann N Y Acad Sci. 2015 Feb 3.
17. Doty RL. Office procedures for quantitative assessment of olfactory function. Am J Rhinol. 2007 Jul -
Aug;21(4):[ADDRESS_508770]. Chem Senses 10:297 –300, 1985.
19. Doty RL, Shaman P, Dann M. Development of the University of Pennsylvan ia Smell Identification Test: a 
standardized microencapsulated test of olfactory function. Physiol Behav. 1984 Mar;32(3):[ADDRESS_508771];50(5):667 -77.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3002 Amendment 2
Status: Approved , Date: 3 June 2016 [ZIP_CODE]. Dmitrienko A, Ta mhane AC. Mixtures of multiple testing procedures for gatekeepi[INVESTIGATOR_154893]. Stat Med. 2011 Jun 15; 30(13):1473 -1488.
22. Duloxetine (Cymbalta®): US Prescribing Information. Lilly [LOCATION_003], LLC, Indianapolis, Indiana, [LOCATION_003]; Dec 2014. 
http://pi. lilly.com/us/cymb alta-pi.pdf (accessed 9 Feb 2015).
23. Duloxetine (Cymbalta®): Summary of Product Characteristics. Eli Lilly Nederland, Houten, The Netherlands;
Aug 2014. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_ -
_Product_Information/human/000572/WC500036781.pdf (accessed 6 Mar 2015).
24. Duman RS, Aghajanian GK. Synaptic dysfunction in depression: potential therapeutic targets. Science. [ADDRESS_508772] 5;338(6 103):[ADDRESS_508773] in the rat cortex and spi[INVESTIGATOR_34407] d. Eur J Pharmacol. 
1997;333:99 -104.
26. Endou M, Hattori Y, Nakaya H, Gotoh Y, Kanno M. Electrophysiologic mechanisms responsible for inotropic 
responses to ketamine in guinea pig and rat myocardium. Anesthesiology. 1992;76:409 -418.
27. Escitalopram (Cipralex®): US Prescribing Information. Lundbeck Canada I nc., Quebec, Canada; 12 Nov 2014. 
http://www.lundbeck.com/upload/ca/en/files/pdf/product_pi/Cipralex_November_2013/Cipralex.pdf 
(accessed 9 Feb 2015).
28. Escitalopram: Summary of Product Characteristics. Actavis Group PTC ehf., Iceland; Jul 2014. 
http://www.medicines.org.uk/emc/medi cine/[ZIP_CODE] (accessed 6 Mar 2015).
29. EuroQol Group. About EQ -5D. http://www.euroqol.org/ab out-eq-5d.html (accessed 18 Jun 2014).
30. EuroQol Group. EQ -5D-5L User Guide: basic information on how to use the EQ -5D-5L instrument. Version 
2.0; Oct 2013. 
http://www.e uroqol.org/fileadmin/user_upload/Documenten/PDF/Folders_Flyers/UserGuide_EQ -5D-
5L_v2.0_Oct ober_2013.pdf (accessed 6 Aug 2014).
31. Fava M. Diagnosis and definition of treatment -resistant depression. Biol Ps ychiatry. 2003 Apr 
15;53(8):649 -659. Review .
32. Fond G, L oundou A, Rabu C et al. Ketamine administration in depressive disorders: a systematic review and 
meta -analysis. Psychopharmacology (Berl). 2014:231(18):3663 -3676.
33. Freeman MP, Walker R, Laughren TP, Miller KK, Fava M. Female reproductive life cycle and horm ones: 
Methodology to improve clinical trials. J Clin Psychiatry. 2013:74(10):1018 -1021.
34. Geisslinger G, Hering W, Thomann P, Knoll R, Kamp H -D, Brune K. Pharmacokinetics and 
pharmacodynamics of ketamine enantiomers in surgical patients using a stereoselecti ve analytical method. Br J 
Anaesth. 1993;70:666 -671.
35. Guy W. ECDEU Assessment Manual for Psychopharmacology. Rockville, MD: U.S. Department of Health, 
Education, and Welfare; 1976.
36. Haas DA, Harper DG. Ketamine: a review of its pharmacologic properties and u se in ambulatory anesthesia. 
Anesth Prog. 1992;39(3):61 -68.
37. Hagelberg NM, Peltoniemi MA, Saari TI, et al. Clarithromycin, a potent inhibitor of CYP3A, greatly increases 
exposure to oral S -ketamine. Eur J Pain. 2010;14:625 -629.
38. Hijazi Y, Boulieu R. Contribu tion of CYP3A4, CYP2B6, and CYP2C9 isoforms to N -demethylation of 
ketamine in human liver microsomes. Drug Metab Dispos. 2002;30:853 -858.
39. Hodges M, Salerno D, Erlien D. Bazett’s QT correction review ed: evidence that a linear QT correction for 
heart rate is better. J Am Coll Cardiol. 1983;1:694.
40. Humphrey L, Arbuckle R, Moldw in R, et al. The Bladder Pain/Interstitial Cystitis Symptom Score: 
development, validation, and identification of a cut score. Eur Urology. 2012;61:271 -279.
41. Hurt PH, Ritchie EC. A case of ketamine dependence. Am J Psychiatry. 1994 May;151(5):779.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3002 Amendment 2
Status: Approved , Date: 3 June 2016 [ZIP_CODE]. Investigator’s Brochure, JNJ -54135419 -AAC (eske tamine hydrochloride) . Document ID: EDMS -ERI-
49489196.
43. Jansen KL. Ketamine --can chronic use impair memory? Int J Addict. 1990 Feb;25(2):133 -9.
44. Ketala r 10 mg/mL solution for injection/infusion : Summary of Product Characteristics; Aug 2014. [COMPANY_007] 
Healthcare Ireland, Dublin, Ireland. 
http://www.medicines.ie/medicine/5913/SPC/Ketalar+10mg+ml+Injection +Infusion/ (accessed 25 Feb 2015).
45. Ketamine HCl Injection : US Prescribing Information ; Mar 2012 . JHP Pharmaceuticals, LLC. [COMPANY_002]ster, 
Minnesota, [LOCATION_003]. http://www.drugs.com/pro/ketalar.html (accessed 25 Feb2015).
46. Ketanest -S [Summary of Product Characteristics]. Ankeveen, Netherlands: Eurocept BV; 2011.
47. Khan A, Warner HA, Brown WA, Symptom reduction and suicide risk in patients treated with placebo in 
antidepressant clinical trials: an analysis of the Food and Drug Administration database. Arch Gen Psychiatry. 
2000 Apr;57(4):311 -317.
48. Khin, NA. Update on FDA Exploratory Analyses of Aggregated Efficacy Data from Depression Trials. Slide 
presentation at NCDEU; May 28 -31, 2013; Hollyw ood, [LOCATION_012].
49. Leon AC, Olfson M, Portera L, Farber L, Sheehan DV. Assessing psychiatric impairment in primary care with 
the Sheeh an Disability Scale. Int J Psychiatry Med. 1997;27(2):93 -105.
50. Lim DK. Ketamine associated psychedelic effects and dependence. Singapore Med J. 2003;44(1):[ADDRESS_508774], Lam RW. A systematic review and meta -analysi s of 
randomized, double- blind, placebo -controlled trials of ketamine in the rapid treatment of major depressive 
epi[INVESTIGATOR_1841]. Psychol Med. 2015 Mar;45(4):693 -704.
52. Monteggia LM, Zarate C Jr. Antidepressant actions of ketamine: from molecular mechanisms to clini cal 
practice. Curr Opin Neurobiol. 2015 Feb;30C:139 -143.
53. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 
1979;134:[ADDRESS_508775] sizes in depression. Eur Neuro psychoph armacology. 
1994;(4)283 -284.
55. Moore NN, Bostw ick JM. Ketamine dependence in anesthesia providers. Psychosomatics. 1999 Jul -
Aug;40(4):356 -9.
56. Morgan CJ, Curran HV. Acute and chronic effects of ketamine upon human memory: a review. 
Psychopharmacology. 2006;188 :408-424.
57. Morgan CJ, Curran HV; Independent Scientific Committee on Drugs. Ketamine use: a review . Addiction. 2012 
Jan;107(1):27 -38.
58. Morgan CJ, Muetzelfeldt L, Curran HV. Consequences of chronic ketamine self -administration upon 
neurocognitive function and psychological wellbeing: a 1 -year longitudinal study. Addiction. 2010 
Jan;105(1):121 -33.
59. Muetzelfeldt L, Kamboj SK, Rees H, Taylor J, Morgan CJ, Curran HV. Journey through the K -hole: 
phenomenological aspects of ketamine use. Drug Alcohol Depend. 2008 Jun 1;95(3):219 -29.
60. Murrough JW. Ketamine as a novel antidepressant: from synapse to behavior. Clin Pharmacol Ther. 2012 
Feb;91(2):303 -9.
61. Narendran R, Frankle WG, Keefe R, et al. Altered prefrontal dopaminergic function in chronic recreational 
ketamine users. Am J Psychiatry. 2005 Dec;162(12):2352 -9.
62. Opler LA, Opler MG, Arnsten AF. Ameliorating treatment -refractory depression with intranasal ketamine: 
potential NMDA receptor actions in the pain circuitry representing mental anguish. CNS Spectr. 2015 Jan 
26:1-11.
63. Ostad Haji E, Tadic A, Wagner S, et al. Early improvement and serum concentrations of citalopram to predict 
antidepressant drug response of patients with major depression. Pharmacopsychiatry. 2013 Nov;46(7):261 -6.
64. Overall JE; Gorham D R. The Brief Psy chiatric Rating Scale. Psychol Rep. 1962;10:799 -812.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3002 Amendment 2
Status: Approved , Date: 3 June 2016 [ZIP_CODE]. Pal HR, Berry N, Kumar R, Ray R. Ketamine dependence. Anaesth Intensive Care. 2002 Jun;30(3):382 -4.
66. Persson J. Wherefore ketamine? Curr Opin Anaesthesiol. 2010 Aug;23(4):455 -60.
67. Pharm acokinetic Report KET -PK-007. A randomized, open label, single center, single -dose, cross -over study 
to determine the absolute bioavailability and the nasopharyngeal absorption of PMI -150 (intranasal ketamine) 
in healthy adult volunteers. Javelin Pharmaceuticals, Inc. Docu ment No. EDMS -ERI-44757121 ([ADDRESS_508776] 2008).
68. Portmann S, Kwan HY, Theurillat R, Schmitz A, Mevissen M, Thormann W. Enantioselective capi[INVESTIGATOR_154894] P450 enzymes which metabolize 
ketamine an d norketamine in vitro. J Chromatogr A. 2010;1217:7942 -7948.
69. Posner K, Oquendo MA, Gould M, Stanley B, Davies M. Columbia Classification Algorithm of Suicide 
Assessment (C -CASA): classification of suicidal events in the FDA’s pediatric suicidal risk analys is of 
antidepressants. Am J Psychiatry. 2007;164:1035 -1043.
70. Protocol ESKETINTRD2003. A double -blind, doubly -randomized, placebo -controlled study of intranasal 
esketamine in an adaptive treatment protocol to assess safety and efficacy in treatment -resistant depression 
(SYNAPSE). Document ID No. EDMS -ERI-71950055 (28 Apr 2014).
71. Rickels K, Garcia -Espana F, Mandos L, Case GW. Physician Withdrawal Checklist (PWC -20). J Clin 
Psychopharmacol. 2008;28(4):447 –451.
72. Rothman KJ, Michels KB. The continuing unethical use of placebo controls . N Engl J Med. 
1994;331(6):[ADDRESS_508777] psychotic epi[INVESTIGATOR_1865]. Int. J. Environ. Res. Public Health. 2012;9(7):2283 -2292.
74. Rush AJ, Gullion CM, Basco MR, Jarrett RB, Trivedi MH. The Inventory of Depressive Symptomatology 
(IDS): Psychometric properties. Psychol Med. 1996;26(3):477 -486.
75. Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer -term outcom es in depressed ou tpatients 
requiring one or several treatment steps: a STAR*D report. Am J Psychiatry. 2006 Nov;163(11):1905 -17.
76. Safety Report (Interim) ESKETINTRD2003. A double -blind, doubly -randomized, placebo -controlled study of 
intranasal esketamine in an adaptive trea tment protocol to assess safety and efficacy in treatment -resistant 
depression (SYNAPSE). Document ID No. EDMS -ERI-97270375 ( 6 Feb 2015 ).
77. Sagie A, Larson MG, Goldberg RJ, Bengston JR, Levy D. An improved method for adjusting the QT interval 
for heart rate (the Framingham Heart Study). Am J Cardiol. 1992;70:[ADDRESS_508778] Optimized Treatment in 
Depression (iSPOT -D): Outcomes from the acute phase of antidepressant treatment. J Psychiatr Res. 2015 
Feb;61:1 -12.
79. Sertraline (Zoloft®): US Prescribing Information. [COMPANY_007], Inc., New  York, [LOCATION_001], [LOCATION_003]; Aug 2014. 
http://labeling.pfizer.com/ShowLabeling. aspx?id=517 (accessed 9 Feb 2015).
80. Sertraline: Summary of Product Characteristics. Sandoz Limited, Surrey, [LOCATION_008]; Sep 2012. 
http://www.medicines.org.uk/emc/medicine/[ZIP_CODE]/SPC (accessed 6 Mar 2015).
81. Sheehan DV, Harnett -Sheehan K, Raj BA. The measurement of disability. Int Clin Psychopharmacol. 1996 
Jun;[ADDRESS_508779] 3:89 -95. Review.
82. Shram MJ, Sellers EM, Romach MK. Oral ketamine as a positive control in human abuse potential studies. 
Drug Alcohol Depend. 2011 Apr 1;114(2 -3):185 -93.
83. Spi[INVESTIGATOR_4280], Kroenke K, Williams JB, Lowe B. A brief measure for assessing generalized anxiety disorder: the 
GAD -7. Arch Intern Med. 2006;166(10):1092 -1097.
84. Spi[INVESTIGATOR_4280], Kroenke K, Williams JB. Validation and utility of a self -report version of PRIME -MD: the PHQ 
primary care study. JAMA. 1999; 282:1737 -1744.
85. Targum SD, Pollack MH, Fava M. Redefining affective disorders: relevance for drug development. CNS 
Neurosci Ther. 2008;14(1):2 -9.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3002 Amendment 2
Status: Approved , Date: 3 June 2016 [ZIP_CODE]. Trivedi MH, Rush AJ, Ibrahim MH, et al. The Inventory of Depressive Symptomatology, Clinician Rating 
(IDS -C) and Self -Report (IDS -SR), and the Quick Inventory of Depressive Symptomatology, Clinician Rating 
(QIDS -C) and Self -Report (QIDS -SR) in public sector patients with mood disorders: a psychometric 
evaluation. Psychol Med. 2004;34(1):73 -82.
87. Venlafaxine Extended -release: US Prescribing Information. [COMPANY_007], Inc., New  York, [LOCATION_001], [LOCATION_003]; Au g
2014. http://labeling.pfizer.com/ShowLabeling.aspx?id=612 (accessed 9 Feb 2015).
88. Venlafaxine: Summary of Product Characteristics. Actavis Group PTC ehf, Iceland; May 2012. 
http://www.medicines.org.uk/emc/medicine/[ZIP_CODE] (accessed 6 Mar 2015).
89. Vesierra (5 mg/mL solution for injection/infusion): Summary of Product Characteristics, Jun 2014. [COMPANY_007] 
Limited, Kent, [LOCATION_008] http://www.drugs.com/uk/vesierra -5-mg-ml-solution -for-injection -leaflet.html 
(accessed 25 Feb 2015).
90. Vos T, Flaxman AD, Naghavi M, et al. Years lived w ith disability (YLDs) for 1160 sequelae of 289 diseases 
and injuries 1990 -2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012 Dec 
15;380(9859):2163 -96.
91. Walker ER, McGee RE, Druss BG. Mortality in Mental D isorders and Global Disease Burden Implications: A 
System atic Review and Meta -analysis. JAMA Psychiatry. [ADDRESS_508780]. 
1975 Jun;24(6):260 -3.
93. Woolf TF, Adams JD. Biotransformation of ketamine, (Z) -6-hydroxyketamine, and (E) -6-hydroxyketamine by 
[INVESTIGATOR_20325], rabbit, and human liver microsomal preparations . Xenobiotica. 1987;17:839 -847.
94. World Health Organization. Depression (fact sh eet). Oct 2012. 
http://www. who.int/mediacentre/factsheets/fs369/en/ (accessed 5 Feb 2015).
95. Yanagihara Y, Kariya S, Ohtani M, et al. Involvement of CYP2B6 in N demethylation of ketamine in human 
liver microsomes. Drug Metab Dispos . 2001;29:887 -890.
96. Yang P. Recent Advances in Design and Methodology in Psychiatric Clinical Trials. Slide presentation at Joint 
Statistical Meetings; Aug 3-8, 2013; Montréal, QC Canada.
97. Zarate CA Jr, Singh JB, Carlson PJ, et al. A randomized trial of an N- methyl-D-aspartate antagonist in 
treatment -resistant major depression. Arch Gen Psychiatry. 2006 Aug;63(8):856 -64.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3002 Amendment 2
Status: Approved , Date: 3 June 2016 151Attachment 1: Prohibited Concomitant Medications with Intranasal Study  
Medication (Esketamine or Placebo )
This list of medications is not all-inclusive ; if necessary, please contact [CONTACT_154990] a medication(s).
Please refer to the local prescribing information of the subject’s oral antidepressant treatment for 
information regard ing prohibited concomitant medications. 
Except where specifically noted, the prohibited medications listed in the following table are prohibited 
from 1 week (or 5 half-lives, whichever is longer) prior to the first dose of intranasal study medication 
until after the last dose of intranasal study medication. Note: If amedication is part of the antidepressant 
treatment regimen being taken at the time of signing the ICF (ie, start of screening/ prospective 
observational phase), it must be continued unchanged until the end of Week 4 of the 
screening /prospective observational phase , therefore this requirement is not applicable. In such cases the 
investigator may choose to taper the relevant medication during the up to 3-week taper period based on 
their clinical judgment.
Note in the following table : N, Prohibited ; Y,Permitted, with restrictions (please refer to the column
label ed “Comments” for additional guidance ).
Drug ClassEpi[INVESTIGATOR_154895] ( as 
needed )Continuous 
Use CommentsReason for 
Prohibition
Amantadine N N PD interaction
Anorexiants 
(eg, phenter mine , 
phendimetrazine )N N Safety
Anticholinesterase 
inhibitorsN N Subject 
population is 
excluded
Anticonvulsants N N Subjects with seizures are excluded.
Use as adjunctive treatment for major 
depressive disorder ( MDD) is 
prohibited. 
-Note: Anticonvulsants used for 
indications other than seizures may be 
allow ed (eg, valproate for migraine ; 
pregabalin )Safety and PD 
interaction
Antidepressants 
(other than the specific 
antidepressant started in 
the induction phase of the 
study)N N-Only [ADDRESS_508781] is taking a monoamine 
oxidase inhibitor (MAOI) during the 
screening/prospective observational 
phase, there must be a minimum 
washout interval of [ADDRESS_508782] dose of intranasal study 
medication.
-Even if used for other indications (eg,
trazodone for sleep ), the useof any 
medication listed on the ATRQ is not 
permitted during the treatment phase.Safety and PD 
interaction
Antipsychotics N N PD interaction
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3002 Amendment 2
Status: Approved , Date: 3 June 2016 152Drug ClassEpi[INVESTIGATOR_154895] ( as 
needed )Continuous 
Use CommentsReason for 
Prohibition
Benzodiazepi[INVESTIGATOR_1651] (at 
dosages less than or equal 
to the equivalent of 6 
mg/day lorazepam) and 
non-benzodiazepi[INVESTIGATOR_403376] 
(including: zolpi[INVESTIGATOR_6730], 
zaleplon, eszop iclone, and 
ramelteon)Y Y P rohibited w ithin 12 hours prior to the 
start of each intranasal treatment se ssion 
or cognition testingSafety and PD 
interaction
Benztropi[INVESTIGATOR_050] Y N Prohibited if use is continuous and 
prohibited w ithin 12 hours prior to the 
start of cognition testingSafety and PD 
interaction. 
Chloral hydrate, 
melatonin, valerianN N Safety and PD 
interaction
Clonidine N N Safety and PD 
interaction
Corticosteriods ( system ic) Y N Inhaled, intranasal, topi[INVESTIGATOR_2855], and 
ophthalmic steroids are not prohibited.
Intermittent IM/IV corticosteroids are 
permitted (chronic use prohibited)PD interaction
Cough/cold 
preparations/nasal 
solutions containing 
vasoconstrictors, 
decongestantsY Y Intranasally -administered decongestants 
(vasoconstrictors) should not be used 
from [ADDRESS_508783] intranasal dose of study 
medication.
Examples (not all -inclusive): Efavirenz, 
nevirapi[INVESTIGATOR_050], barbiturates, carbamazepi[INVESTIGATOR_050], 
glucocorticoids, modafinil, 
oxcarbazepi[INVESTIGATOR_050], phenobarbital, 
phenytoin, rifabutin, rifampin, and St. 
John's wortPK
Dextromethorphan N N PD interaction
Diphenhydramine Y N Prohibited w ithin 12 hours prior to the 
start of each intranasal treatment sessionSafety
Ketanserin N N Safety
Lithium N N PD interaction
Mem antine N N PD interaction
Methyldopa N N Safety and PD 
Interaction
Metyrosine N N Safety and PD 
interaction
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3002 Amendment 2
Status: Approved , Date: 3 June 2016 153Drug ClassEpi[INVESTIGATOR_154895] ( as 
needed )Continuous 
Use CommentsReason for 
Prohibition
Non-vitamin K antagonist 
oral anticoagulation agents 
(eg, dabigatran, 
rivaroxaban, api[INVESTIGATOR_154897] N Safety
Opi[INVESTIGATOR_2438] N N PD interaction
Psychostimulants 
(eg, amphetamines , 
methylphenidate, and 
modafinil, armodafin il)N Y Prescribed psychostimulants taken for 
indications other than MDD can be 
continued but must not be taken within 
12 hours prior to the intranasal 
treatment session or for 2 hours after the 
intranasal treatment session.Cardiovascular 
safety
ADHD medications (eg, 
atom oxetine, guanfacine)N Y Can be continued but must not be taken 
within [ADDRESS_508784]. John’s Wort N N PD interaction 
and PK
Thyroid hormone 
supplement for treatment 
of thyroid condition only 
(not for depression)N Y Safety
Thyroxine/ 
triiodothyronine (T3), 
thyroid h ormone 
prescribed for depressionN N PD interaction
Warfarin N N Primary 
condition 
where used is 
excluded
Abbreviations: N, Prohibited; PD, pharmacodynamics; PK, pharm acokinetics; Y, Permitted, w ith restrictions (please 
refer to the column labeled “Comments” for additional guidance).
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3002 Amendment 2
Status: Approved , Date: 3 June 2016 154Attachment 2: [LOCATION_001] Heart A ssociation Classification of Cardiac Disease
[LOCATION_001] Heart Association Classification of Cardiac Disease
Category Description
Functional Capacity
Class I Patients with cardiac disease but without resulting limitation of physical activity. Ordinary physical 
activity does not cause undue fatigue, palpi[INVESTIGATOR_332], dyspnea, or anginal pain.
Class II Patients with cardiac disease resulting in slight limitation of physical activity. They are comfortable at 
rest. Ordinary physical activity results in fatigue, palpi[INVESTIGATOR_332], dyspnea, or anginal pain.
Class III Patients with cardiac disease resulting in marked limitation of physical activity. They are comfortable 
at rest. Less than ordinary activity causes fatigue, palpi[INVESTIGATOR_332], dyspnea, or anginal pain.
Class IV Patients with cardiac disease resulting in inability to c arry on any physical activity without 
discomfort. Symptoms of heart failure or the anginal syndrome may be present even at rest. If any 
physical activity is undertaken, discomfort is increased.
Objective Assessment
A No objective evidence of cardiovascular disease.
B Objective evidence of minimal cardiovascular disease.
C Objective evidence of moderately severe cardiovascular disease.
D Objective evidence of severe cardiovascular disease.
Source: Criteria Committee of the [LOCATION_001] Heart Association. Functional capacity and objective assessment. In: 
Dolgin M, ed. Nomenclature and Criteria for Diagnosis of Diseases of the Heart and Great Vessels, 9th ed. [LOCATION_011], 
MA: Little, Brow n & Co; 1994, 253 -255.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3002 Amendment 2
Status: Approved , Date: 3 June 2016 155Attachment 3: Oral A ntidepressant Titrat ion Schedule for Double -Blind 
Induction Phase
The titration schedule for the 4 oral antidepressants to be used in the current study is provided below. 
Adjustments to the titration schedule may be required in other countries in order to conform to local 
prescribing information.
Global titration schedule 
Oral Antidepressant 
(Active Com parator)Titration Schedule
Week 1
(Starting Day 1)Week 2
(Starting Day 8)Week 3
(Starting Day 15)Week 4
(Starting Day 22)
Duloxetine 60 mga60 mg 60 mg 60 mg
Escitalopram 10 mg 20 mg 20 mg 20 mg
Sertraline 50 mg 100 mg 150 mg 200 mg
Venlafaxine XR 75 mg 150 mg 225 mg 225 mg
aSubjects should be initiated with 60mg/day. Subjects that have in the past shown increased sensitivity 
towards serotonin reuptake inhibitors (SSRI) /norepi[INVESTIGATOR_5608] (SNRI) can,at the 
discretion of the treating physician ,be started on a 30mgdose and up-titrated into thetherapeutic range 
of 60 mg by [CONTACT_154904]2
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3002 Amendment 2
Status: Approved , Date: 3 June 2016 156Attachment 4: Anticipated Events
An anticipated event is an adverse event (serious or non -serious) that commonly occurs as a consequence 
of the underlying disease or condition under investigation (disease related) or background regimen. For 
the purposes of this study the following events will be considered anticipated events.22,23,27,28,42,79,80,87,88
For esketamine and major depressive disorder (MDD) (including treatment -resistant depression [TRD]; 
based on DS M-5):
 Suicidal thinking, ideation, and behavior
 Sleep changes, difficulty sleepi[INVESTIGATOR_007], reduced sleep, abnormal sleep, abnormal sleep, tiredness, fatigue, 
and reduced energy
 Difficulty in sexual desire, performance or satisfaction
 Reduced appetite and weight c hanges (loss or increase)
 Activation or hypomania/ mania
 Excessive happi[INVESTIGATOR_008]
 Irritabi lity, anger, and impulsive behavior
 Agitation, feeling anxious/anxiety, tension, panic attacks, and phobia
For esketamine, regarding events related to concomitant therapy with oral antidepressants (from the 
product’s reference safety information/US prescribing information):
 Duloxetine
 Most commonly observed adverse reactions from pooled studies of all indications (incidence of 
at least 5% and at least twice the incidence inplacebo subjects) were nausea, dry mouth, 
somnolence, fatigue, constipation, decreased appetite, and hyperhidrosis (sweating). Duloxetine 
treatment worsens glycemic control in some subjects with diabetes.
 Increased the risk compared to placebo of suicidal thinking and behavior; serotonin syndrome; 
hepatotoxicity; hepatic failure; orthostatic hypotension, syncope; abnormal bleeding; severe 
skin reactions, including erythema multiforme and Stevens -Johnson Syndrome (SJS); activation 
of mania or hypomania; hyp onatremia.
 Venlafaxine XR
 According to the US prescribing information, adverse events in short -term studies occurring in 
at least 5% of subjects receiving venlafaxine XR and at a rate twice the incidence in placebo 
subjects : abnormal ejaculation, gastrointestinal complaints (nausea, dry mouth, and anorexia), 
central nervous system complaints (dizziness, somnolence, and abnormal dreams), and 
sweating. Sustained hypertension is noted within Warnings and Precautions section.
 Increased the risk compare d to placebo of suicidal thinking and behavior , treatment -emergent 
insomnia and nervousness , activation of mania/hypomania , hyponatremia , mydriasis, abnormal 
bleeding , sustained hypertension , and serotonin syndrome.
 Escitalopram
 Most commonly observed adve rse reactions (incidence of approximately 5% or greater and 
approximately twice the incidence in placebo subjects ) were insomnia, ejaculation disorder 
(primarily ejaculatory delay), nausea, sweating increased, fatigue, and somnolence.
 Increased the risk compared to placebo of suicidal thinking and behavior, serotonin syndrome, 
activation of mania/hypomania, hyponatremia and abnormal bleeding
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3002 Amendment 2
Status: Approved , Date: 3 June 2016 157 Sertraline
 Most common treatment -emergent AEs associated with sertraline (incidence of at least 5% for 
sertraline or at least twice the incidence in placebo subjects) were ejaculation failure, dry mouth, 
increased sweating, somnolence, tremor, dizziness, fatigue, pain, malaise, abdominal pain, 
anorexia, constipation, diarrhea/loose stools, dyspepsia, nausea, agitation, insomnia, and 
decreased libido, and serotonin syndrome. 
 Increased the risk compared to placebo of suicidal thinking and behavior, activation/mania; 
bleeding events related to SSRI use (have ranged from ecchymosi s, hematomas, epi[INVESTIGATOR_3940], and 
petechiae to life-threatening hemorrhages), hyponatremia (appears to be the result of the 
syndrome of inappropriate antidiuretic hormone secretion [SIADH]); serotonin syndrome
Reporting of Anticipated Events
These events will be captured on the eCRF and in the database, and will be reported to the sponsor as 
described in Section 12.3.1 , All Adverse Events. Any event that meets serious adverse event criteria will 
be reported to the sponsor within the appropriate timeline as described in Section 12.3.2, Serious Adverse 
Events. These anticipated events are exempt from expedited r eporting as individual single cases to Health 
Authorities. However, if based on an aggregate review, it is determined that an anticipated event is 
possibly related to study drug, the sponsor will report these events in an expedited manner.
Anticipated Even t Review Committee (ARC)
An Anticipated Event Review Committee (ARC) will be establ ished to perform reviews of pre-specified 
anticipated events at an aggregate level. The ARC is a safety committee within the sponsor’s organization 
that is independent of the sponsor’s study team. The ARC will meet to aid in the recommendation to the 
sponsor’s study team as to whether there is a reasonable possibility that an anticipated event is related to 
the study drug. 
Statistical Analysis
Details of statistical analysis of anticipated events, including the frequency of review and threshold to 
trigger an aggregate analysis of anticipated events will be provided in a separate Anticipated Events 
Safety Monitoring Plan (ASMP).
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3002 Amendment 2
Status: Approved , Date: 3 June 2016 158INVESTIGA TOR AGREEME NT
[STUDY_ID_REMOVED]